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INTRODUCTION 
 
Enzymes play a major role in most of the biochemical processes and reactions that are at 
the basis of life. However, enzymatic alterations are involved in many human diseases, 
making enzymes very attractive by the pharmaceutical industry and academia. Indeed, 
enzymes are the ideal targets for drug discovery processes aimed to the development of 
molecules able to modulate their activity and eventually block their negative 
consequences. 
In the present work, the attention has been focused on the nickel-dependent urease as a 
target enzyme. Urease is found in several organisms, such as bacteria, algae, fungi and 
higher plants and catalyses the rapid hydrolysis of urea to give ammonia and bicarbonate, 
causing an overall increase of pH. The relevance of urease derives from the fact that it is 
a virulence factor for several human pathogenic microorganisms. A paradigm in this 
sense is Helicobacter pylori, a Gram-negative ureolytic bacterium that exploits the urease 
activity to colonize the human gastric mucosa causing chronic gastritis, peptic and 
duodenal ulcers. It is the only bacterium that has been classified as a “class 1” carcinogen 
by the World Health Organization (WHO). Moreover, WHO has recently identified the 
twelve most important antibiotic-resistant bacteria for which new treatments are urgently 
required and, among those, nine organisms are ureolytic.1 Urease is also involved in agro-
environmental issues. Being present in the soil in large quantities, it substantially 
decreases the efficacy of urea-based fertilizers used in agriculture because of ammonia 
volatilization, thus causing economic and environmental problems. For these reasons, the 
scientific community has devoted intense efforts in the last several decades for the 
development of efficient and specific inhibitors of urease able to counteract its negative 
effects both from a medical and an agro-environmental point of view. The overall 
conserved tridimensional structure of ureases among the species, together with the !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!#!(www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/)!
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availability of high-resolution X-ray crystal structures of ureases from different 
organisms, strongly enhances the significant role that structure-based drug design can 
have in the process of discovery of new urease inhibitors, both as drugs and as molecules 
to be used as nitrogen stabilizers in agriculture.  
In this study, a combination of biochemistry and structural biology has been applied to 
the urease system to determine the inhibition mode of several known urease inhibitors, 
with the aim to fully characterize both their interactions and binding efficacy towards the 
enzyme. All the results shown in here will be useful to develop novel and more efficient 
urease inhibitors, necessary to modulate its activity and to counterbalance its negative 
effects. 
As the reader will notice, a relevant portion of this dissertation is included as Annexes. In 
particular, a complete description of urease is given in the published book chapter 
available as Annex 1. This book chapter should be intended as an introduction section, to 
be read together with Chapter 1. The reader will be also guided through the other 
Annexes present in this work during the reading of the thesis, each representing a 
scientific article published as results of the studies carried out by me, together with other 
collaborators, during the course of the Doctoral Program in Cellular and Molecular 
Biology. 
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CHAPTER 1 
 
STRUCTURE-BASED DRUG DESIGN  
IN DRUG DISCOVERY 
 
1.1 Drug discovery: past and present 
 
In the past, development of medicines was usually driven by the knowledge acquired on 
endogenous ligands without a simultaneous awareness on the structure of their cognate 
biological receptors. Such a paradigm can be highlighted by the emblematic example of 
steroid hormones. In fact, at the beginning of the 20th century the important role of 
steroidal molecules in many biological aspects was proved on a biochemical basis. Later, 
in 1932, their overall tridimensional structure was determined by X-ray crystallography.1 
The resulting combination of the biochemical and structural information available on 
steroids allowed understanding how the substituted groups present at specific positions 
around the scaffold provide specific biological activity, endorsing the development of 
new drugs.2, 3 
The first idea of modern drug discovery was what we now call “classical” 
pharmacology.4 It was based on the phenotypic screening of small molecule libraries to 
be tested in living cells or whole organisms with the aim of identifying compounds with 
an appropriate therapeutic effect. Nowadays, with the improvements in genomics, 
molecular biology and related techniques that allow production of large quantities of 
purified proteins, this process has been overturned. Databases of small molecules are used 
to perform high throughput screenings in order to evaluate their ability to interact with 
proteins potentially involved in diseases. Good candidates resulting from the initial 
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screening are then tested in vitro and in vivo to detect their real efficacy. This new 
workflow is usually referred to as reverse pharmacology.4 
In the last 20 years, advances in computational methods have contributed to the rise of the 
so-called structure-based drug design (SBDD) as the basis of drug discovery in reverse 
pharmacology (Figure 1). Today, SBDD is a fundamental part of most drug discovery 
programs carried out by companies, simultaneously becoming a major research field for 
academic laboratories.5 As a part of the drug discovery process, it is worth noting that 
structure-based drug design is important in the discovery of drug leads rather than drug 
products. Many years may be necessary to improve a drug lead in order for it to be used 
as a drug effective and tolerated by human body. Additionally, time will also be spent in 
order for the drug to pass through the clinical trials and possibly reach the market.6 
 
 
Even though SBDD can be theoretically applied to every kind of macromolecule (i.e. 
proteins, nucleic acids and more complex supramolecular assemblies), in this chapter our 
discussion will be focused on SBDD performed on enzyme targets. First, a brief 
introduction on the procedure, as well as a description of the most relevant drug design 
methods will be given. In the last part of the chapter we will focus on the two peculiar 
and recurring aspects of the SBDD process, the structural characterization of the target in 
the absence and in the presence of ligands and the biochemical characterization of the 
ligand-target interactions. 
 
 
 
 
Figure 1: Schematic representation of the drug discovery process. The shaded boxes emphasize where 
SBDD plays a significant role. Redrawn from: 3D structure and the drug-discovery process.6 
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1.2 An overview of structure-based drug design 
 
Structure-based drug design (SBDD) is an iterative process usually proceeding through 
multiple steps. The structure-based term stands for the need of a tridimensional structure 
of the target macromolecule, alone and/or in complex with ligands, in order for the drug 
design process to be tailored at an atomic level. The structural determination of the target 
can be pursued by using three main methodologies: i) X-ray crystallography, ii) NMR 
spectroscopy, and iii) homology modelling.5, 7 
In the first step of a general SBDD approach, the available structural information on the 
target is exploited to screen small molecule databases by using computer-aided 
approaches in order to select compounds with potential binding affinity for the target 
itself. Next, biochemical experiments are carried out in order to corroborate the binding 
efficacy of the molecules selected by computational procedures (hits) and select those 
showing an at least micromolar affinity, in vitro. In the second step, structure 
determination of the target in complex with the active hits selected in the previous step is 
carried out. The latter aspect is necessary to depict, at an atomic level, the mode of 
interaction between the macromolecule and the testing compounds, on a structural point 
of view. Moreover, this would show possible portions of the hits that can be improved in 
order to further optimize the efficacy of ligand binding. In the third step, biochemical and 
structural information obtained by the previous phases is exploited to chemically modify 
the hits, and further biochemical experiments are carried out to verify the effects of the 
chemical modifications in terms of binding efficacy. By iteratively repeating the 
procedure, an overall optimization of the molecules should be observed in terms of 
binding properties and specificity for the target.5, 7  
 
 
1.2.1 Identification of a potential binding site on the target 
 
A typical target of a SBDD campaign can be an enzyme involved in a disease. Thus, with 
the aim of discovering a new drug that would counterbalance its negative effects, the first 
mandatory step is the determination of the enzyme structure. This can be achieved by 
using techniques such as X-ray crystallography, NMR spectroscopy and homology 
modelling,5, 7 as we will discuss in Section 1.3. Here we can assume that one of these 
techniques has been successfully applied and the tridimensional structure of the enzyme 
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under study is already available. In these circumstances, the following step is the 
exploitation of the structural information for the identification of a potential binding site 
for the ligand on the target. In the case of enzymes, the most interesting potential binding 
site for a ligand is certainly the active site. This is in fact the most direct way through 
which enzyme activity can be suppressed. An alternative strategy can be to identify a 
region that is not directly involved in the enzyme catalysis but that controls 
conformational changes that are necessary for the catalysis to occur.8 Focusing on non-
enzyme targets, some interesting arguments can be pointed out. If the subject of our study 
is a cellular receptor, numerous studies have demonstrated that the binding site for the 
endogenous ligand is a valuable potential target for the design of cognate ligands, usually 
small peptides, that bind by exploiting mimicry.9, 10 Otherwise, if the goal of SBDD is to 
find a molecule able to modulate a protein-protein interaction, potential binding sites can 
be the assembly patches that allow this interaction to occur, which are often characterized 
by relatively compact epitopes consisting of clustered amino acid side chains within the 
dimensions of a small molecule framework.11 Moreover, an interesting point is the 
possibility to use RNA secondary structural elements as target sites. In fact they are 
usually species specific, able to bind ligands and are often involved in disease states.12, 13 
 
 
1.2.2 Drug design methods 
 
Once a potential binding site on the enzyme under study has been identified by analysing 
its tridimensional structure, the following objective is the screening of small molecules in 
order to find a good initial compound that potentially interacts with the target. Small 
molecules are usually selected by computational methods, such as: i) direct inspection, ii) 
virtual ligand screening, and iii) de novo generation. 
Direct inspection relies on a direct structural analysis of ligands that are already known to 
bind the target macromolecule. If we are working with an enzyme, attention can be 
focused on substrates, possible cofactors or already established enzyme inhibitors. Direct 
inspection essentially consists in a chemical modification of such known molecules in 
order for the interactions between the enzyme binding site and the molecule itself to be 
maximized, transforming the latter in a potent inhibitor. There are a number of studies 
demonstrating that analogues of the substrate or modified cofactors can be good 
candidates for drug development against enzymes.14-17 Such chemically modified 
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molecules are preliminary tested in silico, by docking procedures that score the 
interaction between the binding site and the putative ligand.18-20 Thus, the most promising 
molecules are synthetized (or purchased, if commercially available) and tested in vitro to 
confirm their binding efficacy.5, 21 
In virtual ligand screening (VLS), small molecule databases (e.g. Asinex, Chembridge, 
Princeton, Enamine or Zinc) are docked to the target binding site, scoring the orientation 
results according to the predicted interactions.22 One advantage of this approach is the 
possibility of refining the database search in order to filter molecules with a specific 
motif. Molecules that give best results are then purchased and tested in vitro to verify 
their effective properties through biochemical assays. However, databases for VLS do not 
provide structurally novel molecules, as they are usually already commercially 
available.23 
In the de novo generation, small fragments or portions of molecules (benzene rings, 
amino groups, carbonyl groups, etc.) are docked into the targeted binding site. With an 
iterative process, fragments can be then linked together in order to build a novel molecule 
that has never been synthesized before and to obtain larger inhibition potency.22, 24 
These three computational methods can be used alone or can be combined. For example, 
the experimentally active compounds found after a virtual screening step can be 
optimized by using a direct inspection approach. 
 
 
1.3 Structure determination of the target 
 
As introduced at the beginning of this chapter, the prior requirement for any structure-
based drug design is the availability of a tridimensional structure of the macromolecule 
against which we want to develop new drugs. Such a structure will further guide the drug 
discovery process throughout all the steps of SBDD, playing a significant role in the 
“ping-pong” procedure that passes through the structural determination and chemical 
improvements of the testing molecules. We already mentioned the three main 
methodologies used to provide a structural characterization of the target useful in SBDD, 
X-ray crystallography, NMR spectroscopy and homology modelling.5, 7 However, the 
following discussion will cover only X-ray crystallography and NMR spectroscopy, as 
they are the two experimental methodologies of choice. They both allow the 
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determination of high-resolution structures at an atomic level and, when possible, they 
have to be intended as complementary approaches. Homology modelling consists in the 
prediction of the tridimensional structure of a protein starting from its amino acid 
sequence by a structural comparison with one or more homologue proteins of known 
structure25, 26 and it is usually used when no tridimensional structure of the protein under 
study is available. On the other hand, the structures obtained by homology modelling do 
not have the resolution and the accuracy required for SBDD. 
X-ray crystallography has been historically the most common method adopted for the 
structural data gathering useful in the iterative process of SBDD.27-29 As a main technique 
used in our laboratory, a detailed description of X-ray crystallography bases are given in 
Appendix B. Besides theory, a crystallographic structure suitable as a target for drug 
design must present some mandatory features.5 In general, the structural model must be 
chemically correct, with a final refined structure consistent with the stereochemical 
parameters. Also, low coordinate errors, as well as B-factors of the atoms belonging to 
the binding region not greater than the average B-factor for the macromolecule, are 
needed. A number of tools, usually used prior to a PDB deposition, can be exploited to 
check the reliability of a structural model, such as PROCHECK,30 WHATIF31 or the 
wwPDB validation web server (http://www.wwpdb.org/).32 There are some advantages in 
the use of this technique with respect to NMR spectroscopy. First, X-ray crystallography 
can be applied to macromolecules virtually without any size limitation.33 High-resolution 
crystal structures are available for proteins, nucleic acids, as well as bigger systems such 
as macromolecular complexes and viruses.34 Moreover, it enables the direct visualization 
of the ordered solvent molecules located inside and around the protein model. This 
information can be used to improve the process of drug discovery. For example, ordered 
water molecules can be incorporated into the proposed ligand, enhancing ligand-binding 
properties by increasing the entropy of the system upon water release.35 Additionally, 
ordered water molecules can be considered as actual ligands, and interactions between the 
candidate molecules and water molecules themselves can be maximized.36 In general, 
technical improvements regarding X-ray crystallography, such as microfocused 
beamlines, new generation detectors, and the innovative use of free-electron lasers have 
reduced the number and dimension of crystals required to determine tridimensional 
structures. However, there is no denying that the need of a crystal can be a bottleneck in 
!!
CHAPTER 1: STRUCTURE-BASED DRUG DESIGN IN DRUG DISCOVERY 
!
! !
"#!
the characterization of the interaction mode of the ligand with the macromolecule. Some 
proteins simply do not crystallize. In addition, co-crystallization or soaking can give 
different results, for example, when proteins require a conformational change for the 
ligand binding to occur, or when crystal packing negatively affects the ligand binding 
itself.37 The non-physiological conditions present in a protein crystal can also give 
artifacts, even though numerous studies have demonstrated that a macromolecule crystal 
can be referred to an ordered gel with interstitial spaces through which water and other 
small molecules freely diffuse.38 
To complement the information acquirable with X-ray crystallography, as well as to 
overcome the technique-related issues, NMR spectroscopy is also a valuable technique 
for drug design purposes. In general, the main advantage of NMR with respect to X-ray 
crystallography is that the interaction between the target and the ligand can be evaluated 
in solution and, by using appropriate approaches, this interaction can be characterized on 
both a structural and kinetic point of view. In particular, NMR experiments can be 
performed on a protein-ligand mixture by following the resonances of either the ligand or 
the protein.39 In the so-called ligand-based NMR methods, no labeling is needed and the 
detectable resonances, usually pursued through NOE-type experiments40, 41 and water 
ligand-observed spectroscopy (Water-LOGSY),42 belong to the hydrogen atoms of the not 
bound ligand (the protein-bound ligand behaves like a protein, with a slow tumbling time 
and undetectable signals). A comparison between the resulting NMR spectra collected for 
the ligand in the presence or in the absence of the protein can reveal binding 
information.43 In protein-based NMR methods, a complete map of the amino acid 
residues involved in the interaction with the testing compound can be obtained upon a 
sequence-specific assignment of the backbone resonances. A typical 1H-15N 
Heteronuclear Single-Quantum Correlation (HSQC)44 collected for the protein in the 
absence and in the presence of the molecule would result in a chemical shift perturbation 
(CSP)45 of the residues directly involved in the interaction with the ligand. In this context, 
if the tridimensional structure of the protein is available, the binding site for the ligand on 
the protein can be easily mapped. Other techniques that do not require a backbone 
assignment rely on intermolecular NOEs measurements.46 NMR can overcome X-ray 
crystallography within the drug design process in some instances, for example when one 
is studying membrane proteins, which are difficult to crystallize. In this case, 
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macromolecule-ligand interactions can be evaluated with NMR by mixing in solution 
natural or artificial membranes and allowing the protein resonances to be detectable.47 
However, the main limitation of NMR spectroscopy is in the size of the macromolecules 
that can be studied, with sensitivity losses and spectral complexity that allow to work 
only with macromolecules up to 50-60 kDa.48 This is an addition to the limited resolution 
of NMR structures with respect to X-ray structures. 
 
 
1.4 Biochemical assays on the testing compounds 
 
After the first computational screening of small molecules potentially interacting with the 
target enzyme, as well as during each step of lead optimization, an in vitro biochemical 
analysis on the testing molecules has to be performed in order to determine a structure-
activity relationship (SAR) of the interaction between ligand and target.49 A typical 
evaluation flowchart for the determination of the binding mode of a ligand towards an 
enzyme is schematically presented in Figure 2. Most of the procedures listed in the 
scheme and described below are examined in detail in Appendix A, hence the following 
discussion will resume them in order to depict an overview on how they are involved in 
the SBDD process. 
 
Figure 2: Evaluation flowchart for the compounds tested in the optimization phase of a structure-based drug design 
campaign. Redrawn from: Lead optimization and structure-activity relationships for reversible inhibitors.49 
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In general, a preliminary evaluation of ligand efficacy is made by a concentration-
response analysis in order to determine the IC50, namely the concentration of inhibitor 
that causes a loss of enzyme activity equal to 50%. By measuring the reaction velocity of 
our target enzyme in the absence (v0) and in the presence of increasing amounts of 
inhibitor (vi) (at fixed concentrations of enzyme and substrate), it would result in a 
progressive decrease of reaction velocity by increasing the concentration of inhibitor, 
following a sigmoidal behaviour, until no residual activity would be detectable. A plot of 
percentage residual activity (vi/v0 %) as a function of inhibitor concentration can be 
drawn as in Figure 3, and IC50 can thus be calculated as the mid-point in the semi-
logarithmic plot by the following equation: 
 
 (2.1) 
!
!
Figure 3: Dose-response semi-log plot of enzyme residual activity as a function of inhibitor concentration. The IC50 
value for the inhibitor is graphically determined. Redrawn from: Lead optimization and structure-activity 
relationships for reversible inhibitors.49 
 
IC50 is commonly used to rank-over the relative efficacy of the testing compounds. 
However, a more exhaustive characterization of the inhibition mechanism can be carried 
out by determining whether the inhibition is reversible or irreversible and, in the former 
case, information on the type of reversibility (i.e. rapid or slow) is also achievable. The 
most common procedure to detect a reversible behaviour is to perform a progress curve 
experiment by measuring the recovery of enzyme activity after a large dilution of the 
enzyme-ligand mixture, as described in Figure 4. In such an analysis, a rapid reversible 
 
residual activity % = 100
1+ [I] / IC50( )
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inhibition would result in almost complete recovery of enzyme activity, with a progress 
curve profile similar to the one of the enzyme not treated with the inhibitor. A slowly 
reversible inhibition (slow-binding) would result in a curvilinear progress curve, with a 
lag phase followed by a linear one, while an irreversible inhibition would otherwise result 
in a non-recovery of enzyme activity. 
 
Figure 4: Recovery of enzyme activity after rapid dilution. Analysis of the resulting progress curve provides 
information on the inhibition mode of the ligand, as described in the main text. Redrawn from: Lead optimization 
and structure-activity relationships for reversible inhibitors.49 
 
As a following step, the fine biochemical characterization of the kinetic parameters that 
regulate the inhibition process has to be performed. In general, a reversible inhibitor is 
characterized in terms of reversible inhibition type, determining whether it acts with a 
competitive, uncompetitive or non-competitive reversible inhibition mechanism and 
determining the equilibrium dissociation constant Ki (M) between the inhibitor and the 
enzyme. On the contrary, irreversible inhibition can occur through an affinity labeling or 
a mechanism-based process.50 Inhibitors that are referred to as affinity labels are molecule 
with a medium to high intrinsic reactivity towards amino acid residues. In general, such 
molecules covalently modify the enzyme in a non-specific manner. For this reason a drug 
design procedure based on this kind of molecules is highly insidious. On the other hand, 
mechanism-based inhibitors have to be converted in the actual inhibitor species by a 
catalytic event performed by the enzyme, in order to act either as an affinity label, a 
transition state analogue, or a tight binding reversible inhibitor.51 These molecules usually 
act as competitive inhibitors!and are also named suicide substrates. The need of an initial 
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reaction with the enzyme makes these inhibitors high selective, therefore quite useful as 
potential drug leads. 
Concluding, the fine biochemical characterization of the SAR and the determination of 
related kinetic parameters is necessary in order to quantitatively measure the binding 
efficacy of the ligands towards the enzyme, therefore judging by comparison the 
improvement in lead optimization during each step of the SBDD process. 
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CHAPTER 2 
 
THE ACTIVE SITE OF UREASE  
AS A BINDING TARGET 
 
2.1 A biochemical and structural characterization of two 
reversible inhibitors of urease 
 
Two papers have been published by our group in 2014 and 2016, regarding kinetic and 
structural studies on the inhibition of urease by two inhibitors, fluoride and sulphite. 
The model enzyme used for these studies was urease from Sporosarcina pasteurii (SPU), 
a widespread ureolytic soil bacterium. Isothermal titration calorimetry was used in the 
6.5–8 pH range to determine the kinetic parameters of the inhibitions, while X-ray 
crystallography was used to depict, at an atomic level, the structural details of the 
interactions between the enzyme and the inhibitors. 
In the publication describing the inhibition of urease by fluoride, we reported that this ion 
acts as a pH-dependent inhibitor of urease, with a mixed inhibition mode. In order to 
provide a structural basis for this kinetic observation, a peculiar structural study was 
carried out. Indeed, in order to distinguish the iso-electronic fluoride ions and solvent 
molecules with significantly meaningful statistics, ten X-ray crystal structures of SPU 
were individually determined, using five crystals of the native enzyme and!five crystals of 
the protein co-crystallized in the presence of fluoride, an unprecedented approach. The 
analysis of these structures revealed the presence of two fluoride ions coordinated to the 
Ni(II) metal centres in the active site, a result that is fully consistent with the mixed 
inhibition mode pointed out by the kinetic experiments. In particular, one fluoride ion 
replaces the water molecule (W1) bound to Ni(1), thus acting as a competitive inhibitor 
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by interfering with the binding of the substrate urea to the same metal ion in the first step 
of the catalysis, while another fluoride ion replaces the hydroxide ion bridging the two 
Ni(II) ions, interfering with the nucleophilic attack on the substrate urea and thus acting 
as an uncompetitive inhibitor. The analysis of the hydrogen-bonding network around the 
nickel-bound fluoride ions further provides a basis for the interpretation of the pH-
dependence of inhibition. 
In the paper in which the inhibition of urease by sulphite was characterized, we reported a 
pH-dependent and competitive inhibition mode of sulphite, with an inhibition constant of 
0.19 mM at pH 7.0, the latter increasing as the pH increases and becoming negligible at 
pH 8.0. The X-ray crystal structure of SPU inhibited by sulphite, determined at 1.65 Å 
resolution, provides a rationale for this kinetic behaviour. Indeed, the structure reveals 
that sulphite binds to the two Ni(II) ions of urease active site in a tridentate mode, by 
using all its three oxygen atoms. Such a binding mode is fully consistent with the 
competitive inhibition mode observed in the biochemical analysis. The analysis of the 
hydrogen-bonding network around the nickel-bound sulphite further provides a basis for 
the interpretation of the pH-dependence of inhibition. 
The original papers describing the inhibition of urease by fluoride and sulphite are 
available in this dissertation as Annex 2 and Annex 3, respectively. The original citations 
are here below. 
 
• Fluoride inhibition of Sporosarcina pasteurii urease: structure and thermodynamics. 
S. Benini, M. Cianci, L. Mazzei and S. Ciurli (2014), J. Biol. Inorg. Chem., 19:1243. 
 
• Kinetic and structural studies reveal a unique binding mode of sulfite to the nickel 
center in urease. 
L. Mazzei, M. Cianci, S. Benini, L. Bertini, F. Musiani and S. Ciurli (2016), J. Inorg. Biochem., 154:42. 
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CHAPTER 3 
 
CHEMISTRY AT THE UREASE SURFACE 
 
3.1 A biochemical and structural study on two urease 
inactivators 
 
After the two papers describing the inhibition of urease by fluoride and sulphite and their 
interactions within the active site, I have devoted my efforts in order to evaluate the 
possibility to modulate urease activity by blocking the conserved mobile flap that is 
involved in the regulation of substrate entrance into, and products exit from, the active 
site. Two papers resulted from this work, describing kinetic and structural studies on the 
inhibition of two urease inactivators (see APPENDIX A for further details regarding 
irreversible inhibition): 1) 1,4-Benzoquinone (BQ), and ii) catechol (CAT). For these 
studies, the bacterial urease from Sporosarcina pasteurii (SPU) and the plant urease from 
Canavalia ensiformis (jack bean, JBU), were used as model enzymes. Kinetic 
experiments were carried out by using a spectrophotometric method, while the structural 
characterization of the inhibition was achieved using X-ray crystallography. 
The results of the kinetic study show that 1,4-Benzoquinone (BQ) irreversibly and 
stoichiometrically inhibits SPU, in a concentration- and time-dependent manner. The X-
ray crystal structure of SPU inactivated by BQ, determined at 2.07 Å resolution, reveals 
the presence of a 1,4-hydroquinone moiety covalently bound to the thiol group of Cys!322 
that belongs to the mobile flap. This observation has been rationalized on the basis of the 
reactivity of thiols with benzoquinones, following a Michael-type reactivity. 
In a similar fashion, the X-ray crystal structure of SPU inhibited by CAT, determined at 
1.50 Å resolution, proved that catechol binds to the same thiol group of Cys!322. In this 
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case, however, the kinetic data collected on the inhibition of JBU by catechol indicated 
the presence of a more complex inhibition mechanism, which involves an initial lag phase 
followed by a rapid decrease of urease activity, as a function of time. This inhibition 
profile was successfully modelled by assuming a radical-based autocatalytic multistep 
mechanism, the latter being proposed and discussed in the paper.  
In general, BQ and CAT abolish urease activity through a stabilization of the flap in the 
open conformation. In the enzymatic mechanism of urease-catalysed urea hydrolysis, the 
flap must switch from an open to a closed conformation in order to stabilize the reaction 
intermediate. In the presence of BQ and CAT, the flap is blocked in the open 
conformation and the catalysis cannot occur.  
Altogether, these results have provided strong evidences on the possibility to develop BQ 
and CAT derivatives able to interact with the cysteine residue and to act as urease 
inactivators. Both quinones and polyhydroxylated aromatic functionalities are found in a 
large number of natural compounds that can be potentially tested as urease inhibitors. 
The original papers describing the inhibition of urease by BQ and CAT are available in 
this thesis as Annex 4 and Annex 5, respectively. The original citations are here below. 
 
• Inactivation of urease by 1,4-benzoquinone: chemistry at the protein surface. 
L. Mazzei, M. Cianci, F. Musiani and S. Ciurli (2016), Dalton Trans., 45:5455. 
 
• Inactivation of urease by catechol: Kinetics and structure. 
L. Mazzei, M. Cianci, F. Musiani, G. Lente, M. Palombo and S. Ciurli (2017), J. Inorg. Biochem., 
166:182. 
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CHAPTER 4 
 
UREASE INHIBITION BY NBPT,  
A SUICIDE SUBSTRATE 
 
4.1 Introduction 
 
Phosphoramides are a class of well-known and very potent urease inhibitors, acting with 
a slow-binding inhibition mechanism.1 The inhibition process involves a first hydrolytic 
event performed in situ by urease, with the subsequent formation of a tetrahedral moiety 
that blocks the enzyme active site by mimicking the transition state that would be formed 
during the enzyme reaction of urea hydrolysis. It has been demonstrated that, irrespective 
of the starting compound, the inhibition is always brought about by diamidophosphate 
(DAP).2-4 In this context, significant information on the structural basis of urease 
inhibition by phosphoramides was provided by Benini and co-workers in 1999, who 
reported the X-ray crystal structure of the bacterial urease from Sporosarcina pasteurii 
(SPU) in complex with DAP after the treatment of the enzyme with 
phenylphosphorodiamidate (PPD).5 
N-(n-butyl)thiophosphoric triamide (NBPT) is a particular derivative of such compounds, 
where an oxygen atom of the phosphoryl scaffold has been replaced by a sulphur atom. 
NBPT is the nitrogen stabilizer mostly used in agriculture to counteract ammonia 
volatilization resulting upon the use of urea as a nitrogen fertilizer and it is regarded as 
the most effective urease inhibitor in aerobic soils.6 It is commercialized by Koch 
Fertilizer, LLC, under the commercial name of Agrotain® in a number of formulations. 
Several studies have been conducted on the efficacy of NBPT in inhibiting ureases from 
different sources and in reducing ammonia volatilization upon urea addition, either in 
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vitro or in soils.7-12 These studies commonly assert that NBPT has little or no effect as a 
urease inhibitor, while it must be converted to its oxo-analogue, N-(n-butyl)phosphoric 
triamide (NBPTO), in order for a strong inhibition to occur. Also, the latter conversion 
takes place predominantly in soils, rather than in solution. In 2001, Kot and coworkers 
partially reverted previous evidences, demonstrating that NBPT itself is able to inhibit 
plant urease, even though its efficacy is smaller than its oxo-analogue.13 
In the present work a biochemical and structural characterization of the NBPT inhibition 
on two ureases, the bacterial enzyme from Sporosarcina pasteurii (SPU) and the plant 
enzyme from Canavalia ensiformis (jack bean, JBU) is reported. The results of the 
kinetic experiments prove that NBPT acts as a slow-binding inhibitor of the enzyme. The 
X-ray crystal structure of SPU inhibited by NBPT, determined at 1.28 Å resolution, 
demonstrates that the inhibitor directly interacts with the nickel ions in the urease active 
site, undergoing an in situ hydrolysis that generates a tetrahedral moiety blocking the 
active site in a fashion similar to that proposed for phosphoramides. 
 
 
4.2 Materials and methods 
 
4.2.1 Enzyme and inhibitor sources 
 
Urease from Sporosarcina pasteurii (SPU) was expressed and purified from the native 
source following a previously described procedure.14 Protein quantification was carried 
out by measuring the activity using a pH-STAT method15 and considering its specific 
activity of 2500 units mg-1 and Mr = 250 kDa. Urease from Canavalia ensiformis (jack 
bean, JBU) type C-3, powder (!600,000 units/g) was purchased from Sigma-Aldrich and 
was quantified following manufacturer’s information. 
N-(n-butyl)thiophosphoric triamide was purchased from Apollo Scientific. 
 
 
4.2.2 Enzymatic assays 
 
Pre-incubation experiments were carried out at room temperature by using a 
spectrophotometric assay and an Agilent Cary 60 UV-Vis Spectrophotometer. The pH 
indicator cresol red was used to monitor the overtime increase of pH due to urease 
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activity, following a previously described procedure.14 In the case of SPU-NBPT 
experiments, a solution of 50 nM SPU dissolved in 2 mM HEPES buffer at pH 8.0, 
containing 1 mM Na2SO3, was diluted 50 times using a 2 mM HEPES buffer solution at 
pH 8.0, containing 30 mg L-1 cresol red and 2 mM EDTA (Buffer CR). In the case of 
JBU-NBPT experiments, a solution of 250 nM JBU dissolved in 20 mM HEPES buffer, 
at pH 8.0, was diluted 50 times in the same Buffer CR. Then, solutions containing 
different concentrations of NBPT, in 2 mM HEPES buffer at pH 8.0, were added to either 
the SPU or the JBU urease solutions prepared as described above (final concentration of 
NBPT in the range 0-400 !M). The time zero of the pre-incubation experiment was 
considered as the time of the mixing of the urease and the inhibitor solutions. 
Subsequently, at fixed times, aliquots of the pre-incubation solutions were taken and 
added to a solution containing urea to a final concentration of 100 mM, and the time-
dependent absorbance change at 573 nm was monitored. The enzyme activity was 
calculated as the slope of the linear portion of the absorbance vs. time curve. The values 
of the residual activity at different pre-incubation time points were then calculated by 
normalizing each activity value to the activity measured at time zero of pre-incubation. 
Residual activities were finally expressed as percentage values, as a function of pre-
incubation time. 
 
 
4.2.3 Crystallization, data collection and structural determination 
 
A 11 mg mL-1 urease solution in 20 mM HEPES buffer at pH 7.5, containing 50 mM 
Na2SO3 and 2 mM EDTA, was incubated for 1 h in the presence of increasing 
concentrations of NBPT (in the range 1-16 mM) dissolved in the same buffer. 
Subsequently, 2 !L of each SPU-NBPT solution was diluted with 2 !L of a precipitant 
solution consisting in 1.6-2.0 M ammonium sulphate dissolved in 50 mM sodium citrate 
buffer at pH 6.3, and containing the same concentration of NBPT. Crystallization trials 
were performed at 293 K using the hanging-drop method, equilibrating the drop against 1 
mL of the precipitant solution using 24-well XRL Plates (Molecular Dimensions). Rice-
shaped protein crystals appeared in most of the crystallization conditions within two 
weeks and grew to a size of 0.1 x 0.1 x 0.3 mm3. Crystals were scooped up using 
cryoloops and transferred to a cryoprotectant solution of 20% ethylene glycol dissolved in 
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50 mM sodium citrate buffer at pH 6.3, also containing 2.4 M ammonium sulphate and 
the same concentration of NBPT present in the crystallization drop. The crystals were 
then flash-cooled and stored in liquid nitrogen. 
Diffraction data were collected at 100 K using synchrotron radiation at the EMBL P13 
beamline of the Petra III storage ring, c/o DESY, Hamburg (Germany). The beamline was 
equipped with a Si(111) crystal monochromator (FMB Oxford), a DECTRIS Pilatus 6M 
detector, and a MD2 goniometer (MAATEL-EMBL) with a horizontal spindle axis. 
Reflection images were recorded by performing helical scans along the crystal to achieve 
higher resolution by minimizing radiation damage. 
Data processing and reduction was carried out with XDS16 and AIMLESS.17 The crystals 
were isomorphous with respect to those of native urease and other complexes of the same 
enzyme. The crystal structure of SPU in complex with diamidophosphate (PDB code 
3UBP, 2.00 Å resolution)5 devoid of solvent molecules and ligands, was used as a initial 
model for the rigid body refinement of the !"# SPU trimer, carried out using Refmac.18 
Model building and water or ligand addition/inspection were conducted using Coot.19, 20 
The structure was isotropically refined, including the hydrogen atoms in the riding 
positions, and then anisotropically refined to final R and Rfree of 11.18 and 13.99, 
respectively. The X-ray diffraction data and final refinement statistics are given in Table 
1. Figures were generated using PyMol (The PyMOL Molecular Graphics System, 
Version 1.8 Schrödinger, LLC.), and CrystalMaker (http://www.crystalmaker.com). 
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Table 1: Data collection, processing and refinement statistics  
Data collection  
Wavelength (Å) 0.9537 
Detector DECTRIS Pilatus 6M 
Crystal-to-Detector distance (mm) 225.3 
Oscillation angle (degrees) 0.100 
Number of images 1300 
Space group P6322 
Unit cell (a, b, c, Å) 131.74, 131.74, 188.93 
Resolution range (Å)1 97.67 – 1.28 
Total number of reflections1 3479631 (171907) 
Unique reflections1 243949 (11805) 
Multiplicity1 14.3 (14.6) 
Completeness1 (%) 99.4 (98.1) 
Rsym1,2 (%) 0.117 (2.260) 
Rpim 1,3 (%) 0.033 (0.625) 
Mean I half-set correlation CC(1/2) 1 0.999 (0.673) 
Mean I/!(I)1 15.9 (1.5) 
Refinement statistics  
Number of monomers in the asymmetric unit 3 
Rfactor4 (%) 11.18 
Rfree4 (%) 13.99 
Cruickshank’s DPI for coordinate error5 based on Rfactor (Å) 0.030 
Wilson plot B-factor (Å2) 10.4 
Average all atom B-factor6 (Å2) 16.645 
RMS (bonds)4 0.01 
RMS (angles)4 1.477 
Total number of atoms 7055 
Total number of water molecules 766 
Solvent content (%) 55.52 
Matthews Coefficient (Å3/Da) 2.76 
Ramachandran plot7  
Most favored regions (%)  89.9 
Additionally allowed regions (%) 9.2 
Generously allowed regions (%) 0.8 
Disallowed regions (%)  0.2 
 
1highest resolution bin in parentheses; 
2!!"# ! !! ! ! !!!"# !!!!"#  , where I is the intensity of a reflection, and !  is the mean intensity of all symmetry 
related reflections j; 
3!!!!! ! ! !! ! ! ! !! ! !!!"# ! ! !!!!"#  , where I is the intensity of a reflection, and !  is the mean intensity 
of all symmetry related reflections j, and N is the multiplicity;21 
4taken from REFMAC;18 Rfree is calculated using 5% of the total reflections that were randomly selected and excluded 
from refinement;  
5!"# ! !!"#$%& ! !!"# ! !"#$%!! !!"#$%!!"#$!!!"#"$%  , where Natoms is the number of the atoms included in the refinement, Nrefl 
is the number of the reflections included in the refinement, Dmax is the maximum resolution of reflections included in the 
refinement, compl is the completeness of the observed data, and for isotropic refinement, Nparams ! 4Natoms;22  
6taken from BAVERAGE;23 
7taken from PROCHECK.23 
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4.3 Results and discussion 
 
4.3.1 Biochemical characterization of NBPT inhibition on urease 
 
The inhibition of NBPT on SPU and JBU was investigated by performing pre-incubation 
experiments at pH 8.0, and the results are shown in Figure 1 (see Appendix A for details 
about pre-incubation experiments). The calculated values for the percentage residual 
activity as a function of pre-incubation time were optimally fitted to a single exponential 
decay (Figures 1A and 1C). The resulting pseudo-first order constants kobs (s!1) showed a 
linear dependence on the concentration of NBPT (Figure 1B and 1D). The value for the 
second-order kinetic constant resulting from the linear fit of the kobs vs. NBPT 
concentration plot is 29.9 ± 0.4 M!1s!1 and 24.2 ± 0.3 M!1s!1 for the inhibition of NBPT 
on SPU and JBU, respectively. This second-order kinetic constant refers to the 
association constant kon that regulates the formation of the enzyme-inhibitor complex (see 
Appendix A for theoretical details regarding kinetic constants). The kinetic behaviour 
observed in the pre-incubation experiments is consistent with a slow-binding inhibition 
mechanism that follows a first-order kinetic with respect to both the two reactants 
(SPU/JBU and NBPT). Furthermore, the similar values obtained for kon in the case of 
bacterial and plant ureases demonstrate that the reaction of NBPT with the active site of 
urease and the consequent formation of stabilizing interactions can be generalized among 
ureases from different organisms, without any species-specific effect. The measured 
values of kobs (kon) are similar but slightly different from the value previously reported by 
Kot and co-workers for the inhibition of JBU by NBPT (110 ± 10 M!1s!1).13 Probably, 
this difference can be ascribed to the different experimental setup used. In fact, they have 
determined the association constant by performing time-course experiments. In such 
experiments, substrate (urea) and inhibitor are simultaneously added to the enzyme, so 
that competition effects can arise, affecting the measurement.  
In order to determine the inhibition constant Ki, (given by the koff/kon ratio, see Appendix 
A for details) the value of the first-order rate constant koff, that regulates the dissociation 
of the enzyme-inhibitor complex, would be also needed. In general, a good estimation of 
koff can be derived from the y-intercept of the linear fit of the kobs vs. [I] plot. As one can 
notice from Figures 1B and 1D, in the experimental conditions used for this measurement 
the linear fit appears to intercept at the origin, suggesting a very low dissociation constant 
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value. The value of koff previously reported in the case of JBU inhibition by NBPT is 
(0.17 ± 0.03) ! 10-4 s"1,13 confirming that NBPT hardly dissociates from the urease active 
site. 
!
Figure 1: Inhibition of ureases by NBPT. (A and C) SPU and JBU residual activities vs. time plots at different NBPT 
concentrations, respectively. (B and D) Linear plots of kobs as a function of NBPT concentration in the case of SPU 
and JBU, respectively. In both panels, the lines represent the result of an exponential or linear fit of the data. 
 
 
4.3.2 Structural analysis of SPU inhibited by NBPT 
 
The structure of SPU co-crystallized in the presence of NBPT reveals the well-known 
quaternary structure of Sporosarcina pasteurii urease, consisting of a (#$%)3 trimer of 
trimers where the # subunit is formed by an (#$)8 barrel domain and a $-type domain, the 
$ subunit is mainly characterized by $ strands, and the % subunit consists of #$ domains. 
The refined crystallographic model closely matches that of native urease (PDB code 
4CEU),24 with a global root mean square deviation (RMSD) between their backbones 
equal to 0.17, 0.20 and 0.14 Å for the #, $ and % subunits, respectively. A more detailed 
per-residue analysis is presented in Figure 2. A comparison between the backbones of the 
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native and inhibited enzymes in terms of pairwise RMSD per residue (Figure 2A) 
displays a considerable superimposition of both the ! and " subunits. However, a 
substantial difference in the residue range 310-340 belonging to the # subunit comes to 
light. This region corresponds to a conserved highly flexible helix-loop-helix motif, also 
known as mobile flap, which controls the access of the substrate into the active site cavity 
of urease.25 Several crystallographic studies on native SPU, as well as other inhibited 
forms of the enzyme, have described the flap in a open conformation.25 A remarkable 
exception is given by the X-ray crystal structure of SPU inhibited by diamidophosphate 
(DAP), a transition state analogue that is generated in situ by the enzymatic hydrolysis of 
phenylphosphorodiamidate (PPD).5 This model has the flap in a closed conformation, the 
latter being proposed to stabilize the intermediate of the catalysis. The evaluation of 
pairwise RMSD per residue between the backbones of the DAP- and NBPT-inhibited 
enzymes (Figure 2B) yields in small values for the region comprised in the 310-340 
residue range of the # subunit, thus revealing the closed conformation of the mobile flap 
in the NBPT-inhibited SPU.  
 
Figure 2: Pairwise root mean square deviation (RMSD) per residue. (A) Comparison between the !, " and #  
subunits in the native (PDB code 4CEU) and NBPT-inhibited SPU. (B) Comparison between the !, " and #  subunits 
in the DAP- and NBPT-inhibited SPU. The region belonging to the mobile flap is comprised in the 310-340 residue 
range of the ! subunit. 
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The electron density belonging to the protein active site is well defined (Figure 3). The 
overall architecture of the active site, in terms of those residues that directly interact with 
the two Ni(II) ions, is highly conserved with respect to the native enzyme.5, 24 The two 
Ni(II) ions are well ordered [B-factors of 11.6 and 10.5 Å2 for Ni(1) and Ni(2), 
respectively] and are separated by 3.7 Å, a distance similar to that found in the native 
enzyme (3.6 Å). The two Ni(II) ions are bridged by the carboxylate group of the 
carbamylated Lys!220*, which is bound to Ni(1) by O"1 (at 2.0 Å) and to Ni(2) by O"2 (at 
2.0 Å). Ni(1) is further coordinated by His!249 N# (at 2.0 Å) and by His!275 N$ (at 2.0 Å), 
whereas Ni(2) is bound to His!137 N$ (at 2.1 Å), His!139 N$ (at 2.1 Å) and Asp!363 O#1(at 
2.1 Å). The unbiased omit electron density map shown in orange in Figure 3 (calculated 
with Fourier coefficients Fo-Fc and phases from the refinement of NBPT-inhibited SPU 
structure using the DAP-inhibited SPU structure as an initial model after removal of the 
DAP moiety and other solvent/ligand molecules), as well as the 2Fo-Fc electron density 
map, reveal the presence of additional electron density around the two Ni(II) ions that 
does not match the solvent molecules usually present in the active site of native SPU. 
This electron density has a tetrahedral shape and indicates the presence of a non-protein 
ligand that completes the coordination spheres of the two Ni(II) ions by binding to them 
through three atoms, with a fourth atom pointing away from the bimetallic centre. This 
tetrahedral arrangement exactly replaces the cluster of four water molecules existing in 
the active site of enzyme in its resting state. 
 
Figure 3: Atomic model of the active site of SPU inhibited by NBPT. The nickel-coordination environment is shown 
superimposed on the final 2Fo–Fc electron density map contoured at 1.5 ! (cyan), while the unbiased Fo–Fc omit map 
corresponding to the ligand is shown contoured at 3 ! (orange). Carbon, nitrogen, oxygen and nickel atoms are 
grey, blue, red and green, respectively. 
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Considering the presence of NBPT in the crystallization solution, attempts to fit this 
entire molecule into such an electron density failed, because the latter lacks the portion 
ascribable to the NBPT butyl group. As described in the introduction of this chapter, the 
ability of urease to hydrolyse amides and esters of phosphoric acid in situ is well-
documented in the literature.2 Moreover, the crystallographic study on the inhibition of 
SPU by PPD (PDB code 3UBP), demonstrated that PPD undergoes an hydrolytic event 
by the enzyme to give phenol and DAP, the latter acting as the actual inhibitor by 
mimicking the tetrahedral transition state that would occur during the hydrolysis of urea.5 
NBPT is a thiophosphoric triamide, with an n-butyl amine as a group bound to the 
phosphorous atom. The enzymatic hydrolysis of such a compound would result in the 
formation of a diamidothiophosphate, with the release of n-butyl amine. It is also known 
that phosphoramides undergo uncatalysed hydrolysis in solution.26 In the case of NBPT, 
such a hydrolysis would result in the loss of ammonia, rather than n-butyl amine (due to 
the smaller basicity of the former). Hence, in solutions of NBPT, three different species 
can simultaneously be present (Figure 4): i) N-(n-butyl)thiophosphoric triamide (NBPT), 
ii) N-(n-butyl)thiophosphoric diamide (NBPD), and iii) N-(n-butyl)thiophosphoric acid 
(NBPA), so that the three theoretical derivatives originated upon hydrolysis by urease 
would be i) di-amidothiophosphoric acid (DATP), ii) mono-amidothiophosphoric acid 
(MATP), and iii) thiophosphoric acid (TP), with their relative conjugate bases. 
 
!
Figure 4: Schematization of the hydrolytic event catalysed by urease on NBPT derivatives. The three NBPT 
derivatives that can be originated by the uncatalysed reaction occurring in solution and the products generated by 
the subsequent enzyme hydrolysis are represented on the left and on the right, respectively. The hydrolysis 
performed by urease on all these derivatives results in the release of a molecule of n-butyl amine. 
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Three independent refinement procedures were therefore carried out by modelling DATP, 
MATP or TP into the additional electron density shown by the omit electron density map. 
The following analysis was thus performed in order to discern between the three 
possibilities on a structural basis and chemical grounds. Two main criteria were used to 
understand the correct orientation of the ligand bound to the two Ni(II) ions. First, the 
large scattering factor of sulphur allowed to unequivocally locate its position as the distal 
atom pointing away from the bimetallic centre. Second, as concluded in the case of the 
PPD-to-DAP conversion in the presence of SPU,5 NBPT would undergo an initial 
nucleophilic attack on the P atom by the activated hydroxide ion located in the bridging 
position of the binuclear metallic centre, with the subsequent release of n-butyl amine and 
the formation of a tetrahedral moiety that has the hydroxyl functionality bridged between 
the two Ni(II) ions. These conclusions are schematically reported in Figure 5. In such a 
context, the identity of the terminal ligands L1 and L2 bound to Ni(1) and Ni(2), 
respectively, can be provided by a structural analysis, resulting in the identification of the 
actual moiety that binds to the active site of SPU. Indeed, as shown in Figure 5, the L1 
atom bound to Ni(1) must have two non-bonding electron pairs available, one deputed to 
coordinate Ni(1) and the other to receive a hydrogen bond from His!222 N" (at 2.71 Å) 
that is protonated, as inferred by the interaction of His!222 N# with the peptide NH group 
of Asp!224 (at 2.9 Å). In such a situation, an hypothetical P-NH2 group would not satisfy 
this requirement, because in this case the only lone pair on the N atom would be needed 
to coordinate Ni(1); on the other hand, a P-OH group bound to Ni(1) would satisfy this 
criterion, because the O atom would have two lone pairs. A similar analysis revealed the 
presence of two hydrogen bonding acceptor atoms in the vicinity of the L2 atom bound to 
Ni(2), namely the backbone carbonyl O atoms of Ala!170 and Ala!366 (both at 3.0 Å). This 
implies that L2 acts as a two-hydrogen bonding donor, suggesting the presence of a P-
NH2 group bound to Ni(2). These preliminary structural analysis implies that MATP is 
the moiety bound in the active site of SPU, with two P-OH groups located at the bridging 
(LB) and L1 positions, respectively, and a P-NH2 group located at the L2 position, with the 
S atom located at the distant LD position, pointing away from the Ni(II) ions and towards 
the active site entrance. 
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Figure 5: Structural scheme showing the hydrogen-bonding network between the nickel-bound thiophosphoramide 
derivative and the surrounding residues at the active site of SPU. 
 
In order to support this conclusion, a statistical analysis of the B-factor values for the 
atoms bound to the Ni(II) ions in the alternative refinements was carried out (Table 2). 
The refined B-factor value provided for the L1 atom bound to Ni(1) is significantly 
smaller in the case of DATP (9.6 Å2) than in the case of MATP (12.1 Å2) or TP (12.2 Å2), 
and even smaller than that of the Ni(II) atoms, an unrealistic result that strongly supports 
the presence of a P-OH group in the L1 position. The refined B-factor value provided for 
the L2 atom bound to Ni(2) is significantly higher in the case of TP (14.3 Å2) than that 
found for MATP (11.6 Å2), the latter being very close to the B-factor of Ni(2) (10.5 Å2), a 
more realistic result that strongly supports the presence of a P-NH2 group at the L2 
position. Altogether, these structural data strongly support the presence of a MATP 
moiety as the actual inhibitor found in the active site of urease crystallized in the presence 
of NBPT. 
 
Table 2: B-factor values for the independently refined DATP, MATP and TP at 1.28 Å 
 
 
 
 
 
The final refinement procedure was therefore performed by modeling MATP in the active 
site of the inhibited urease crystal structure (Figure 6). MATP binds to Ni(1) and Ni(2) by 
its OL1 and NL2 atoms, respectively. The second MATP oxygen atom (OB) symmetrically 
bridges the two Ni(II) ions, while the sulfur atom points away from the binuclear metallo-
Ligand DATP 1 @ 1.28 Å MATP @ 1.28 Å TP @ 1.28 Å 
Ni(1) 11.5 11.5 11.5 
Ni(2) 10.5 10.5 10.5 
P 13.1 12.9 12.8 
LB 13.0 12.9 13.0 
L1 9.6 12.1 12.2 
L2 11.5 11.6 14.3 
LD 14.6 14.6 14.6 
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center towards the active site cavity opening (Figure 6A). Refined selected distances and 
angles are given in Table 3. An extended network of hydrogen bonds stabilizes the 
MATP molecule within the active site cavity (Figure 6B). As previously described for the 
case of PPD-to-DAP,5 the Ni(1)-bound MATP oxygen atom (OL1) receives a hydrogen 
bond from His!222 N" (at 2.71 Å), while the Ni(2)-bound MATP NH2 group (NL2) acts as 
a donor of two hydrogen bonds to the carbonyl backbone O atoms of Ala!170 (at 3.0 Å, 
not shown) and Ala!366 (at 3.0 Å), respectively. Furthermore, the nickel-bridging MATP 
oxygen atom (OB) is at hydrogen-bonding distance from Asp!363 O#2 atom (2.6 Å), 
implying the presence of a proton shared between the latter and the nickel-bridging 
MATP oxygen. Finally, the sulfur atom of MATP is at hydrogen-bond distance from the 
His!323 N" (3.24 Å). The P-S bond length (1.95 Å) in MATP molecule is consistent with 
the presence of a double bond between the phosphorous and the sulfur atoms, thus 
suggesting the protonated state of His!323 N". Moreover, it strongly supports the idea that 
the actual inhibitor is the neutral amidothiophosphoric acid (NH2)PS(OH)2, with the 
orientation of MATP in the active site of urease that closely matches that of DAP in the 
structure of SPU inhibited by DAP.5 
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Table 3: Selected distances and angles around the Ni(II) ions in the crystal structure of native SPU (PDB 
code 4CEU), DAP-inhibited SPU (PDB code 3UBP) and MATP-inhibited SPU 
Ni - L Distances (Å) 4CEU 
@ 1.50 Å 
3UBP 
@ 2.00 Å 
SPU-MATP 
@ 1.28 Å 
Ni(1) - Lys220* O!1 1.94 2.06 1.98 
Ni(1) - LB 2.08 2.32 2.16 
Ni(1) - L1 2.24 2.24 2.12 
Ni(1) - His249 N" 2.03 1.99 2.00 
Ni(1) - His275 N# 2.02 2.10 2.02 
Ni(2) - Lys220* O!2 2.08 1.92 2.05 
Ni(2) - LB 2.12 2.34 2.22 
Ni(2) - L2 2.07 2.32 2.17 
Ni(2) - His137 N# 2.11 2.13 2.10 
Ni(2) - His139 N# 2.08 2.16 2.11 
Ni(2) - Asp363 O"1 2.10 2.12 2.09 
Ni(1) ••• Ni(2) 3.67 3.82 3.72 
L1 ••• L2 2.37 2.55 2.60 
L - Ni - L Angles (°)    
Lys220* O!1 - Ni(1) - His249 N" 100.4 111.0 101.5 
Lys220* O!1 - Ni(1) - His275 N# 107.2 105.6 104.0 
Lys220* O!1 - Ni(1) - LB 96.6 95.4 96.8 
Lys220* O!1 - Ni(1) - L1 108.2 102.7 105.3 
His249 N" - Ni(1) - His275 N# 98.6 103.0 99.0 
His275 N# - Ni(1) - LB  94.6 87.4 94.9 
LB - Ni(1) - L1 67.0 66.9 69.4 
L1 - Ni(1) - His249 N" 89.3 87.9 87.2 
His249 N" - Ni(1) - LB 154.2 147.2 153.5 
His275 N# - Ni(1) - L1 141.6 143.2 148.0 
Lys220* O!2 - Ni(2) - His137 N# 90.8 90.0 90.4 
Lys220* O!2 - Ni(2) - His139 N# 91.7 94.0 91.5 
Lys220* O!2 - Ni(2) - L2 92.9 99.4 98.7 
Lys220* O!2 - Ni(2) - LB 95.6 99.8 96.9 
Asp363 O"1 - Ni(2) - His137 N# 82.8 79.7 81.5 
Asp363 O"1 - Ni(2) - His139 N# 86.4 82.4 83.4 
Asp363 O"1 - Ni(2) - L(2) 94.5 92.3 91.4 
Asp363 O"1 - Ni (2) - LB 89.1 88.0 91.6 
L2 - Ni(2) – LB 67.7 70.6 69.3 
LB - Ni(2) - His137 N# 95.0 92.6 93.4 
His137 N# - Ni(2) - His139 N# 108.5 107.9 107.6 
His139 N# - Ni(2) - L(2) 88.4 86.9 88.7 
Lys220* O!2 - Ni(2) - Asp363 O"1 172.4 167.5 168.6 
LB - Ni(2) - His139 N# 155.3 155.2 157.4 
His137 N# - Ni(2) - L2 162.6 161.9 161.2 
Ni(1) - LB - Ni(2) 122.1 110.2 116.6 
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As described above, the conformational change involving the closing (or the opening) of 
the flap does not significantly modify the position of the active site residues directly 
involved in the binding of the Ni(II) ions. However, this event drastically changes the 
positions of some of the amino acid side chains that, though not directly involved in 
nickel binding, face the active-site cavity and are considered important for the catalytic 
mechanism. In particular Cys!322, His!323 and His!324, which belong to the flap region, are 
approximately shifted by 5 Å with respect to the structure of native SPU. The backbone 
of the Ala!366 residue is also affected by the conformational change of the flap, even 
though it does not belong to the flap region: while in the native SPU the carbonyl O atom 
of Ala!366 is turned away from the Ni(II) ions and points towards the active site entrance, 
in the SPU-MATP structure it is turned towards the bimetallic active site, at hydrogen-
bonding distance from the MATP nitrogen atom bound to Ni(2). 
 
!
Figure 6: Atomic model of the active site of MATP-bound SPU. (A) Nickel-coordination environment is shown 
superimposed on the final 2Fo–Fc electron density map contoured at 1.5 !. The map of the inhibitor is shown in blue. 
(B) The crystallographic structure of the same environment is represented. Putative hydrogen bonds are shown as 
thin blue lines. Spheres are drawn using the relative atomic radii values in CrystalMaker. Carbon, nitrogen, oxygen, 
sulphur, phosphorous and nickel atoms are grey, blue, red, yellow, orange and green, respectively. 
 
These structural results further corroborate the current most accepted model for the 
reaction mechanism through which urease catalyses the hydrolysis of urea (described in 
details in Annex 1). The closing of the flap and the peculiar tetrahedral shape of MATP, 
as well as DAP, induce the formation of a strong hydrogen-bond network that blocks the 
flap in a closed conformation, thus disabling the protein for further substrate hydrolysis. 
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4.4 Conclusions and future perspectives 
 
In this work a biochemical and structural study on the inhibition of urease by N-(n-
butyl)thiophosphoric triamide (NBPT) has been carried out. Kinetic experiments have 
pointed out the slow-binding inhibition mode of NBPT. Structural data support the idea 
that NBPT in its mono-deaminated form first interacts with the active site. Our current 
hypothesis is that, independently on the rate of the uncatalysed hydrolysis of NBPT to 
give NBPD or NBPA and the concomitant presence of other hydrolysed species, the 
active site of urease will select only NBPD to enter the active site, the latter being the 
only NBPT derivative presenting the correct functionalities in order for its interaction 
with the bimetallic active site to be stabilized and the following hydrolytic event to occur. 
After the binding to the two Ni(II) ions, NBPD undergoes in situ hydrolysis with the 
formation of a tetrahedral moiety that mimics the transition state of the reaction of urea 
hydrolysis. This intermediate analogue stabilizes the mobile flap, involved in the entrance 
of substrate in the active site, in a closed conformation, thus precluding the protein from 
further substrate hydrolysis. 
It is worth noting that this work is not to be understood as complete as some issues are 
still to be clarified. For example, efforts will be spent with the aim to research 
experimental evidences other than those provided by crystallographic results that would 
corroborate our structural information on MATP as the actual ligand in the active site of 
urease. These studies will involve both quantum-mechanical and/or docking calculations 
and analytic experiments, such as high-resolution mass spectrometry and 31P and 1H 
NMR. Another aspect to deal with is the determination of a reliable inhibition constant, 
Ki. First, differently from inhibitors that interact with enzymes through a rapid 
equilibrium, inhibition of slow-binding inhibitors is more complex to address because of 
their intrinsic time-dependent behaviour. Also, our data are consistent with the 
description of NBPT as a competitive inhibitor of urease, competing with urea for the 
binding to the active site. This fact complicates matters further, because the measured Ki 
value may also be affected by the concentration of substrate used in the experiments. 
Undeniably, this is the first study showing on a structural basis the efficacy of NBPT in 
inhibiting urease, a role so far ascribed only to NBPTO, the NBPT oxo-analogue. 
Globally, the biochemical and structural details provided by this work, together with the 
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future results that will clarify the aspects described above, will pave the way for a 
structure-based design with the aim to develop more efficient urease inhibitors necessary 
to regulate its activity and to counterbalance its adverse effects. 
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CONCLUSIONS 
 
Urease as is a nickel-dependent enzyme that catalyses urea hydrolysis, triggering an 
overall pH increase and causing negative effects for human health as well as agriculture. 
Therefore, a tight control of its activity is required and several classes of inhibitors were 
studied in the last decades. 
In this thesis, kinetic and structural studies of urease inhibition by a list of known 
inhibitors have been presented. The enzyme used for most of the experiments has been 
urease from the soil bacterium Sporosarcina pasteurii (SPU). In some cases, as the active 
site and, more in general, the overall structure of ureases is conserved, a plant urease from 
Canavalia ensiformis (jack bean, JBU) has been chosen as an alternative or a 
complement. The two main experimental approaches used in this work have been kinetic 
experiments and X-ray crystallography. In particular, five chemical species have been 
characterized both kinetically and structurally regarding their inhibitory properties 
towards urease: i) fluoride, ii) sulphite, iii) 1,4-benzoquinone (BQ), iv) catechol (CAT), 
and v) N-(n-butyl)thiophosphoric triamide (NBPT). The kinetic characterization of SPU 
inhibition by fluoride and sulphite has been carried out through isothermal titration 
calorimetry. Both these ligands act as reversible and pH-dependent inhibitors. In 
particular, fluoride acts with a mixed inhibition mechanism, while sulphite is a 
competitive inhibitor. The crystal structures of SPU inhibited by fluoride and sulphite, 
determined at 1.59 Å and 1.65 Å, respectively, have revealed that both inhibitors directly 
interact with the two Ni(II) ions in the active site. The study on the inhibition of urease by 
fluoride allowed an accurate depiction of the rationale for the inhibition mechanism, 
which further corroborated the currently accepted model for the catalytic mechanism. On 
the other hand, the coordination of sulphite to the two Ni(II) ions in the active site is 
unprecedented, and could stimulate scientists to develop inhibitors based on this scaffold. 
Differently from the previous cases, BQ and CAT have been kinetically characterized by 
using a spectrophotometric method. They both act as irreversible inhibitors of urease. The 
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inhibition mechanism of BQ, determined on SPU as a model enzyme, displays a classical 
exponential decay profile, with a very potent binding efficacy. Differently from the 
former, CAT has revealed a more complex inhibition behaviour, with an initial lag phase 
followed by a rapid increase of inhibition potency over time that has been interpreted as 
an inactivation process in which an autocatalytic radical-based mechanism is involved. X-
ray crystal structures of SPU bound to BQ and CAT (determined at 2.07 Å and 1.50 Å 
resolution, respectively) have revealed that they covalently bind to a conserved cysteine 
residue located on a flexible flap that, even though not directly involved in the catalysis, 
modulates the access of the substrate urea into the active site cavity. So far, these X-ray 
crystal structures are the only two protein structures deposited in the PDB showing a 
covalent inhibition caused by a quinone or catechol as an extra-protein ligand. 
In the last part of this work, a biochemical and structural characterization of urease 
inhibition by NBPT, a commercial product extensively used as a nitrogen stabilizer in 
agriculture, has been carried out. Biochemical experiments, performed by using a 
spectrophotometric method, have demonstrated that NBPT acts as a slow-binding 
inhibitor of urease, with an inhibition efficacy similar for bacterial and plant ureases. The 
X-ray crystal structure of SPU inhibited by NBPT disclosed that NBPT acts a suicide 
substrate. In fact, it is enzymatically hydrolysed in situ, with the formation of a 
tetrahedral product that directly interacts with the two Ni(II) ions in the active site with a 
very small dissociation constant. This is the first study that demonstrates, on a structural 
point of view and at atomic level, that NBPT is able to inhibit urease, reverting 
previously literature data that ascribed the inhibition process to its oxo-analogue, N-(n-
butyl)phosphoric triamide (NBPTO). 
The data reported in this dissertation, together with the knowledge on urease inhibitors 
already available in the literature, will pave the way towards a rational structure-based 
drug design, with the aim to develop new molecules acting as urease inhibitors. In 
particular, the three main scaffolds that will be investigated are quinones, polyphenols 
and phosphoramides, the latter in both their thio- and oxo-form. The analysis of the 
structure-activity relationships of the modified scaffolds will be of primary importance to 
further guide the drug discovery process, with the main goal being the development of 
new molecules with potential applications in medicine as well as in agro-environmental 
settings. 
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APPENDIX A 
 
AN OUTLINE OF BASIC ENZYMOLOGY 
 
A.1 A historical recap of enzymology 
 
Enzymology refers to a branch of science concerned with the study of enzymes. 
Historically, the term enzyme was first provided in 1877 by the German scientist Kühne, 
who combined concepts that the French chemists Payen and Pasteur previously learned 
by studying intra- and extra-cellular alcoholic fermentation in yeasts. In that period, 
biochemical identity of enzymes was unknown and “vitalism” (the hypothesis that living 
and non-living organisms are distinct because the former contain some non-physical 
element and are governed by different non-physical principles than the latter) was still a 
more than accepted scientific hypothesis. In the following years, two important 
milestones contributed to inaugurate enzymology, as we know it today. The first was 
provided by Buchner’s experiments in 1897, through which he demonstrated the ability 
of yeast extracts to carry out sugar fermentation processes even in the absence of living 
whole yeast cells.1 The second milestone was achieved in 1926, when James Sumner 
reported that enzymes were proteins and could be crystallized.2 For these extraordinary 
discoveries Buchner and Sumner were awarded the Nobel Prize in Chemistry in 1907 and 
1946, respectively. Looking more deeply into the enzyme mode of action, the initial 
evidence that enzymes form a complex with substrates in order for the reaction to occur 
was given in 1880 by Wurtz3 and in 1902 by Brown,4 who pointed out the peculiar 
behaviour of the interaction between enzymes and substrates that leads to the enzyme 
saturation effect. The qualitative evidences were finally rigorously defined in 
mathematical form by Henry,5 Michaelis and Menten,6 and Briggs and Haldane,7, who 
gave a great contribution to modern biochemistry. The brief list stated above is only an 
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example on how, in ca. fifty years, science went through the belief that living organisms 
were driven by vitalistic forces to a thorough understanding of the physical principles that 
regulate chemical reactions in living organisms, reaching a more chemical and molecular 
awareness. In the next paragraphs a brief description of the kinetics involved in enzyme-
catalysed reactions will be provided, focusing on the role of inhibitors in modulating 
enzyme activity. 
 
 
A.2 Enzyme kinetics 
 
An enzyme (E in the following schemes and equations) is a biological macromolecule, in 
most cases a protein, able to catalyse a certain chemical reaction in which a substrate (S) 
is transformed into a product (P), as described in the simplified Scheme 1. In order for 
this process to occur, enzyme and substrate must first interact in order to form a complex 
(ES) in the active site of the enzyme. 
 
 
E +S
k1
k!1
! "!!# !!! ES
k2" #" E + P  
Scheme 1 
 
ES complex represents a thermodynamic equilibrium, the latter being governed by k1, 
namely the second-order rate constant (M-1 s-1) that regulates the association rate of 
substrate end enzyme to give the ES complex, and by k-1, namely the first-order rate 
constant (s-1) that regulates the dissociation rate of the complex. The equilibrium 
dissociation constant (KS) that numerically quantifies this process is described by the ratio 
of k-1 to k1: 
 
KS =
[E][S]
[ES]
=
k!1
k1
 (A.1) 
 
Where [E], [S] and [ES] are the molar concentrations of E, S and ES, respectively. 
According to Scheme 1, the overall velocity (v) of an enzyme-catalysed reaction is 
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directly proportional to the concentration of the ES complex, and it can be described by 
the following first-order equation: 
 
 v = k2[ES]   (A.2) 
 
A first mathematical description of such a proportionality was developed by Henry5 and 
by Michaelis and Menten6 in 1903 and 1913, respectively. The so-called rapid-
equilibrium model assumes that, at any time, the concentration of substrate is much larger 
than the concentration of enzyme, the latter acting as a catalyser. Moreover, the velocity 
is measured in the initial stages of the reaction (initial velocity), so that the concentration 
of substrate already converted into products is negligible. In such an approach, rapid 
equilibrium between enzyme and substrate to form ES complex is followed by a slower 
conversion of ES complex to free enzyme and product(s), resulting in k2 << k-1, as defined 
in Scheme 1. According to this model, the ES complex can be described by the following 
expression: 
 
 
[ES] = [E][S]
KS + [S]
 (A.3) 
 
Where KS is the equilibrium dissociation constant as defined in Equation A.1. After the 
formation of the ES complex, the reaction proceeds through a number of subsequent 
chemical steps to give product(s). If the conversion passes through a single chemical step, 
the process is governed by the first-order rate constant k2, as shown in Scheme 1. In most 
of cases, however, product formation involves a series of rapid chemical events following 
the formation of ES complex. In such a complex contest, the rapid-equilibrium model 
includes all the rate constants controlling each singular chemical step in an overall first-
order catalytic rate constant kcat, with the following rearrangement of Scheme 1: 
 
 
E +S
k1
k!1
! "!!# !!! ES
kcat" #"" E + P !
Scheme 2 
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So that in the expression for the reaction velocity (Equation A.2) k2 is replaced by kcat as 
follows: 
 
 v = kcat[ES]   (A.4) 
 
The final expression for the rapid-equilibrium model, referred to as Henry-Michaelis-
Menten equation, combines Equations A.3 and A.4, in order to describe the dependence 
of initial velocity as a function of [S]: 
 
 
v =
kcat[E][S]
KS + [S]  
 (A.5) 
 
It has to be noted that at infinite substrate concentration, all the molecules of enzyme will 
be saturated by the substrate, so that [ES] = [E]. Therefore, at very high substrate 
concentration the term kcat[E] tends towards a maximum value, referred to as the 
maximum reaction velocity Vmax: 
 
 Vmax = kcat[E]   (A.6) 
 
An implementation to the rapid-equilibrium model was provided in 1925 by Briggs and 
Haldane, with the steady-state model.7 This model does not need that a rapid equilibrium 
occurs (k2 << k-1 is not a required assumption anymore), rather it assumes that the 
reaction will go towards a steady-state phase, during which the concentration of ES 
complex is constant, being the rate of ES formation (governed by k1) balanced by the 
dissociation rate of ES, either to give products or to dissociate back in E + S, and both 
giving the free form of the enzyme (governed by k-1 and k2). In steady-state conditions, 
the concentration of the ES complex as a function of [S] can be described by the 
following expression: 
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[ES] = [E][S]
[S]+
k!1 + k2( )
k1
 (A.7) 
 
As for the rapid-equilibrium model, we can assume the catalytic rate constant kcat as the 
overall rate constant that takes into account the contribution of singular rate events 
following the ES complex formation, so that we can combine Equations A.4 and A.7 to 
obtain the expression for the initial velocity as a function of [S]: 
 
 
v = kcat[E]
[S]
[S]+
k!1 + k2( )
k1
 (A.8) 
 
If we set the following simplification for the denominator: 
 
 
(k!1 + k2 )
k1
= KM  (A.9) 
 
Equations A.6, A.8 and A.9 can be combined to give the final expression for the steady-
state model: 
 
 
v =
Vmax[S]
[S]+ KM
  (A.10) 
 
Where KM is commonly referred to as Michaelis constant. Even though the above 
mathematical derivation has been provided by Briggs and Haldane7, Equation A.10 is 
commonly known as the Henry-Michaelis-Menten equation.  
A comparison between the expressions for the rapid-equilibrium and for the steady-state 
models allows one to realize that they slightly differ one to the other. In particular, in the 
rapid-equilibrium model the equilibrium dissociation constant KS is used, while the 
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steady-state model replaces it with KM. As stated above, Ks is a thermodynamic constant 
represented by the ratio of k-1 to k1, whereas KM has to be treated as a kinetic constant, 
rather than a thermodynamic one, represented by the ratio of (k-1 + k2) to k1. Therefore, 
despite different physical properties, Ks and KM become equivalent under the specific 
conditions in which k2 << k-1.  
 
 
A.2.1 Biochemical significance of KM and kcat 
 
On a chemical point of view, KM is a combination of first-order rate constants (k-1 and k2) 
with a second-order rate constant (k1). Therefore, it has units of molarity, as well as [S]. A 
first important biochemical significance of KM can be highlighted by carrying out an 
experimental measurement of the initial velocity at a concentration of substrate that 
exactly matches KM. In such conditions, Equation A.10 can be rewritten as follows: 
 
 
v =
Vmax[S]
[S]+ [S]
=
Vmax
2
 (A.11) 
 
From this treatment we can evince that KM experimentally matches the concentration of 
substrate yielding a half-maximal reaction velocity in the experimental conditions used. 
KM is a specific parameter characteristic of any enzyme-substrate pair. Even though it is 
not an equilibrium dissociation constant, KM directly reflects the reciprocal binding 
affinity for a certain enzyme towards a substrate. In general, for an enzyme able to 
catalyse a certain reaction on more than one substrate individually, a different KM value is 
reported for each enzyme-substrate couple. Urease, for instance, can hydrolyse urea and 
hydroxyurea among other substrates, with the two KM values falling in the range 1 - 4 
mM and 1 - 125 mM, respectively.8 Moreover, either by changing the experimental 
conditions, such as pH, temperature or ionic strength, or by using mutant species of an 
enzyme (with mutations belonging to residues involved in the enzyme-substrate 
recognition), KM values for an enzyme-substrate pair may be strongly affected. 
As described above, kcat is defined as a first-order catalytic constant that regulates the 
overall rate velocity of an enzyme-catalysed reaction. In literature, kcat is also known as 
the turnover number for the enzyme (s-1) in the presence of a certain substrate, describing 
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the number of catalytic events that take place per unit time. Biochemically, it represents 
the maximum rate of an enzyme reaction in the presence of infinite substrate availability. 
In particular, it is related to the biochemical steps subsequent to the formation of ES 
complex, so that alterations in the late phases of enzyme reaction would yield in changes 
of kcat. Similarly to KM, kcat perturbations can be caused by enzyme mutations as well as 
specific parameters related to the experimental conditions used. Since kcat is usually the 
result of the multiple contribution of sequential biochemical steps, it provides a lower 
edge on the first-order rate constant of the slowest step following substrate binding, i.e. 
the rate-determining step, whereas it can not give information on the rates of singular 
steps. 
As a conclusive remark, it has to be noted that the best description of the catalytic 
efficiency of a certain enzyme for a substrate is given by the ratio of kcat over KM (M-1 s-1). 
This is because substrate specificity often results from differences in the transition state, 
which is an activated E*S complex that it is formed after the ES complex formation. 
Therefore this would give differences in kcat rather than in KM, the latter being affected by 
the formation of initial ES complex only. 
 
 
A.2.2 Experimental determination of the kinetic parameters 
 
Nowadays, the most common way to determine the kinetic constants kcat and KM for a 
certain enzyme reaction consists in measuring the initial velocity at increasing 
concentrations of substrate (through one of the several experimental techniques 
available9), as shown in Figure 1. The obtaining results can be plotted and directly fitted 
by using Equation A.10 (Figure 1A).10 However, the widespread availability of user-
friendly nonlinear curve-fitting programs is relatively recent. In the past, determination of 
the kinetic constants was carried out by transforming the data to produce linear plots. The 
most commonly used method for linearizing such experimental data is the Lineweaver 
and Burk approach.11 Starting from the Michaelis-Menten equation, some rearrangements 
can be done in order to obtain a reciprocal form of the same equation, as follows: 
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1
v
=
KM
Vmax
1
[S]
!
"#
$
%&
+ 1
Vmax
 (A.12) 
 
This expression is described as a classical equation for a straight line (y= ax + b) where a 
is the slope and b is the y-intercept, while the independent and dependent variables x and 
y are described by the reciprocal value for the substrate concentration and the initial 
velocity, respectively (Figure 1B).10 In such a representation, the values for KM and Vmax 
can be graphically determined. In particular, the y-intercept corresponds to 1/Vmax value, 
while the slope of the resulting linear fit defines KM/Vmax. Additionally, the x-intercept 
value defines the -1/KM value. Even though the Lineweaver-Burk linearization approach 
is out-dated for enzyme-substrate kinetic parameters determination, it is still a valuable 
tool for certain purposes, as enzyme inhibition studies. Use of this approach will be 
discussed in the next paragraph. !!
"#$%&'! () Plots of initial velocity as a function of substrate concentration. (A) Initial velocity measurements of a 
typical enzyme carried out at increasing concentrations of substrate. The line corresponds to the fit of the data 
performed according to Equation A.10. (B) Lineweaver-Burk linearization of data in (A). In this case, the line 
corresponds to a linear fit of the data. Redrawn from the book chapter: Enzyme reaction mechanisms.10 
 
 
A.3 Enzyme inhibition 
 
Enzyme inhibition is a biochemical process through which the rate of an enzyme-
catalysed reaction is reduced or totally abolished by a ligand, namely an inhibitor. 
Modern chemists and biochemists spend efforts in studying the inhibition of enzymes for 
a number of reasons, most of them being related to pharmaceutical and agricultural 
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aspects. First, inhibitors are used as drugs to counteract diseases and metabolic 
dysfunctions caused by enzyme alterations.12 Also, inhibitors are commonly used in 
agriculture to contrast the negative effects potentially caused by insects and parasites, as 
well as soil processes that would determine problems in plant growth.13 Inhibitors are 
commonly sorted in two major classes, according to their inhibition mode: i) reversible 
inhibitors, that bind the enzyme in a reversible manner, and ii) irreversible inhibitors, also 
named inactivators, which irreversibly block the enzyme upon the formation of a covalent 
bond between some critical functionalities of the enzyme and the inhibitor itself.  
 
 
A.3.1 Reversible inhibitors 
 
In general, a reversible inhibitor (I) reversibly binds to a target enzyme to give an 
enzyme-inhibitor binary complex (EI) according to the following simplified reaction 
scheme: 
 
E + I
kon
koff
! "!!# !!! EI  
Scheme 3 
 
This chemical process is governed by kon, namely the second-order rate constant (M-1 s-1) 
that regulates the association of inhibitor end enzyme to give the EI complex, and by koff, 
namely the first-order rate constant (s-1) that regulates the dissociation of the EI complex. 
As for the case of the ES complex formation, a thermodynamic equilibrium can be 
quantified by the dissociation constant Ki (M), the latter being defined by the ratio of koff 
to kon: 
 
Ki =
koff
kon  
 (A.13) 
 
Where Ki also quantifies the inhibition strength of the inhibitor on the enzyme molecule, 
by means that at an inhibitor concentration equal to Ki value the enzyme is half-saturated 
by the inhibitor itself. To better understand the chemical bases of reversible inhibition, we 
should take into account that, in solution, the global system consists of three components, 
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the enzyme, the substrate and the inhibitor. Therefore, equilibrium is established as 
follows: 
 
 
In addition to the thermodynamic and kinetic constants already defined, Scheme 4 
introduces the parameter !, useful to exhaustively describe the inhibition process. In 
particular, ! quantifies the contribution to which the inhibitor affects the enzyme affinity 
for the substrate. If this contribution is zero, the enzyme maintains the same affinity for 
the substrate and ! = 1. Alternatively, if the binding of the inhibitor negatively influences 
further binding of substrate to the enzyme, ! > 1, becoming an infinite value for the case 
in which binding of substrate is completely excluded. Reversible inhibitors can be 
grouped in competitive, non-competitive or uncompetitive with respect to their inhibition 
mechanism, the latter being determined by a characteristic value of !.14 An overview on 
how reversible inhibitors affect the enzyme kinetics is given in Figure 2. 
A competitive inhibitor binds to the free enzyme only, competing with substrate for the 
binding to the enzyme active site. A reversible inhibitor cannot bind to the enzyme 
simultaneously to substrate so that, at any time, a fraction of the enzyme population will 
be bound to the substrate and will yield in ordinary catalytic activity, while another 
fraction will be bound to the inhibitor in a catalytically inactive form. This behaviour is 
described by ! tending towards an infinite value. As a consequence, a higher 
concentration of substrate will be needed by the enzyme in order to reach half-maximal 
velocity. In other words, an inhibitor that conforms to a competitive inhibition 
mechanism will affect the apparent value of KM that describes the enzyme-substrate pair, 
while Vmax is not affected. In the steady-state condition, the initial velocity of the reaction 
is affected as described by the following equation: 
 
Scheme 4 
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v =
Vmax[S]
[S]+ KM 1+
[I]
Ki
!
"#
$
%&
 (A.14) 
 
A representative plot of reaction velocity as a function of [S] in the presence of increasing 
concentrations of inhibitor is shown in Figure 2A. As briefly expressed in Section A.2.2, 
a useful tool for the analysis of the inhibition mode is the Lineweaver-Burk linearization 
method. In a representative Lineweaver-Burk plot the contribution of a competitive 
inhibitor to the kinetic properties of the system is well distinguishable (Figure 2B). In 
fact, the y-intercept value defining 1/Vmax is constant for all the concentrations of inhibitor 
tested, while the slope and the x-intercept, defining KM/Vmax and -1/KM, respectively, are 
strongly affected by changing [I]. 
A non-competitive inhibitor can bind to both the free enzyme E and the ES complex. In 
this case, two equilibrium dissociation constants, rather than only one, correctly define 
the global affinity of the inhibitor for the enzyme. The first one, namely Ki, describes the 
equilibrium between I and E, while the second dissociation constant, namely !Ki and 
sometimes referred to as Kiu, describes the equilibrium between I and the ES complex. In 
non-competitive inhibition the ! value can be bigger, equal or smaller than 1. In the first 
case, !Ki is higher than Ki, meaning that the inhibitor prefers to bind to the free enzyme, 
rather than the ES complex. In the case in which ! is smaller than 1, !Ki is smaller than 
Ki, resulting in a binding preference of the inhibitor for the ES complex. The special case 
in which ! is equal to 1 gives a !Ki value equal to Ki value. Chemically speaking, this 
corresponds to an equivalent affinity of the inhibitor for both the free enzyme and the ES 
complex. From a structural point of view, a non-competitive inhibitor negatively 
influences enzyme activity by interacting with a portion of the enzyme different from the 
active site. Hence, such an inhibitor does not compete with substrate for the active site of 
enzyme. As a consequence, measurements of the reaction rate in the presence of a non-
competitive inhibitor would result in a strong influence on the apparent Vmax, while the 
apparent KM is not affected. A general non-competitive inhibitor affects the initial 
velocity as described by the following equation: 
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v =
Vmax[S]
[S] 1+ [I]
!Ki
"
#$
%
&'
+ KM 1+
[I]
Ki
"
#$
%
&'
 (A.15) 
 
A representative plot of reaction velocity as a function of [S] measured at increasing 
concentrations of inhibitor is shown in Figure 2C. The resulting Lineweaver-Burk plot 
(Figure 2D) points out the decreasing trend of Vmax upon increase of inhibitor 
concentration (the y-intercept, defining 1/Vmax, increases by increasing the concentration 
of inhibitor tested). In such an inhibition mode, the x-intercept gives information about 
the magnitude of !. In fact, the linear fitting would intercept above or below the x-axis in 
the case of ! > 1 and ! < 1, respectively. 
Differently from previous cases, an uncompetitive inhibitor binds to the ES complex 
only. In order for the interaction between E and I to occur, formation of the ES binary 
complex is needed. An uncompetitive inhibitor affects the enzymatic activity determining 
a decrease of both apparent Vmax and KM values that is proportional to [I]. In 
uncompetitive inhibition ! is always smaller than 1. This behaviour reflects a decrease of 
the dissociation constant that describes the equilibrium between I and the ES complex 
!Ki, the latter becoming the only significant term in the rate velocity equation as follows: 
 
 
v =
Vmax[S]
[S] 1+ [I]
!Ki
"
#$
%
&'
+ KM
 
(A.16) 
 
The characteristic plot that describes the contribution of an uncompetitive inhibitor to the 
initial velocity as a function of [S] is shown in Figure 2E. The resulting Lineweaver-Burk 
plot (Figure 2F) yields in a series of parallel lines, where the 1/Vmax value is not constant 
at increasing concentrations of inhibitor, while KM/Vmax is constant. 
The global view of the different reversible inhibition modes allows one to compare the 
general equations that describe each mode of action (Equations A.14, A.15 and A.16). In 
particular, it should be noted that both competitive and uncompetitive inhibitions could 
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be described as special cases of non-competitive inhibition where in turn !Ki and Ki 
become negligible.  
 
 
 
 
 
Figure 2: Steady-state velocity as a function of substrate concentration in the presence of different reversible 
inhibition modes. (A-B) Reaction velocity in the presence of a competitive inhibitor, untransformed and 
linearized data, respectively. (C-D) Reaction velocity in the presence of an uncompetitive inhibitor, 
untransformed and linearized data, respectively. (E-F) Reaction velocity in the presence of a non-competitive 
inhibitor, untransformed and linearized data, respectively. Redrawn from the book chapter: Reversible modes of 
inhibitor interactions with enzymes.14 
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A.3.2 Slow-binding inhibitors 
 
In reversible inhibition, a binding equilibrium for an enzyme-inhibitor system is 
established rapidly compared with the turnover rate of the enzyme-catalysed reaction. 
However, a distinct class of inhibitors, called slow-binding inhibitors, can alter enzyme 
activity by means of a slow interaction with the enzyme. In slow-binding inhibition, the 
equilibrium between enzyme, inhibitor, and enzyme-inhibitor (EI) complex is established 
on a time scale of seconds to minutes, so that the inhibition strength varies with time. For 
this reason, slow-binding inhibitors are also referred as to time-dependent inhibitors. 
They can act by the following two mechanisms: i) simple reversible slow-binding, also 
referred to as mechanism A,15 or ii) enzyme isomerization, also referred to as mechanism 
B,15 which are schematically represented in Scheme 5.  
Simple reversible slow-binding inhibition (Scheme 5A) involves the formation of a EI 
complex in a single step, whose equilibrium is regulated by smaller kon and koff than those 
regulating the ES complex formation. Hereafter, kon and koff will be referred to as k3 and a 
k-3, respectively. Thus, formation of ES complex is instantaneous, while formation of EI 
complex is much slower. Oppositely to the simple reversible slow binding, enzyme 
isomerization (Scheme 5B) involves a two-step process: first, enzyme and inhibitor form 
an EI complex through a rapid equilibrium governed by k3 and k-3. Next, the enzyme 
undergoes a slow isomerization step, governed by k4 and k-4, after which a new form of 
the complex, E*I, arises with increased affinity for the inhibitor. In this type of inhibition 
mechanism, the actual affinity has to be determined with respect to E*I complex rather 
than EI, so that any determination of Ki has to take into account this additional step. 
 
Scheme 5 
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Slow-binding inhibitors can be distinguished from classical reversible inhibitors by 
measuring the concentration of product [P] as a function of initial substrate and inhibitor 
concentrations over time (Figure 3).16 A simple experimental procedure able to point out 
a slow-binding inhibition mechanism is a time-course experiment, also known as 
progress-curve experiment. In the presence of a fast equilibrium inhibition process, 
product formation linearly increases over time. By contrast, in the presence of a slow-
binding inhibitor, product formation over time follows the behaviour represented in 
Figure 3A. In the initial phase of the reaction, [P] increases linearly with time. Here, the 
equilibrium between enzyme and inhibitor has not been established, so that the slope of 
the curve yields the initial velocity (v0) of the enzyme reaction. In the intermediate phase 
of the time course, a significant curvature in [P] as a function of time emerges. At this 
stage, enzyme and inhibitor are interacting, but the system has not reached equilibrium, 
yet. In the late phase of the reaction, the increase of [P] with time reverts to linearity, with 
a slope yielding the steady-state velocity (vs) value reached after the enzyme-inhibitor 
equilibrium has been established. A mathematical depiction of the progress curve as that 
described above is expressed by the following equation: 
 
 
[P] = vst +
v0 ! vs
kobs
1! exp !kobst( )"# $%  (A.17) 
 
Where kobs is the rate constant that regulates the conversion from the initial velocity phase 
to the steady-state velocity phase. As stated above, slow-binding inhibition occurs in a 
time scale within seconds and minutes. However, in some instances the establishing 
equilibrium is so slow that it may be convenient to determine the residual activity of the 
enzyme, by means of measuring the initial velocity of the reaction under study before and 
after the pre-incubation of enzyme and inhibitor, as a function of pre-incubation time 
(Figures 3B and 3C). The resulting experimental curve would thus be described by the 
following exponential decay expression: 
 
 vt = vs exp(!kobst)  (A.18) 
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Where vt is the reaction velocity measured after a pre-incubation time t and vs is the 
reaction velocity at pre-incubation time equal to 0. 
 
 
 
 
 
 
As we can notice by comparing the two alternative experimental setups, the process is 
described by a pseudo-first order time constant kobs that governs how fast the inhibition 
process takes place and that depends on concentration of inhibitor tested. In order to 
discern whether the inhibition is governed by a simple reversible or an enzyme 
isomerization mechanism, the dependence of kobs as a function of [I] must be defined 
(Figure 4).  
In the case of a simple reversible slow-binding inhibitor, kobs linearly depends on [I] by 
the following equation: 
 
Figure 3: Kinetic profile of a slow-binding inhibition (A) Typical progress curve for an enzyme reaction in 
the presence of a slow binding inhibitor. (B) Typical pre-incubation experiments in the presence of a slow-
binding inhibitor that conforms to a binding mechanism A. (C) Typical pre-incubation experiments in the 
presence of a slow-binding inhibitor that conforms to a binding mechanism B. Redrawn from the book 
chapter: Slow-binding inhibitors.16 
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 kobs = k3[I]+ k!3  (A.19) 
 
where k3 and k-3 can be graphically determined from the slope and the y-intercept of the 
resulting plot, respectively (Figure 4A). It has to be noted that k3, as well as the resulting 
Ki (Ki = k-3/ k3) is an apparent value, since it may be influenced on the concentration of 
substrate.  
In the case of an enzyme-isomerization mechanism, kobs hyperbolically depends on [I] as 
follows: 
 
kobs = k!4 +
k4
1+
Ki
app
[I]
"
#$
%
&'
 (A.20) 
 
where Kiapp represents the apparent inhibition constant value for the EI complex (fast 
equilibrium). The resulting plot will give k-4 and k4 + k-4 from non-zero y-intercept and the 
maximum asymptotic value of kobs, respectively (Figure 4B). Moreover, the concentration 
of inhibitor yielding a half-maximal value of kobs corresponds to Kiapp. This value can be 
then correlated to the true value of Ki by determining the inhibition mode of the molecule 
(i.e. competitive, non-competitive or uncompetitive) and by relating Ki to Ki*, the 
inhibition constant that regulates the high affinity E*I complex, by the following formula: 
 
 
Ki
* =
Ki
1+
k4
k!4
"
#$
%
&'
 (A.21) 
 
Figure 4: Plot of kobs as a function of [I] in the case of a slow-binding inhibitor that conforms to mechanism 
A (A) and to mechanism B (B), respectively. Redrawn from the book chapter: Slow-binding inhibitors. 
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A.3.3 Irreversible inhibitors 
 
The inhibition types discussed so far have reversibility as a peculiar common feature. 
Unlike the previous cases, irreversible inhibitors, also known as inactivators, are 
molecules that covalently bind to an enzyme, leading to its catalytic inactivation (Figure 
5).17 Kinetically, the formation of a covalent bond is a slower process as compared to the 
non-covalent interactions influencing equilibrium between an enzyme and a reversible 
inhibitor, therefore irreversible inhibition can be depicted as a particular case of slow-
binding inhibition. The distinctive trait of an irreversible inhibitor is its stoichiometric 
inhibitory action on the enzyme so that, whenever the concentration of the inhibitor is 
equal or higher than the [E], the steady-state velocity reached during a progress curve 
experiment will be zero (Figure 5A). The equation that describes the formation of product 
as a function of time for an irreversible inhibitor is a simplified form of that used for the 
slow binding inhibition, as follows: 
 
 
[P] =
v0
kobs
1! exp !kobst( )"# $%  (A.22) 
 
As for the reversible slow-binding inhibition, the inactivation rate of an irreversible 
inhibitor is determined by the dependence of kobs on the inhibitor concentration. In 
particular, there are three main mechanisms through which irreversible inhibition takes 
place (described in Scheme 6): i) non-specific affinity labelling, ii) quiescent affinity 
labelling and iii) mechanism based inactivation. 
 
 
(non-specific affinity label)    E + I kinact[I]! "!!! E-I
(quiescent affinity label)    E + I
k3[I]
k#3
! "!!!# !!!! EI
k4! "! E-I
(mechanism-based)    E + I
k3[I]
k#3
! "!!!# !!!! EI
k4
k#4
! "!!#!! EA
k5! "! E-A
!
Scheme 6 
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Generally, a non-specific affinity label is a molecule that is intrinsically prone to be 
chemically modified, as it contains chemical functionalities highly reactive towards 
complementary functional groups belonging to the enzyme. Thus, such an inactivator 
covalently modifies the enzyme in a non-specific manner, by binding many amino acid 
groups. Inactivation occurs through a single inactivation step, with kobs linearly dependent 
on [I], as shown in Figure 5B. The slope of the resulting linear fit gives a measure of the 
effectiveness of the inhibitor and it is reported in literature as kinact/KI. kinact and KI are 
usually complex rate constants. A full description of these parameters is available in 
literature18. Besides their complexity, kinact/KI ratio is the key metric that chemists and 
biologists use in order to compare the inactivation strength of a series of molecules during 
Structure-Activity Relationship (SAR) experiments. 
Slightly different from the non-specific affinity label, a quiescent affinity label is a 
molecule presenting two features: i) functionalities that reversibly interact with the target 
enzyme, and ii) weak electrophilic functionalities with a non-intrinsic reactivity. Such a 
molecule first reversibly interacts with the enzyme. In this contest, the enzyme can orient 
the molecule so that the covalent binding reaction can occur. This kind of inactivation is 
more selective than the nonspecific affinity label.  
Finally, a mechanism-based inactivator relies on its transformation, caused by a catalytic 
event performed by the enzyme, in order to become a species that may act either as an 
affinity label, a transition state analogue, or a tight binding reversible inhibitor.19 Since 
these molecules have to be processed by the active site during the first step, they 
necessary act as competitive inhibitors and are also named suicide substrates. The need of 
an initial reaction with the enzyme makes these inhibitors high selective, therefore quite 
useful as potential drugs.
 
 
As described above, in the quiescent affinity label and in the mechanism-based 
mechanisms the reaction passes through a two-step inactivation process. In both cases, 
kobs hyperbolically depends on the concentration of inhibitor (Figure 5C), resulting in a 
behavior described by the following equation: 
 
 
kobs =
kinact
1+
KI
[I]
!
"#
$
%&
 (A.23) 
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As for the previous case, the effectiveness of inactivation is given by the ratio of kinact on 
KI. 
 
 
  
Figure 5: Inactivation kinetics of irreversible inhibitors. (A) Progress curve for an enzyme reaction in the 
presence of an irreversible inhibitor. (B) A plot of kobs as a function of [I] for in the case of a non-specific 
affinity label. (C) A plot of kobs as a function of [I] in the case of an irreversible inhibitor that conforms to a 
two-step inactivation mechanism, either quiescent affinity label or a mechanism-based. Redrawn from the 
book chapter: Irreversible enzyme inactivators.17 
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APPENDIX B 
 
MACROMOLECULAR CRYSTALLOGRAPHY 
 
B.1 A brief history of macromolecular crystallography 
 
2014 was celebrated as the International Year of Crystallography (IYCr-2014) to 
commemorate the centenary of X-ray crystallography discovery, dated back in 1914. In 
that period Max von Laue, William Henry Bragg and William Lawrence Bragg were 
awarded Nobel prizes for Physics for having pioneered the use of X-rays in obtaining 
structural information from crystals.1, 2 Since that time, X-ray crystallography has come a 
long way. About biological macromolecular X-ray crystallography (usually referred to as 
bio-crystallography), a great number of brilliant discoveries have been achieved in a 
century. Among the others, three breakthroughs deserve a special mention. In 1926, 
Sumner demonstrated that enzymes were proteins and that they could be crystallized 
retaining their functions.3 In 1958, the first three-dimensional model of a protein, 
myoglobin, was published.4 In the same period, Watson and Crick structurally described 
for the first time the double helix of DNA.5 
Parallel to the exponential growth of bio-crystallography, the establishment of the Protein 
Data Bank (PDB)6, 7 as a single repository for structural models obtained by X-ray 
crystallography (and later for structures obtained by NMR spectroscopy, electron 
microscopy and other techniques) provided a unique resource for scientific community 
and determined a further increase of the structural information available on 
macromolecules. Nowadays, X-ray crystallography has become a technique of choice in 
the structural determination of proteins, as well as protein-protein/protein-nucleic acids 
complexes. Additionally, great developments in protein production methods (i.e. 
recombinant DNA techniques), establishment of crystallization facilities and 
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improvements in the hardware of X-ray sources (i.e. synchrotron radiation and free 
electron laser) have pushed X-ray crystallography towards the exploration of structure-
activity relationship (SAR) between proteins and ligands, such as substrates and 
inhibitors. In this context, elucidation of enzyme mechanisms, as well as specificity of 
protein-inhibitor interactions, led X-ray crystallography to become an important tool in in 
structure-based drug discovery and development. In this chapter the bases of 
macromolecular crystallography applied to proteins will be overviewed. 
 
 
B.2 Protein crystallization 
 
X-ray protein crystallography relies on the obtainment of a protein in a crystalline form. 
Crystallization of proteins is a physico-chemical process that proceeds through two steps: 
i) nucleation, a phase transition by which the protein passes from being in solution to an 
ordered solid state yielding assemblies referred to as critical nuclei, and ii) crystal 
growth.8 The crystallization process occurs in super-saturated conditions realized by 
reducing protein solubility, as described in Figure 1. Variation of experimental 
parameters as temperature, pH and ionic strength can induce super-saturation. However, 
this condition is frequently achieved by using precipitant agents, which reduce protein 
solubility by competing for water molecules, by increasing attraction between 
macromolecules, or by producing volume-exclusion effects.8 
 
 
Figure 1: The phase diagram shows an undersaturated region, in 
which the protein is soluble, and a supersaturated region, 
characterized by a non-equilibrium state in which the protein is 
beyond its solubility limit. The supersaturated region is divided 
in three zones. In the precipitation zone the conditions are too 
extreme and amorphous aggregation occurs. In the labile area 
nuclei can grow, while in the metastable area nuclei will develop 
into crystals. Equilibrium conditions are re-established by the 
formation of a solid state, either amorphous precipitate or 
crystals, until the saturation limit is attained. 
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Growing protein crystals is usually a two-step approach. First, initial crystallization 
conditions are pursued by the use of commercial crystallization screenings that combine 
potential crystallization solutions and conditions. At this stage crystal dimensions and 
diffraction properties are usually not satisfying. Therefore, a systematic variation of the 
initial crystallization parameters is carried out, by the use of trial matrices, in order to 
optimize crystallization conditions and obtain crystals suitable for X-ray diffraction 
experiments.9 
Nowadays, vapour diffusion and batch method are the most common approaches used for 
growing protein crystals.8 Vapour diffusion involves the establishment of supersaturated 
conditions upon equilibration of the ionic strength between a drop, containing the protein 
solution and some amounts of a precipitant, and the reservoir, containing a higher 
concentration of precipitant.10 On the other hand, the batch method is largely used for 
initial screening of crystallization conditions and it consists in adding the precipitant at 
supersaturated conditions and covering the solution with silicone oil.11 Other 
crystallization methods are dialysis and liquid-liquid diffusion.8 
Growing protein crystals in the presence of ligands may be desirable in at least two cases. 
First, for the initial phase estimation of structure factors, the insertion of heavy atoms is 
often needed. Moreover, the use of X-ray crystallography in the process of drug 
discovery implies the obtainment of a protein bound to drug-like molecules, in order to 
have structural information on their interaction. Although details on these subjects will be 
discussed in Section B.7 and in Chapter 1, respectively, here it is worth mentioning that 
these approaches can be accomplished by either co-crystallization, in which protein and 
ligand are pooled in the same crystallization drop in order for a co-crystal to grow, or 
soaking, in which a protein crystal is immersed in a ligand solution in order for the ligand 
to be bound into the protein crystal.10 
 
 
B.3 Crystals and symmetry 
 
In a protein crystal, as a particular case of a more general crystalline form, a protein 
(motif) is regularly repeated in the space by translational and symmetry operations. A 
basic tridimensional entity called unit cell, whose dimensions are defined by three vectors 
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a, b and c, while its angles are named !, " and #, undergoes a discrete translation in the 
crystal.12 A single unit repeated through symmetry operations forms the inner content of 
the unit cell. The smallest part of the unit cell not showing any symmetry element is 
referred to as asymmetric unit.12 The only symmetry operation occurring within the unit 
cell of a protein crystal is the rotation around an axis (the other two possible symmetry 
operations, reflection across a mirror plane and inversion through a point do not occur 
because of protein chirality). In general, the particular set of symmetry operations that 
order the content of a unit cell define 32 crystallographic point groups or crystal 
classes.13 However, due to protein chirality, in protein crystallography only 11 
crystallographic point groups occur, the latter describing 7 crystal systems. Moreover, the 
translational repetition of the unit cell in space originates a crystalline lattice, where each 
lattice point is defined as a specific arrangement of atoms reproduced many times in the 
crystal, each one having the same environment and orientation with respect to each other 
point in the lattice. The unit cell and the related lattice points can undergo a translation 
along the tridimensional lattice (x, y, z) equal to the length of each cell vector, a, b and c. 
Depending on the crystal system and how translations occur, 14 Bravais lattices can be 
produced. Location of the lattice points in the unit cell upon its translation in the lattice 
defines four centring types for the unit cell: i) primitive (P), ii) face-centred (F), iii) base-
centred (C), and iv) body-centred (I).13 Additionally to the rotation symmetry, the screw 
axes are an internal symmetry operation in protein crystals, where a rotation is combined 
with a translation parallel to the rotation axis. The overall combination of the point 
groups with the Bravais lattices and the internal symmetry operations originate 230 space 
groups.13 In protein crystallography this number is reduced to 65 chiral space groups.12 
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LATTICE 
PARAMETERS CRYSTAL SYSTEM 
POINT GROUP 
(HERMANN – MAGUIN NOTATION) 
CELL TYPE 
(BRAVAIS LATTICE) SPACE GROUP 
a!b!c 
"!#!$!90° TRICLINIC 1 P P1 
a!b!c 
"=$=90° 
#!90° 
MONOCLINIC 2 
P P2, P21 
C C2 
a!b!c 
"=#=$=90° ORTHORHOMBIC 222 
P P222, P2221, P21212, P212121 
I I222, I212121 
C C2221, C222 
F F222 
a=b!c 
"=#=$=90° TETRAGONAL 
4 P P4, P41, P42, P43 I I4, I41 
422 P 
P422, P4212, P4122, P41212, P4222, 
P42212, P4322, P43212 
I I422, I4122 
a=b!c 
"=#=90° 
$=120° 
TRIGONAL 
3 P P3, P31, P32 R* R3 
32 P 
P312, P321, P3112, P3121, P3212, 
P3221 
R* R32 
 HEXAGONAL 
6 P P6, P61, P65, P62, P64, P63 
622 P P622, P6122, P6522, P6222, P6422, P6322 
a=b=c 
"=#=$=90° CUBIC 
23 
P P23, P213 
I I23, I213 
F F23 
432 
P P432, P4232, P4332, P4132 
I I432, I4132 
F F432, F4132 
 
* R=Rhombohedrally-centered: lattice points on the cell corners with two additional points along the longest body diagonal (only applies for the hexagonal crystal family)
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B.4 How to produce X-rays for protein crystallography 
 
Three devices can be used for the production of X-rays for protein crystallography: X-ray 
tubes, rotating anodes and synchrotron radiation. X-rays produced by either an evacuated 
tube or rotating anodes are usually used as laboratory sources. X-ray tubes consist of a 
cathode from which electrons are emitted and accelerated across the vacuum towards a 
metal anode. Impact of the electrons on the anode causes a conversion of kinetic energy 
into X-rays, producing: a) a low intensity continuous spectrum of X-rays (the so-called 
bremsstrahlung spectrum or white radiation), and b) characteristic high intense emission 
lines that depend on the anode material. The characteristic wavelength of the X-rays 
emission is then selected by a monochromator and the resulting monochromatic X-rays 
are collimated and focused onto the crystals. A rotating anode exploits a similar 
procedure, but the anode target rotates at high speed to efficiently dissipate heat, so that a 
more intense X-ray beam can be produced. The wavelength produced by both X-ray tubes 
and rotating anodes is fixed by the choice of anode target material and not tunable. The 
most common element used as an anode is copper, with a !=1.54 Å. 
Synchrotron radiation produces more intense X-rays, whose wavelength is tunable, a 
useful feature to minimize absorption or perform multiple anomalous diffraction (MAD) 
experiments (details of the technique are described below). In order for X-rays to be 
produced, electrons (or positrons) are first accelerated in a linear accelerator and then 
injected and maintained as bunches in a storage ring. Magnetic insertion devices (IDs), 
such as bending magnets, wigglers and ondulators, deviate the path of the particles while 
they travel around the ring. Change in particles trajectory causes the emission of a narrow 
fan of polychromatic radiation over a tightly defined angle tangential to the ring. 
Therefore, radiation is tunable by selecting the appropriate wavelengths with 
monochromators. A new-generation source of X-ray synchrotron radiation is the free 
electron laser (FEL). In a FEL, a beam of electrons linearly accelerated to near-light 
speed passes through a series of IDs, being forced to wiggle transversely along a 
sinusoidal path within the ID. Change in electrons trajectory results in the release of 
incoherent monochromatic photons. Bunching of electrons occurs through a self-
organization of electrons in relativistic conditions known as collective instability,14 so 
that the radiation emitted by bunched electrons is coherent and reaches a power several 
!!
APPENDIX B: MACROMOLECULAR CRYSTALLOGRAPHY 
!
! !
"#!
orders of magnitude higher than that of the circular storage rings. The wavelength of the 
radiation emitted is tunable by changing the energy of the electron beam or the magnetic-
field strength of the insertion devices. 
 
 
B.5 Principles of crystallography 
 
B.5.1 Principles of X-ray diffraction 
 
X-ray diffraction by crystals can be treated as a special case of reflection by using the 
Bragg’s model, as shown in Figure 2. The incident beam is reflected from sets of 
equivalent and parallel planes in the crystal, which are defined by the lattice indices h, k 
and l, each one representing the number of planes, describing that particular hkl set, that 
intersect the unit cell along a, b and c, respectively. X-ray diffraction can be explained, 
using the description above, by the Bragg’s law, as follows: 
 
 2dhklsin! = n"  (B.1) 
 
In this equation, dhkl is the interplanar distance of a set of hkl planes and ! is the angle of 
the reflected beam with respect to the hkl set of planes. According to this model, 
diffraction occurs when the reflection ! angle is such that the difference in path length for 
X-rays reflected from two successive planes of the same hkl set is equal to an integer 
number of wavelengths (being the wavelength assumed as the one of the incident beam). 
In that case, X-rays are reflected in phase with each other, constructively interfering and 
giving rise to a diffracted beam. For other reflected ! angles, waves reflected by 
successive planes will destructively interfere, thus no diffraction beam will be produced. 
 
Figure 2: Diffraction of X-rays and description of the Bragg’s model in real space. 
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Bragg’s Law as defined above is an explanation of how diffraction arises in real space. 
However, a good point is to look at diffraction in the reciprocal space. In the reciprocal 
space a crystal can be defined in terms of a reciprocal lattice, as it has been already 
defined in terms of crystalline lattice in real space. A geometrical reconstruction of the 
Bragg’s model in the reciprocal space is the Ewald’s sphere (Figure 3). This is a useful 
tool because each reflection arising from the interaction between the incident X-rays and 
the planes in the crystal gives a diffraction pattern that is reciprocal to the direct lattice. In 
the reciprocal space, dimensions of the unit cells are a*=1/a, b*=1/b and c*=1/c, so that an 
ab plane of a unit cell in real space will yield in an a*b* plane in the reciprocal space. A 
reciprocal lattice can be constructed starting from any lattice point O, the latter being a 
lattice point also in the real space. When a X-ray beam (in the XO direction) impacts on 
the crystal along the a*b* plane, a circle of radius 1/! (with ! being the incident X-ray 
wavelength) can be drawn by centring it in the point C on the OX direction and passing 
through O. This circle represents the wavelength of the incident X-ray beam in the 
reciprocal space. In such a situation, the reciprocal lattice point P lies on the circle. The 
angle PBO corresponds to the reflection angle " and the triangle PBO, being inscribed in 
a semicircle, it is a right triangle, so that: 
 
 
sin! = OP
BP
= OP
2
"
 (B.2) 
 
Since P is a reciprocal lattice point, the length of OP is 1/dhkl and the expression above 
can be rearranged as follows: 
 
 2dhklsin! = "  (B.3) 
 
That is the Bragg’s law with n=1. If we now rotate the reciprocal lattice about O (by 
rotating the crystal), point P' will cross the circle. In this new situation, P' has h'k'l' 
indices points, so that: 
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 2dh' k' l'sin! = "  (B.4) 
 
Concluding, the Ewald’s sphere reconstruction provides an understanding for whether 
reflections will occur or not. Whenever a crystal is rotated so that a reciprocal lattice 
point intersects the Ewald’s sphere, Bragg’s law is satisfied and diffraction will take 
place. Because a diffraction data collection is usually carried out by rotating a crystal 
while it is irradiated by X-rays, many reciprocal lattice points will cross the Ewald’s 
sphere, each one giving rise to a reflection.15 The reflection originated by the reciprocal 
lattice point Phkl will give the hkl reflection that is, according to the Bragg’s model, the 
reflection of a hkl set of planes in real space. Bragg’s model assumes that the number and 
direction of the reflections are the result of the dimensions of the unit cell, whereas the 
intensity Ihkl of each reflection is the result of the content of the unit cell, in particular of 
the electron density belonging to a set of equivalent hkl planes. 
Figure 3: Diffraction of X-rays in the reciprocal space described by the Ewald’s sphere.  
 
 
B.5.2 The structure factor 
 
The intensity Ihkl of a reflection is, numerically, the squared amplitude of the structure 
factor Fhkl (|Fhkl|2), with the latter being a periodic function of the electron density 
distribution in the unit cell, as follows: 
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Fhkl = f jexp 2! i hx j + ky j + lz j( )"# $%
j=1
n
&  (B.5) 
 
The term fj is called the atomic scattering factor of an atom j. The atomic scattering factor 
is a mathematical description of an atom as a centrosymmetric scatterer, and it is related 
to the number and position of the electrons in its orbitals. The kinetic energy available at 
a certain temperature different rom 0 K causes the periodic change in the position of 
atoms (vibration) around an average position. This vibration, whose amplitude is 
temperature-dependent, is called B-factor or temperature factor and is described by the 
following expression: 
 
 B j = 8!
2U j
2    (B.6) 
 
where Uj2 is defined as the mean-square displacement of atom j from its rest position and 
is expressed in Å2. The structure factor Fhkl describes a reflection hkl given by the 
contribution of the atoms located in the unit cell and assumed as spherical clouds of 
electron density. The contribution of each atom j to Fhkl depends on two factors: i) the 
atom type contributes to the amplitude of Fhkl, while ii) the position (xj, yj, zj) of the atom 
j in the unit cell, contributes to the phase of Fhkl, being the latter a periodic oscillation 
function. The total structure factor Fhkl can be alternatively described considering the 
electron density (!) belonging to each atom in the unit cell as a function of the unit cell 
volume, thus resulting in Fhkl as the total sum of contribution of each volume element of 
the unit cell to the total scattering, as follows: 
 
 
Fhkl = !(x,y,z)exp 2" i hx + ky + lz( )#$ %&
l
'
k
'
h
'  dxdydz   (B.7) 
 
The electron density is the Fourier transform of the structure factor, hence: 
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!(x,y,z) = 1
V
Fhklexp "2# i hx + ky + lz( )$% &'
l
(
k
(
h
(   (B.8) 
 
In this equation, V is the unit cell volume. This expression indicates how to obtain the 
electron density from the measurement of all the reflections resulting from an X-ray 
diffraction experiment. However, since structure factors describe the diffraction of an 
electromagnetic wave, three parameters are needed for a complete description: amplitude, 
frequency and phase. The amplitude of structure factors has already been discussed and is 
a measurable amount. Frequency corresponds to that of the incident X-ray beam, since X-
ray diffraction entails elastic scattering (electrons sensing the oscillating electric field of 
the incident X-ray beam will oscillate with the same frequency). The phase of the 
structure factors, that is described in Equations B.7 and B.8 by the coordinates x, y and z, 
is the main crystallographic problem to be solved. In fact, by performing a diffraction 
experiment phases of all the structure factors are lost, because the x, y, and z position of 
each atom (and thus electrons) within the crystal and with respect to the source of the X-
ray beam is an unknown in the experimental set up. In Section B.6 an overview of the 
experiments that are usually performed in order to estimate the structure factor phase and 
reconstruct the electron density of a protein structure is briefly given. 
 
 
B.6 Recap of data collection, processing and reduction 
 
Nowadays, an X-ray diffraction experiment is performed by collecting diffraction images 
upon crystal rotation in order to fulfil Bragg’s law crossing as many reciprocal lattice 
points as possible.15 Diffraction images are usually recorded by new generation 
semiconductor charge-coupled detectors (CCD) or active pixel sensors in complementary 
metal–oxide–semiconductor detectors (CMOS). In order to minimize radiation damage, 
due to the absorption of X-rays by the protein and the solvent molecules with the 
resulting loss of electrons and formation of free radicals, data collection is performed at 
cryogenic temperature (100 K) by using a cryo-cooling nitrogen stream flowing onto the 
crystal during the experiment.16 Once data collection is completed, the recorded 
diffraction images undergo a data processing and reduction protocol through some 
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sequential steps. The essence of this process is to transform and relate each two 
dimensional section of the reflection, recorded on the surface of the detector in multiple 
images, to a single value for each h, k, l value. Assuming that all data collection 
parameters (crystal to detector distance, crystal rotation angle, etc.) are available, the first 
step is the determination of the crystal lattice and cell parameters. Next, the intensity (Ihkl) 
of each reflection is measured with its standard deviation !I, and all symmetry-related 
observations of a given reflection are grouped together in unique reflections. The data 
processing and reduction processes further yield a statistical treatment describing the 
overall data quality. In general, final statistical parameters are given with respect to either 
the number of the recorded images or the resolution of the data. The agreement between 
the intensities of symmetry-related reflections are quantified by R-factors such as Rmerge 
and Rmeas.17, 18 In particular, Rmerge measures the spread of n independent measurements of 
the intensity of the same reflection (Ihkl) around their average value, while Rmeas is an 
adjusted version of Rmerge that takes into account multiplicity, another important 
parameter that defines the average number of measurements for that unique reflection. 
Other important statistical parameters obtained are data completeness and a resolution 
value beyond which the ratio between reflection intensities and standard errors is smaller 
than 2.0. Altogether, these parameters allow the crystallographer to judge the quality of 
collected data, in order to choose the correct resolution cut-off and the final number of 
images to use for the next step of structure refinement and model building.19 Current 
software available for data processing are XDS20 and MOSFLM,21 while data reduction 
tools are usually implemented within suites for macromolecular crystallography, such as 
CCP422 and PHENIX.23 
 
 
B.7 Initial phase estimation 
 
There are three main diffraction experiments that can be performed in order for an initial 
phase value to be estimated: i) isomorphous replacement, ii) anomalous diffraction, and 
iii) molecular replacement. 
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B.7.1 Isomorphous replacement 
 
This technique relies on the strong diffraction caused by elements with high atomic 
numbers (i.e. heavy atoms). The experiment consists in carrying out data collections on 
native crystals and isomorphous derivative crystals, in which a heavy metal has been 
inserted by either co-crystallization or soaking. In a typical multiple isomorphous 
replacement (MIR) three datasets, one for the native protein and two for the derivative 
crystals (each derivative crystal containing a different heavy atom), are collected. If we 
define, for each hkl reflection, FP as the structure factor for the native protein and FPH' as 
the structure factor for the first derivative, FPH' = FP+FH', where FH' is the structure factor 
of the first heavy atom. First, determination of heavy atom position in the unit cell is 
carried out by a difference Patterson function24 calculated using the intensities of each 
reflection for the native (|FP|) and the derivative (|FPH'|), respectively. This results in a 
Patterson map showing the heavy atom location in the unit cell that, in turn, allows 
knowing the phase for FH'. FP, FPH' and FH' can be described as vectors and their 
relationship can be shown by the Argand diagram in Figure 4, where the structure factor 
for the native protein is described as the following vector difference: 
 
 FP = FPH'! FH'  (B.9) 
 
The amplitude of the three vectors (their lengths in the plane) is known, as well as the 
phase of FH'. By drawing a vector with module equal to -FH' at the origin of the plane, the 
circle of radius FHP centered on the head of the -FH' vector defines all the points which 
give the vector difference |FHP'|-FH'. Next, another circle of radius FP centered on the 
origin can be drawn in order for it to intersect the |FHP'|-FH' circle in two points. The 
resulting two FPa and FPb vectors, drawn from the origin to the intersection of the two 
circles, represent the two possible phase solutions for the structure factor hkl (Figure 4A). 
In order to unambiguously resolve this phase uncertainty, an analogous experiment with a 
second derivative crystal is necessary. In fact, a similar trigonometric approach (this time 
using FH'' and FPH'') would give two new phase values for the structure factor of the 
native protein, one of them corresponding to one of the two previously determined, thus 
representing the correct solution (Figure 4B). 
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Figure 4: Argand diagram used for the estimation of initial phase by multiple isomorphous replacement. (A) Two 
possible solutions for the phase of FP are available by calculating the vector solution of Equation (B.9). (B) A second 
derivative factor structure |FHP''| is represented by the points on the dashed-line circle. The correct phase value for 
FP is given by the intersection of the |FHP''| circle with the two circles previously drawn. 
 
 
B.7.2 Anomalous diffraction 
 
Anomalous diffraction exploits heavy atoms or modified amino acids (i.e. 
selenomethionine) as anomalous scatterers in order to estimate the initial phase of a 
structure factor and relies on the fact that these elements have characteristic absorption 
edges in the X-ray region, so that a data collection performed at the appropriate 
wavelength can maximize their anomalous scattering behavior. The result of this 
absorption reflects on the structure factors. In fact, in the absence of anomalous 
scattering, structure factor vectors Fhkl and F-(hkl) have the same magnitude, so that the 
phase angle ! is !hkl = -!–(hkl) and Ihkl = I–(hkl) (a property described by the Friedel’s law). 
In the presence of anomalous scattering, Friedel’s law is no longer valid and the structure 
factors Fhkl and F-(hkl) differ because of a variation of scattering factors f, the latter being 
the result of the absorption of part of the incident X-ray beam. The scattering factor f(") 
of a generic atom at a particular wavelength " it is defined by the following expression: 
 
 f (!) = f °(")+ f '(!)+ if ''(!)   (B.10) 
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and it results from a combination of two contributions: i) the normal scattering factor (f 
°), which is independent of the wavelength, whereas it depends on the diffraction angle 
(!) (it decreases as the scattering angle increases), and ii) the complex anomalous 
component having real (f ') and imaginary (f ") parts, which are dependent on the 
wavelength, whereas they do not depend on the scattering angle (because the anomalous 
scattering originates from an interaction of the incident beam with inner core electrons).25 
The scattering contribution of a structure factor can be separated in two components, a 
normal and an anomalous scattering,26 so that the intensity I(h) of a reflection h (where h 
stands for hkl) measured at a particular wavelength " is given by: 
 
 
| ! FT(h) |
2=| °F(h) |2 +a(!) | °FA(h) |
2
+b(!) | °F(h) || °FA(h) | cos °"(h)# °"A(h)$% &'
+c(!) | °F(h) || °FA(h) | sin °"(h)# °"A(h)$% &'
 (B.11) 
 
Where A is the anomalous scatterer and: 
 
a(")=(f 2+ f ''2)/f °2 
b(")=2(f '+f °) 
c(")=2(f ''/f °) 
 
Normal scattering factors f ° are available from quantum mechanical calculations, while 
the anomalous scattering factors f ' and f '' can be determined from a combination of 
theory and X-ray absorption spectra,27 through which the wavelength-dependent factors 
a("), b(") and c(") can be determined, while the quantities |°F(h)|, |°FA(h)| and °#(h)-
°#A(h) can be determined by trigonometric analysis. A combination of Patterson and 
probability approaches finally gives the solution of the phase problem as a probability 
distribution.28 
The experimental procedure for phase estimation by exploiting anomalous diffraction is 
usually carried out through the so-called multiple-wavelength anomalous diffraction 
(MAD) experiments, in which two datasets are collected at two different wavelengths, the 
latters providing a maximal difference between f ' and f ''. In this context, the tunability of 
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synchrotron beam lines is needed. A third wavelength is usually used to collect a dataset 
at lower wavelength in order to have high-resolution data to be used once the phase will 
be available. An extreme simplification of the experimental setup used for anomalous 
diffraction is the single wavelength anomalous diffraction (SAD), in which a single 
dataset is recorded at a wavelength with a good f '' followed by density modification to 
solve the phase ambiguity.29, 30 
 
 
B.7.3 Molecular replacement 
 
Differently from the other methods, in which the estimation of initial phases is strictly 
experimental, molecular replacement (MR) is a trial-and-error method that enables the 
solution of the phase problem of an unknown protein crystal (target) by exploiting a 
known protein structure as an initial model. The main requirement for MR to be 
successful is the structural similarity between the model and the target in terms of low 
root mean square deviation (r.m.s.d.) of atomic position and high sequence identity.31 The 
use of molecular replacement as method of choice for the structural determination of 
macromolecules has increased parallel to the expansion of the PDB. Nowadays up to 70% 
of deposited structures are determined by MR.31, 32 Besides the possibility to follow 
different approaches (see below for details), MR procedure essentially consists in 
orienting and positioning the model in the unknown crystal in order for the resulting 
calculated diffraction pattern to best match the diffraction pattern collected on the target 
protein. 
Rotation and translation operations can be carried out by following two procedures: i) a 
Patterson methods, or ii) a Maximum-likelihood methods. Molecular replacement has 
been based on the properties of the Patterson function.24 and the resulting Patterson map. 
In the Patterson method the correct orientation of the model is determined by a rotation 
function (R), defined as a convolution between the Patterson function calculated with the 
squared structure factor amplitudes belonging to the target protein (Pobs) and the Patterson 
function calculated from the model rotated around an origin (Pcalc):33 
 
 
R(C) = Pobs (u)Pcalc (Cu)du
U
!   (B.12) 
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where C is the operator element that describes the rotation of the Pcalc coordinate system 
with respect to Pobs, while U is the integration volume. Rotation results are scored 
depending on how well the two Patterson functions superimpose their maxima. Best 
results from the orientation step are then used as an input for the determination of the 
correct position of the model in the target crystal. This step is carried out by a translation 
function (T),34 defined as a convolution between the Patterson function of the observed 
data (Pobs) at the point u and the Patterson function of the model (Pcalc) translated at the 
new point u+t. 
 
 
T(t) = Pobs (u)Pcalc (u + t)du
U
!   (B.13) 
 
Common macromolecular crystallography tools that exploit the Patterson method for 
structural determination through molecular replacement are AMoRe35, MOLREP36 and X-
PLOR.37 
Unlike the traditional Patterson methods, in maximum-likelihood methods the probability 
of any orientation-position combination of the model in yielding the observed structure 
amplitudes of the target is calculated.31, 38 Here, the translation function is defined as a 
sequential positioning of any starting orientation of the model at grid points inside the 
unit cell. At each testing position the translation is known, so that the phase is known and 
the complete structure factors of the model (Fcalc) can be calculated and subtracted by the 
phase contribution in order to have an unphased calculated structure factor comparable 
with the observed unphased structure factors (Fobs). The probability of observing a 
particular Fobs is given by P(|Fobs|||Fcalc|), with the whole procedure regulated by the so-
called Rice function.39, 40 Rice function outputs probabilities for each tested translation, 
selecting the best solutions. Conceptually similar to the former, maximum-likelihood 
rotation function assumes that the model is sequentially rotated on a grid in the angular 
space and the orientation that predicts the experimental data whit highest probability is 
selected by applying a Rice distribution. The results from both the translational and the 
rotational functions are then combined to give the overall probability function over the 
entire dataset. A macromolecular crystallography tool that exploits maximum-likelihood 
methods is Phaser.41 
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B.8 Refinement and model building 
 
As a final step in the process of structure determination, refinement and model building 
are carried out in order to construct a macromolecular model that adequately explains the 
observed experimental data, while making physical and biochemical sense. By doing this, 
model parameters belonging to the initial phase estimation (obtained through MIR or 
MAD experiments) or the initial phasing model (used for the MR experiment) are 
iteratively refined against the experimental data collected during the diffraction 
experiment, in order for the final refined model to satisfy the best approximation between 
the calculated structure factors (Fcalc) and the observed structure factors (Fobs). The 
parameters of the model to be refined are, in general, the atomic position in the unit cell, 
B-factors values and, occupancy (a measure of the fraction of molecules in the crystal in 
which an atom j actually occupies the position specified in the model). Differently from 
small molecules, crystallographic models of macromolecules are complex and the 
number of observations is not sufficient to refine the huge number of model parameters. 
For this reason refinement is usually carried out under the control of stereochemical and 
geometrical restraints that are used as prior knowledge in order to decrease the number of 
model parameters needed. There are two approaches able to provide useful information 
by performing a macromolecular refinement, the least squares and the maximum 
likelihood. 
Least-squares is the simplest and oldest statistical method used in macromolecular 
refinement. It has been introduced by Konnert42 and consists in a minimization of the 
differences between the observed structure factors (Fobs) and the calculated structure 
factors (Fcalc), as follows: 
 
 
f(p) =
( | Fobs |! | Fcalc | )hkl
2
(" obs )hkl
2
hkl
#   (B.14) 
 
By changing the parameters of the model, a set of calculated observations that minimize 
the residual function is determined. Limitations of the least-squares approach, due to the 
need of a very complete model in order for parameters to reproduce all the observations 
or the assumption the measurements of the observations are the only source of errors, risk 
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to get trapped in local minima.43 To overcome these limitations, maximum likelihood 
methods have been implemented in macromolecular refinement procedure.44 Maximum 
likelihood method is a general statistical scheme45 in which experimental observations, as 
well as model parameters, have an error and an uncertainty. First, for every combination 
of model parameters, the probability of each set by considering the prior known 
information belonging to the experimental data (stereochemistry, B-factors, etc.) is 
calculated. This probability is called prior distribution. Next, for every combination of 
model parameters, the probability that the experiment would have resulted as it did is 
calculated. This probability is called likelihood distribution. Only the sets of parameters 
that have high probability in both the distributions are then further combined in order to 
have the so-called posterior distribution, which includes all of the information about the 
values of the model parameters. The basic maximum-likelihood residual f(p) is the 
following: 
 
 
f(p) =
( | Fobs |! | Fcalc | )hkl
2
(" obs )hkl
2 + (" calc )hkl
2
hkl
#   (B.15) 
 
Even though the treatment is very similar with respect to the least-squares, here |Fcalc| is 
not the equivalent quantity calculated starting from the model parameters, but the 
expectation value of this quantity calculated over all the acceptable models similar to p. 
!calc is the width of distribution of values for |Fcalc| over all the acceptable values for p. 
The progresses within and during the iterative refinement procedure can be followed by 
monitoring two statistical factors, R-factor and Rfree, defined as a percentage: 
 
 
R =
|| Fobs
hkl
! |" | Fcalc ||
| Fobs |
hkl
!  (B.16) 
R-factor is a measure of the agreement between the refining model and the experimental 
data, describing how well the refined structure predicts the observed data.46 Rfree, is 
computed on a small, random sample of data never included in the refinement process as 
a cross validation tool in order to avoid over-fitting of the model.47, 48 Rfree is always 
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slightly greater than R-factor, but the two statistics should be comparable because a 
correct model should predict the experimental data with uniform accuracy. An Rfree 
significantly higher than R-factor indicates an over-parameterisation of the model. 
Software for final refinement, such as REFMAC44 and phenix.refine,49 as well as graphics 
programs used to visualize the protein model, the electron density maps and to perform 
manual building are included in CCP422 and PHENIX suites,23 respectively. A very useful 
tool in the final steps of refinement is PDB_REDO,50 a web server through which a 
refined structure can be automatically optimized for the following validation and 
deposition processes. 
 
 
B.9 Structure validation and deposition 
 
After a crystallographic structure has been refined, it has to be validated and deposited in 
the Protein Data Bank.6 The access to PDB provides structural information as atomic 
coordinates of the deposited structures, as well as related structure factors. Availability of 
such structural data is important not only for scientists involved in the determination of 
the crystal structure of an unknown protein by using a starting model for molecular 
replacement, but also for biochemists interested in structure-activity relationship (SAR) 
of proteins or in the process of structure-based drug design (SBDD), as described in 
Chapter 1. 
The validation process, implemented in the web server of worldwide Protein Data Bank 
(wwPDB, http://www.wwpdb.org/) is a needed step prior to deposition and it is important 
to both assess the quality of the final refined structure and allow users to discriminate 
between good and bad data, quantitatively expressing the reliability of the deposited 
model. The wwPDB validation process judges the quality of the structure. First, it 
analyses the reliability of the atomic model, without taking into account the diffraction 
data, in terms of Ramachandran torsion angles, rotameric states of amino acid side chains 
and close contacts between atoms. The geometry of small-molecule ligands is also 
assessed by comparing their structure with related small-molecule crystal structures 
available in the Cambridge Structural Database (CSD) (ccdc.cam.ac.uk).51 For each 
evaluation criterion, a list of outliers is produced and an overall score is computed. As a 
second procedure it analyses the experimental diffraction data, in terms of structure 
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factors, without references to the atomic model, by using phenix.xtriage.23 As a final step, 
an assessment of the fit between the atomic model and the experimental diffraction data is 
carried out by a number of programs.52 As an output, a preliminary wwPDB validation 
report is provided to help the identification of possible issues with the atomic coordinates 
and/or experimental data. Once the depositor approves the preliminary wwPDB 
validation report, a PDB code is provided, and the submission passes to an annotation 
step for further consistency/error checking and subsequent final deposition in the PDB.52 
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CHAPTER 5
Urease
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5.1  Introduction
Urease (urea aminohydrolase, E.C. 3.5.1.5) is an important nickel-dependent 
enzyme found in a large variety of organisms, including plants, algae, fungi, 
and several prokaryotes.1,2 It is involved in the global nitrogen cycle, catalyz-
ing the rapid hydrolytic decomposition of urea.3,4 Urease catalysis causes an 
overall pH increase that has negative consequences both on human health 
and agriculture.2,5 Indeed, urease is the main virulence factor of a large vari-
ety of human pathogens, such as Helicobacter (Chapter 16), Proteus, Klebsiella, 
Pseudomonas, and Mycobacterium spp. In the agricultural context, soil urease 
causes a significant decrease in soil fertilization efficiency using urea, due to 
ammonia volatilization and root damage caused by the increase in soil pH.
Urease holds a significant place in twentieth-century science, having taken 
part in two fundamental landmarks of biochemistry. In 1926 James Sumner 
isolated and crystallized an enzyme from Canavalia ensiformis ( jack bean) 
that, using his own words, “possesses to an extraordinary degree the ability 
to decompose urea into ammonium carbonate”, thus demonstrating for the 
first time that enzymes are proteins.6 This discovery led to Sumner being 
awarded the Nobel Prize in Chemistry in 1946. In 1975, Zerner, Dixon, and 
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co-workers demonstrated the requirement for nickel in jack bean urease 
(JBU) catalysis, providing the first model for the biological role of this metal 
as an enzyme cofactor.7 Since then, ureases from several sources have been 
extensively investigated. Detailed information on their occurrence and roles 
in nature has been acquired. The availability of information on the genetic 
organization of urease operons, as well as the amino acid sequences and crys-
tal structures of native ureases and urease–inhibitor complexes, has led to 
significant steps towards a complete understanding of the molecular basis of 
the catalytic mechanism, including the role of nickel in this system.8–14 This 
chapter gives an account of the achievements made in the biological chem-
istry and structural biology of this peculiar enzyme in the past two decades.
5.2  Biological Significance of Ureases
Urea is the main product of catabolic processes of nitrogen-containing com-
pounds in vertebrates; for example, human urine contains up to 0.4–0.5 M 
urea, corresponding to ca. 10 kg of urea produced per year.15 The stability of 
urea in aqueous solutions is extremely high. Its non-enzymatic decomposi-
tion in water, which occurs through an elimination step to produce ammonia 
and cyanic acid, has a long half-life (t1/2 ca. 40 years 16) while its non-enzymatic 
hydrolysis, never observed experimentally,17 has an estimated even longer 
half-life (ca. 520 years).18 Together, these two aspects would cause grave envi-
ronmental problems in the absence of an efficient enzymatic system able 
to decompose urea. The enzymatic hydrolysis of urea by urease generates 
two ammonium ions and a molecule of bicarbonate,3,4 causing an overall pH 
increase due to product alkalinity. The enzymatic reaction has a half-time 
of a few microseconds, with a kcat/KM that is 3 × 1015 times higher than the 
rate of the uncatalyzed reaction, making urease the most efficient hydrolase 
known, an efficiency ascribed to the presence of two Ni(ii) ions in the active 
site of the enzyme.18
Urease is widespread in nature.1,2,19 Its general biological function is to 
provide organisms with a nitrogen source for growth.12 In plants, urease is 
involved in metabolic pathways of nitrogen-containing compounds, such as 
degradation of urea a$er its internalization, arginase-catalyzed catabolism of 
arginine, and degradation of purines and ureides.19–22 Moreover, urease plays 
a defense function against plant pathogens with a mechanism that is unre-
lated to its enzyme activity23 (see Section 5.7). Among ureolytic prokaryotic 
organisms, this chapter will focus on human pathogenic bacteria showing 
ureolytic activity. The most common sites for ureolytic bacteria infections 
in humans are urinary and gastrointestinal tracts.24,25 The pathogenesis of 
the bacteria is strongly related to the ureolytic activity, in particular the pH 
increase and the toxicity of released ammonia. For example, Proteus mirabi-
lis is a ureolytic bacterium that infects urinary and gastrointestinal tracts in 
human and animals,26 causing kidney stone formation, catheter encrusta-
tion, pyelonephritis, ammonia encephalopathy, and hepatic coma.2,27 Other 
bacteria involved in stone formation belong to Pseudomonas, Klebsiella, and 
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Staphylococcus spp.24–28 Helicobacter pylori is probably the most important 
ureolytic human pathogen bacterium, acting as the major cause of several 
pathologies, such as gastritis, gastroduodenal ulcers, and cancer induced 
by chronic gastroduodenal infections.29 It is a neutrophil bacterium able to 
survive in, and colonize, the acidic environment of the stomach by exploit-
ing the pH increase caused by urease activity. Other lethal ureolytic microor-
ganisms able to infect human body are Mycobacterium tuberculosis,30 Yersinia 
enterocolitica,31 and Cryptococcus neoformans.32
Urease activity is also widespread in soils, deriving primarily from extracel-
lular immobilized soil urease, a residual of dead organisms.33,34 The presence 
of urease in soils allows the worldwide use of urea as a nitrogen fertilizer,35 
because it accelerates the conversion of organic nitrogen into ammonium, 
a mineral nitrogen source usable by plants. However, the efficiency of soil 
nitrogen fertilization with urea is severely decreased by the activity of urease 
itself, when the latter is too fast. In fact, rapid urea breakdown may result in 
a decrease of soil fertility by unproductive loss of soil nitrogen as ammonia, 
which is released in the atmosphere, further contributing to environmental 
pollution. In addition, the release of ammonia can be toxic to plants, while 
the increase in soil alkalinity following urea hydrolysis causes damage to 
plantlets and seedlings, causing significant environmental and economic 
problems.36–38
The broad range of biological aspects in which urease is involved implies 
that a tight control of urease activity is required to counteract its negative 
effects, both in human health and in agriculture. For this purpose, several 
classes of compounds have been studied and tested as urease inhibitors in 
recent decades.12,14,39 An integrated analysis of the main urease inhibitor 
classes will be discussed in Section 5.5.
5.3  Enzymology
The reaction of urea hydrolysis catalyzed by urease occurs in two steps: 
the first, strictly enzymatic, consists of the hydrolysis of urea to give 
ammonia and carbamate, followed by the spontaneous decomposition 
of carbamate to give a second molecule of ammonia and bicarbonate 
(Scheme 5.1).3
The reaction follows a typical Michaelis–Menten kinetic behaviour, with 
values of KM in the 0.2–32 mM range and largely independent of pH.12 By 
contrast, kcat and consequently kcat/KM strongly depend on pH.12 Urease 
is active in the 5–9 pH range. Several pH-dependent studies of urease 
Scheme 5.1
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activity have been carried out in order to elucidate the role of different 
conserved residues in the vicinity of the active site; they identified the 
presence of general acidic groups with pKas of ca. 5 and ca. 6.9 and gen-
eral basic groups with pKas of ca. 6.3 and ca. 9, whose identities have not 
been fully elucidated yet.40–42 Unlike the majority, a distinct subgroup of 
ureases possess an optimum pH in the range 2.0–4.5.12 The overall amino 
acid sequence for these acidic enzymes does not differ from that of the 
neutral ureases as far as the active site residues are concerned, and the 
factors that determine this difference in the pH-dependent activity pro-
files are still unknown.
For ureases, weak substrate and product inhibition are observed. In partic-
ular, JBU shows uncompetitive inhibition by urea (Ki ca. 1–6 M) and noncom-
petitive inhibition by ammonium ions (Ki = 2–118 mM).12
Besides urea, urease catalyzes the hydrolysis of several urea analogues, 
such as formamide, acetamide, N-methylurea, N-hydroxyurea, N,N?-dihy-
droxyurea, semicarbazide, thiourea, as well as different kinds of phosphoric 
acid amides and esters.43 Values of kcat for these substrates are ca. 2–3 orders 
of magnitude lower than that observed for urea, and a kinetic characteri-
zation is complicated due to their simultaneous role as enzyme inhibitors 
(Section 5.5).12
5.4  Urease Structures
Initial structural information on the active site structure in urease was 
obtained by a long list of spectroscopic studies on JBU. The presence of 
six-coordinate octahedral Ni(ii) in the JBU active site was first revealed by 
optical absorption spectroscopy,7,44,45 and later confirmed by X-ray absorp-
tion spectroscopy, which further suggested the presence of Ni(ii) ions coor-
dinated to three histidine N atoms at 2.04 Å, two O atoms at 2.07 Å, and one 
O atom at 2.25 Å.46–48 Magnetic susceptibility experiments on JBU indicated 
the presence of weakly anti-ferromagnetic coupling (  J = ?6.3 cm−1) between 
two high spin (S = 1) and closely spaced octahedral Ni(ii) ions.49 This conclu-
sion received further support from later EXAFS studies, which indicated the 
appearance of a new peak in the Fourier transform upon addition of ?-mer-
captoethanol (BME) to JBU that could be fitted using a model that involved 
the presence of two Ni(ii) ions separated by 3.26 Å and bridged by the thio-
late group of BME.50 In the case of bacterial ureases, X-ray absorption spec-
troscopy studies carried out on urease from Klebsiella aerogenes (KAU)50 and 
Sporosarcina pasteurii (formerly known as Bacillus pasteurii, SPU herea$er)51 
provided a picture of the active site essentially identical to that of JBU.
A more detailed characterization of the urease active site and its overall 
three-dimensional structure was made available with the first report of the 
crystal structure of KAU, in 1995.52 Nowadays, the total number of full struc-
tures of ureases in the Protein Data Bank amounts to 49 (Table 5.1). Among 
these, 44 are ureases from bacterial sources, 4 are from jack bean, and one is 
from pigeon pea (Cajanus cajan).
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Four structures of KAU refer to the native state of the recombinant wild-type 
enzyme, at different levels of refinement or data collection temperature (PDB 
codes 2KAU, 1FWJ, 1EJX, and 1EJW), while one structure involves the apo-
form (PDB code 1KRA) and another one the manganese-substituted enzyme 
(PDB code 1EF2). In addition, 21 structures of KAU mutants are available. In 
the case of SPU, two structures involve the resting state of the enzyme (PDB 
codes 2UBP and 4CEU), while eleven additional structures report on com-
plexes with inhibitors. Two structures of H. pylori urease (HPU, PDB codes 
1E9Z and 1E9Y) are available, with significantly lower resolution than for the 
structures of KAU and SPU: one structure refers to the resting state (PDB 
code 1E9Z) and the other to the acetohydroxamic acid (AHA) complex (PDB 
code 1E9Y). The only available structure of the iron-containing alternative 
urease from Helicobacter mustelae (PDB code 3QGA) does not show any mod-
eled electron density in the active site besides the metal ions and ligated 
residues. The most recent structure from a bacterial source is the native state 
urease from Y. enterocolitica (PDB code 4Z42). Five structures are available 
for plant urease, four of which are from JBU, complexed with AHA (PDB code 
4H9M), phosphate (PHO) (PDB code 4GY7) or fluoride (PDB code 4GOA), and 
one from pigeon pea (PPU) in the native state (PDB code 4G7E). Figure 5.1 
shows the protein architecture for KAU, SPU, HPU, and JBU.
KAU and SPU are representative of most bacterial ureases, with a quater-
nary structure composed of a trimer of trimers of the type (???)3, with ?, ?, and 
? being three different subunits.52,53 The active site is found in the ? subunit, 
giving rise to three active sites per biological unit. In other bacterial ureases, 
the quaternary structure is made of only two subunits to form (??)3 trimers: 
the ? subunit is highly homologous to that found in KAU and SPU, and the 
? subunit is a fusion peptide made of the ? and ? subunits found in the KAU 
and SPU urease. In the case of HPU, four (??)3 trimers form the spherically 
shaped tetramer of trimers [(??)3]4, containing twelve active sites54 that cor-
respond to the shape of the enzyme estimated using electron microscopy.55 
Finally, plant ureases are generally made up of a dimer of homotrimers (?3)2, 
where the ? subunit is derived from the fusion of the corresponding ??? sub-
units found in bacteria.56
In all cases, the secondary and tertiary structures of ureases are very simi-
lar. The ? subunits consist of a TIM barrel domain and a ?-sheet domain, the 
? subunits are located on the external surface of the trimer and are mainly 
composed of ?-sheets, and the ? subunits consist of domains containing 
both ?-helices and ?-sheets. An important structural feature of all ureases 
is the presence of a mobile helix-turn-helix motif in the ?-subunit, flanking 
the active site cavity. The amino acid sequence of this motif is highly con-
served among ureases from different sources. This flap has been found in an 
open or closed conformation, and is thought to be important in modulating 
the aﬄux of substrate and the eﬄux of products to and from the active site 
during catalysis, respectively, as well as moving the catalytically essential and 
conserved ?Cys322 and ?His323 residues (SPU numbering) by about 5 Å to 
and from the active site metal center (Figure 5.2).
Figure 5.1  Ribbon diagram and solvent excluded surface of urease from (A) K. 
aerogenes (PDB code: 1EJZ), (B) S. pasteurii (PDB code: 4CEU), (C) H. 
pylori (PDB code: 1E9Z), and (D) jack bean (PDB code: 3LA4). Ribbon 
colors evidence the chains composing the trimer of oligomers (monomers 
in the case of jack bean) that constitute the minimal quaternary 
structure of urease. Ni(ii) ions are shown as green spheres. The bottom 
panels are rotated by 90° around the horizontal axis versus the top 
panels. Adapted with permission from ref. 14. Copyright (2014) American 
Chemical Society.
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A consensus has been reached on the structure of the coordination envi-
ronment of the Ni(ii) ions in the active site of urease. Indeed all structures so 
far determined indicate the presence of a dinuclear active site, with the two 
metal ions separated by 3.5–3.7 Å, bridged by the oxygen atoms of a carbam-
ylated lysine residue, and bound to two histidines (Figure 5.3).
One Ni(ii) ion is additionally bound to an aspartate carboxylate oxygen. 
The coordination geometry of each Ni(ii) ion is completed by a terminally 
bound water molecule (W1 and W2) and by a nickel-bridging hydroxide ion 
(WB). The assignment of the protonation state for these solvent-derived 
nickel ligands was suggested53 by the value of the first dissociation con-
stant for Ni(H2O)62+ (pKa = 10.6),57 which supports the hypothesis that the 
terminally bound solvent molecules are neutral waters. Moreover, in water-
bridged bimetallic complexes, the first pKa for the bridging water decreases 
significantly to very acidic values, while the pKa for hydroxide deprotonation 
is slightly lower than the pKa of the first ionization of a water bound to a 
single Ni ion.57 Therefore, the estimated pKa for the deprotonation of the Ni 
bridging hydroxide (ca. 9–10) suggests that, at pH 8.0, the nickel-bridging 
solvent molecule is a hydroxide ion. Overall, in native urease two different 
types of ligands bridge the binuclear Ni cluster, the carboxylate group of the 
carbamylated lysine and the hydroxide ion, accounting for the observation of 
weak antiferromagnetic coupling.49
An extended network of hydrogen bonds stabilizes the nickel-bound sol-
vent molecules in the active site: W1 is at 2.9 Å from ?His222 N? (the following 
discussion follows the SPU residue numbering scheme), which is protonated 
and acts as a hydrogen-bonding donor, as deduced from the interaction of 
Figure 5.2  Ribbon diagram and longitudinal section of the open (A, PDB code 
4CEU) and closed (B, PDB code 3UBP) conformations of the flexible flap 
in SPU highlighting the side chain of ?Lys220!, ?Cys322, and ?His323. 
The Ni(ii) ions are shown as green spheres while other atoms are col-
ored according to atom type.
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?His222 N? with the peptide NH group of ?Asp224 (at 2.9 Å). In contrast, W2 
forms a hydrogen bond with ?Ala170 O (at 2.9 Å), which acts as hydrogen 
bond acceptor. This ligand arrangement yields one pentacoordinated Ni(ii) 
ion (Ni1) with a distorted square-pyramidal geometry, and one Ni(ii) ion 
(Ni2) hexacoordinated with a distorted octahedral geometry. An additional 
water molecule (W3) is part of a hydrogen-bonding network completing a 
tetrahedral cluster of four water/hydroxide molecules in close proximity to 
the Ni(ii) ions, hinting at the existence of an active site cavity designed to sta-
bilize a tetrahedral transition state and/or intermediate. In the structure of 
apo-KAU (PDB code 1KRA, Table 5.1), where the Ni(ii) ions were chemically 
removed by lowering the pH in the presence of chelating agents, a treatment 
that decarbamylates ?Lys217, the positions of the remaining ligands are the 
same as in the holoenzyme, indicating a pre-organized metal binding site 
structure. The positions of conserved amino acid residues not involved in Ni 
binding but thought to be important in the catalytic mechanism (?Ala170, 
?His222, ?Gly280, ?Cys322, ?His323, ?Arg339, and ?Ala366) are largely 
invariant in SPU and KAU, except for ?His323, due to the different conforma-
tion of the active site flap. Some differences in the structure of active site res-
idues are observed in the case of native HPU: in particular, the carbamylated 
lysine appears to bridge the two nickel ions using only one of the two ter-
minal oxygen atoms, a consequence of an apparent rotation of the terminal 
–NH-CO2− moiety along the N–C bond by about 90° with respect to the 
Figure 5.3  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in the resting state (PDB code 4CEU). The nickel ions are 
represented in green, while CPK coloring is used for all other atoms. 
Hydrogen bonds are shown as thin blue lines. The SPU residue-num-
bering scheme is used. Only selected residues are shown. Adapted with 
permission from ref. 14. Copyright (2014) American Chemical Society.
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position found in SPU and KAU. In addition, some distances between the 
nickel ions and the coordinating residues are very large (ranging between 2.6 
and 2.7 Å) as compared to those found in KAU and SPU (2.0–2.1 Å), with an 
unusual orientation of the histidine imidazole rings around the metal ions, 
a very short (2.1 Å) Ni–Ni distance, and non-bridging hydroxide. These differ-
ences are most likely ascribed to the much lower resolution of this structure 
as compared to those of KAU and SPU (see Table 5.1).
All structural investigations on urease mutants have been carried out 
using KAU, and the residue-numbering scheme for this urease will be used 
to describe the attempts to relate their structures to the enzymatic mech-
anism. The structure of the ?His219Ala mutant (PDB code 1KRB), which 
features a much lower affinity for the substrate than the wild-type enzyme 
(KM = 1100 versus 2.3 mM) and a ca. 30-fold decrease of kcat,58 and thus indi-
cates a role for ?His219 in substrate binding, shows structural identity with 
native KAU. The structure of the ?His320Ala mutant, (PDB code 1KRC)59 
shows an RMSD for C? atoms of only 0.1 Å from wild-type KAU, and displays 
only a small change in KM but a ca. 30 000-fold decrease in kcat with respect 
to the wild-type enzyme,60 while not showing the pKa = 6.5 observed for wild-
type urease.58,60 The removal of one nickel histidine ligand in the catalytically 
inactive mutant ?His134Ala (ref. 58) resulted in an enzyme featuring only 
Ni1 in the active site (PDB code 1FWI),61 with the position of all remaining 
active site residues, including the carbamylated lysine, invariant with respect 
to the wild-type enzyme structure. Chemical modification of ?Cys319, 
located on the flexible flap covering the active site of KAU, blocks enzyme 
activity,62,63 while the ?Cys319Ala mutant is still ca. 50% as active as the wild 
type urease.64 Structures of the ?Cys319Ala mutant were determined at pH 
6.5 (PDB code 1FWB), pH 7.5 (PDB code 1FWA), pH 8.5 (PDB code 1FWC), 
and pH 9.4 (PDB code 1FWD),65 with no significant structural differences 
observed between the structure of the wild-type and mutant enzymes except 
for a much reduced mobility of the flexible flap covering the active site in the 
mutant. The structures of ?Cys319Asp (PDB code 1FWF), ?Cys319Ser (PDB 
code 1FWG), and ?Cys319Tyr (PDB code 1FWH), which feature, respectively, 
0.03%, 4.5%, and 0% of the activity observed for the wild type, also indicate 
the same active site environment but with a much higher mobility of the 
flap.65 These evidences indicate that ?Cys319 (?Cys322 in SPU), largely con-
served in ureases, is somehow involved in catalysis, possibly having a role in 
positioning other key residues that are located on the mobile flap or in the 
active site, possibly the adjacent ?His320 (?His323 in SPU), in a conforma-
tion best suited for catalysis. The structures of the ?Lys217Glu (PDB code 
1A5K), ?Lys217Ala (PDB code 1A5M), and ?Lys217Cys/?Cys319Ala (PDB code 
1A5L) mutants of KAU, which were structurally characterized to establish the 
importance of the carbamylated lysine ligand for urease activity,66 reveal the 
complete absence of bound Ni ions, indicating the need for the longer side 
chain in order to bind the nickel(ii) ions in the active site defined by the four 
His ligands. The addition of formate to these mutants allowed for a chemical 
rescue of the enzyme, with the structures of the ?Lys217Ala–formate–Ni 
71Urease
complex (PDB code 1A5N) and ?Lys217Cys–formate–Ni complex (PDB code 
1A5O) revealing the presence of a dinuclear Ni center bridged by formate 
instead of the carbamate group of ?Lys217 as in wild-type KAU.66
5.5  Urease Inhibitors
As briefly described in Section 5.2, several classes of compounds have been 
tested as urease inhibitors to counterbalance urease adverse effects both 
in medicine and the agro-environmental field.2,12,14,27,39,67 In this section all 
urease inhibitor classes that have been characterized so far will be discussed.
5.5.1  Sulfur Compounds
Among sulfur compounds acting as urease inhibitors, thiols represent a 
class of historic importance, having been used for structural characterization 
of the active site of plant urease.45,68 Thiols inhibit urease with a competi-
tive mechanism in their thiolate anion form RS−.69 The X-ray structure of the 
SPU : BME complex (PDB code 1UBP, Figure 5.4A)70,71 revealed the structural 
basis for the inhibition of urease by thiol compounds.
Figure 5.4  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with (A) BME (PDB code 1UBP) and (B) sulfite 
(PDB code 5A6T). The nickel ions are represented in green, while CPK 
coloring is used for all other atoms. Hydrogen bonds are shown as thin 
blue lines. The SPU residue-numbering scheme is used. Only selected 
residues are shown. Part (A): adapted with permission from ref. 14. 
Copyright (2014) American Chemical Society.
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The thiolate group of BME bridges the two Ni(ii) ions and chelates the 
metal center with the alcoholic group interacting with Ni1, the interaction 
being further stabilized by a hydrogen bond with the carbonyl oxygen of 
the conserved ?Gly280. Additionally, a second molecule of BME forms a 
disulfide bond with the conserved ?Cys322 residue belonging to the mobile 
flap. The consequent formation of a hydrogen bond between the ?-hydroxyl 
group belonging to BME and the carbonyl oxygen atom of ?Ala366 decreases 
the flexibility of the flap, plugging the entrance to the active site by steric 
hindrance.
Besides thiols, sulfite is a well-documented sulfur compound that acts as 
a competitive urease inhibitor72,73 as well as a stabilizer of the Ni(ii)–urease 
complex in certain cases.43 Biochemical studies performed on SPU demon-
strated that sulfite inhibition is pH-dependent in the 6.5–8.0 range of pH, 
decreasing with increasing pH and becoming negligible at pH 8.0.74 The 
binding mode of sulfite on SPU was revealed by the X-ray structure of the 
SPU : sulfite complex (PDB code 5A6T, Figure 5.4B).74 The inhibitor binds the 
two Ni(ii) ions in the active site in a tridentate binding mode, using two 
oxygen atoms [Ni1–O(1) and Ni2–O(2), respectively], and placing its third oxy-
gen atom, O(B), in the bridging position, thus replacing the terminal and the 
bridging water molecules that were bound to Ni1 and Ni2 in the native form 
of the enzyme. The SPU : sulfite interaction is also stabilized by a hydrogen 
bond network between ligand and residues that surround the active site cav-
ity: sulfite oxygen O(1) forms a hydrogen bond with ?His222 N? (at 2.65 Å), while 
two water molecules are H-bonded to O(1) at 3.19 Å and 3.21 Å. Sulfite oxygen 
O(2) is placed at 2.78 Å from the carbonyl backbone ?Ala170 O, suggesting a 
possible H-bond in which the sulfite O(2) could be protonated. Finally, the 
bridging sulfite O(B) is placed at 2.48 Å from ?Asp363 O?2, again suggest-
ing that these two atoms could share a hydrogen atom through an H-bond. 
The pH-dependent behavior of the inhibition, as well as the hydrogen bond 
network briefly described, exclude the inhibitor acting in the di-anionic SO32− 
form, rather suggesting a bisulfite mono-protonated moiety (HSO3−) as the 
actual inhibitor, as previously reported.73
5.5.2  Hydroxamic Acids
Hydroxamic acids act as urease inhibitors69,75,76 by exploiting their metal- 
binding properties.39 Among them, AHA has been the most studied derivative 
and it acts as a slow-binding inhibitor for plant, bacterial, and fungal ure-
ases.12 X-Ray crystal structures of urease complexed with AHA are available 
for SPU (PDB code 4UBP),77 HPU (PDB code 1E9Y),54 and a mutant of KAU 
(PDB code 1FWE).65 In all cases, AHA interacts with the two Ni(ii) ions in the 
active site (Figure 5.5). The hydroxamate oxygen atom bridges the two Ni(ii) 
ions, while the carbonyl oxygen of AHA chelates one nickel atom in a similar 
fashion as observed for BME (Figure 5.4A). Two H-bonds, between the car-
bonyl AHA O atom and ?His222 N?H, and between the AHA–NH group and 
the O?2 atom of ?Asp363 residue, stabilize the SPU : AHA interaction.
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AHA has been commercialized for medical treatments of urinary tract 
infections caused by pathogenic bacteria.24 However, although it is a urease 
inhibitor, AHA and other hydroxamic acid derivatives produce severe side 
effects.39
5.5.3  Phosphorus Compounds
Awareness of organic compounds containing phosphorus as inhibitory 
agents of urease dates back to the 1970s, when some organophosphorus 
insecticides were shown to inhibit soil urease.78 In the same decade, Dixon 
and co-workers demonstrated the direct involvement of phosphoramidate in 
binding to the nickel ions in the JBU active site.44 Nowadays, amide and ester 
derivatives of phosphoric and thiophosphoric acid are quite effective inhibi-
tors of urease.12 The latter are currently believed to be precursors that become 
inhibitors upon conversion into their oxygen analogues, even though direct 
crystallographic evidence for this hypothesis has not been obtained yet.79,80 
Owing to their inhibition properties, numerous derivatives have been inten-
sively studied and patented for slowing down urea breakdown in soils and 
against infections by ureolytic bacteria.39 Independent of the type of deriva-
tive, the initial enzymatic hydrolysis of the molecule generates diamidophos-
phate (DAP), which is proposed to act as the actual inhibitor.81–83 Consistent 
with this hypothesis, the X-ray crystal structure of SPU crystallized in the 
presence of phenyl phosphorodiamidate (PPD) (PDB code 3UBP, Figure 5.6A)53 
Figure 5.5  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with AHA (PDB code 4UBP). The nickel ions are 
represented in green, while CPK coloring is used for all other atoms. 
Hydrogen bonds are shown as thin blue lines. The SPU residue-num-
bering scheme is used. Only selected residues are shown. Adapted with 
permission from ref. 14. Copyright (2014) American Chemical Society.
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indeed revealed the presence of a molecule of DAP, produced in situ by the 
hydrolysis of PPD and the production of phenol.
DAP binds to Ni1 and to Ni2 through one oxygen and one nitrogen atom, 
respectively, where the Ni1-bound oxygen atom receives a hydrogen bond 
from ?His222 N?H, while the Ni2-bound DAP–NH2 group forms two hydro-
gen bonds with the carbonyl oxygen atoms of ?Ala170 and ?Ala366. The 
second DAP oxygen bridges the two Ni(ii) ions and is placed at hydrogen 
bonding distance from the ?Asp363 O?2 atom. Finally, the second DAP nitro-
gen atom points away towards the cavity opening. The binding mode of the 
DAP molecule is considered to represent an analog of the transition state, 
replacing the tetrahedral cluster of four water/hydroxide molecules found in 
native SPU. This consideration is also strengthened by the closed conforma-
tion of the mobile flap that covers the active site cavity, which allows the 
formation of two additional hydrogen bonds between the distal DAP–NH2 
group and the ?Ala366 O and ?His323 N? atoms.
Despite their strong inhibition properties, the main issue involving inhib-
itors based on the organophosphorus moiety is related to their low hydro-
lytic stability at acidic pH.84,85 For this reason, some non-hydrolysable 
analogs of phosphoramidates, such as aminophosphinic acids, have been 
developed.86,87
Phosphate (PHO) has been found to act as a urease competitive inhibitor.88 
Its inhibition is pH-dependent in the pH range 5.0–8.0, becoming negligi-
ble at pH higher than 7.5–8.0.69,89 A structural study of the SPU : PHO com-
plex (PDB code 1IE7, Figure 5.6B)90 shows a tetrahedral phosphate molecule 
binding to the binuclear Ni(ii) active site through three atoms: a phosphate 
Figure 5.6  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with (A) DAP (PDB code 3UBP) and (B) phosphate 
(PDB code 1IE7). The nickel ions are represented in green, while CPK 
coloring is used for all other atoms. Hydrogen bonds are shown as thin 
blue lines. The SPU residue-numbering scheme is used. Only selected 
residues are shown. Adapted with permission from ref. 14. Copyright 
(2014) American Chemical Society.
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oxygen bridges the two Ni(ii) ions, and two oxygen atoms are bound termi-
nally to each Ni center, with the fourth phosphate oxygen pointing away from 
the metal center. The pH-dependent behavior of urease inhibition by phos-
phate, which suggests interactions involving at least two protonation sites, 
with pKas of ca. 7.2 and 6.5, as well as the H-bonding network established 
between the inhibitor and the active site residues, points out the actual pro-
tonation state of phosphate. The inhibitor is formally bound as the neutral 
phosphoric acid (H3PO4) in the pH range 5–6.5, with the pKa observed at 
ca. 6.5 belonging to the production of the H2PO4− species in the pH range 
6.5–7.2. Above this pH, loss of the second phosphate proton to form HPO42− 
further destabilizes the enzyme–inhibitor interaction.90
5.5.4  Boric and Boronic Acids
Boric and boronic acids are competitive inhibitors of plant and bacterial 
ureases.12 The crystal structure of the SPU : boric acid complex (PDB code 
1S3T, Figure 5.7)91 revealed that the inhibitor bridges the Ni(ii) ions with two 
oxygen atoms, displacing three water molecules and leaving in place the 
bridging hydroxide.
The third inhibitor oxygen atom points away from the metal center. 
A detailed analysis of the H-bonding network surrounding the inhibitor 
established that the protonation state corresponds to the neutral B(OH)3 
molecule, confirming a previously formulated hypothesis.69,92,93
Figure 5.7  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with boric acid (PDB code 1S3T). The nickel ions 
are represented in green, while CPK coloring is used for all other atoms. 
Hydrogen bonds are shown as thin blue lines. The SPU residue-num-
bering scheme is used. Only selected residues are shown. Adapted with 
permission from ref. 14. Copyright (2014) American Chemical Society.
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5.5.5  Citrate
Citrate is a poor urease inhibitor at concentrations higher than 800 mM, 
while at lower concentrations (100–600 mM) the inhibition is masked by 
an activating effect.94 The structure of the complex between citrate and SPU 
(Figure 5.8) shows the presence of a carboxylate group that binds the nickel 
ions in the active site, forming several hydrogen bonds involving the polar 
groups of the inhibitor and the surrounding residues, supposedly stabilizing 
this interaction that, considering the poor inhibition capability of citrate, is 
relatively weak.94
The rest of the active site residues, including the bridging solvent mole-
cule WB, are structurally very similar to the native enzyme structure. The 
activating action of low concentrations of citrate and the inhibiting role at 
high concentrations suggested different binding sites of this species on the 
urease protein, with only the latter involving direct binding to the Ni(ii) ions 
in the active site.94
5.5.6  Fluoride
Fluoride has been extensively studied as a urease inhibitor.44,95,96 It carries 
out its inhibitory role through a complex mechanism, as revealed by bio-
chemical studies performed on SPU.97 In particular, fluoride exerts a mixed 
Figure 5.8  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with citric acid (PDB code 4AC7). The nickel ions 
are represented in green, while CPK coloring is used for all other atoms. 
The SPU residue-numbering scheme is used. Only selected residues are 
shown. Adapted with permission from ref. 14. Copyright (2014) Ameri-
can Chemical Society.
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competitive and uncompetitive inhibition. The pH dependence of the inhi-
bition constants, investigated in the 6.5–8.0 range, reveals a predominant 
uncompetitive mechanism that is stronger at higher pH, and a lesser com-
petitive inhibition that increases at lower pH. Five crystal structures of the 
enzyme in the native form and the same number of structures for the fluo-
ride-inhibited urease were independently determined in order to distinguish 
fluoride from solvent molecules in the active site with solid statistic confi-
dence.97 The result of this detailed analysis indicates that one fluoride ion 
binds to Ni1 of the active site, while another fluoride ion replaces the nickel- 
bridging hydroxide (Figure 5.9).
In this way, the mixed inhibition mode of fluoride was interpreted as fol-
lows: the fluoride ion bound to Ni1 competes with the incoming substrate 
urea (more effective as the pH increases, due to the increase of the concen-
tration of the fluoride anion), while the bridging fluoride ion replaces the 
bridging hydroxide (more effective as the pH decreases, which leads to pro-
tonation of the latter making it more prone to substitution), preventing it 
from carrying out the nucleophilic attack on the substrate urea.
5.5.7  Heavy Metals
Although structural data on urease–metal ion interactions are not available 
yet, biochemical information demonstrates that metal ions act as slow bind-
ing inhibitors on urease, with Hg(ii), Ag(i), and Cu(ii) ions being described 
Figure 5.9  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with fluoride (PDB code 4CEX). The nickel ions 
are represented in green, while CPK coloring is used for all other atoms. 
Hydrogen bonds are shown as thin blue lines. The SPU residue-num-
bering scheme is used. Only selected residues are shown.
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as the strongest.12 Metal ions exert their inhibitory function in a concentra-
tion-dependent manner mainly by reacting with the sul!ydryl groups of 
cysteine residues, in particular with the conserved cysteine residue located 
on the mobile flap, whose modification results in the actual enzyme inhibi-
tion.98 Additionally, Cu(ii) and possibly Ag(i) can react with nitrogen- and 
oxygen-containing functional groups, contributing to an apparent inactiva-
tion process by protein aggregation.98,99 In the case of Cu(ii), generation of 
reactive oxygen species may determine the oxidation of further functional 
groups and subsequent enzymatic inactivation.98
Bismuth compounds represent a class of heavy metal containing mole-
cules widely used as bactericidal agents in the treatment of peptic ulcers and 
H. pylori infections.100–102 Although a detailed characterization of the bacteri-
cidal mode of action has not been elucidated, it has been demonstrated that 
Bi(iii) ions inactivate urease by interacting with the thiol group of the mobile 
flap cysteine residue, at least contributing to bismuth inhibition of urease.103
5.5.8  Quinones
Quinones are a widely occurring class of molecules in nature, being involved 
in biological reduction–oxidation processes. They are also known for their 
bacteriostatic and fungicidal properties,104,105 as well as their ability to inacti-
vate proteins by either covalent modification of thiol groups through nucle-
ophilic addition/substitution or quinone – inducing redox cycling, resulting 
in reactive oxygen species generation and indirect inactivation of protein 
functional groups.106,107 The relevance of quinones as urease inhibitors was 
pointed out by Bremner and co-workers in the 1970s, demonstrating the inhi-
bition properties of p-benzoquinones on soil urease and reporting 1,4-benzo-
quinone (para-benzoquinone, PBQ) as the most promising inhibitor.108–110 In 
the recent past, Krajewska and co-workers carried out several kinetic studies 
on the inhibition of JBU by quinones, demonstrating a general common fea-
ture in the inactivation behavior towards urease.107 These molecules showed 
a slow-binding concentration-dependent inhibition mechanism, consistent 
with the covalent modification of the thiol groups of urease, and in particular 
the conserved cysteine residue on the active site mobile flap. The strength of 
the inactivation was found to be correlated with the electrophilicity of the qui-
none ring, with quinones that possess electron-donating substituents being 
weaker urease inhibitors, due to a decreasing electrophilicity of the quinone 
ring.107 Additionally, in the case of 1,4-naphthoquinone (1,4-NQ), a time- and 
concentration-dependent inactivation of urease has been shown, a mode of 
action that was ascribed to simultaneous covalent modification of the con-
served cysteine on the active site flap and indirect thiol oxidation caused by 
1,4-NQ-catalyzed redox cycling.107 The molecular structural details of the 
inactivation of urease by quinones have been established by the X-ray crystal 
structures of SPU inactivated by PBQ in the presence and in the absence of 
sulfite ions (PDB code 5FSD and 5FSE, respectively, Figure 5.10A,B).111
PBQ covalently binds to the S? atom of the ?Cys322 residue located on 
the mobile flap through one carbon atom from the quinone ring. The PBQ 
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Figure 5.10  Crystallographic structural model of the Sporosarcina pasteurii urease 
active site in complex with (A) p-benzoquinone (PDB code 5FSE), (B) 
2,5-dihydroxy-benzenesulfonate (PDB code 5FSD), and (C) catechol 
(PDB code 5G4H). The nickel ions are represented in green, while 
CPK coloring is used for all other atoms. Hydrogen bonds are shown 
as thin blue lines. The SPU residue-numbering scheme is used. Only 
selected residues are shown.
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oxygen atom at the meta position with respect to the thiol group points 
towards the entrance of the active site channel, forming a hydrogen bond 
with a water molecule (at 2.85 Å) that is also stabilized by hydrogen bonds 
with the carbonyl carbon groups of ?Leu365 (at 2.66 Å) and ?Lys169 (at 2.76 Å) 
residues (not shown in the figure). PBQ binding does not cause a closure of 
the channel within the mobile flap and the active site, suggesting that the 
inactivation of the enzyme by quinones is not caused by the blockage of sub-
strate transport through the path leading into the active site, but it is rather 
due to the prevention of flap closure, a necessary event for the catalysis to 
occur. Interestingly, a site-directed mutagenesis experiment that replaced 
the same cysteine with tyrosine in KAU, supposedly having a similar effect on 
the active site entrance, also causes the abolition of catalytic activity.64
5.5.9  Polyphenols
Polyphenols are natural compounds generally recognized as beneficial to 
human health for their antioxidant properties. Several studies pointed out 
the efficacy of natural polyphenols on urease inhibition. Bremner and Doug-
las first demonstrated that catechol, the simplest molecule featuring a poly-
phenol scaffold, displayed inhibition properties towards soil urease.108 In 
recent studies, the inhibition properties of several polyphenols and flavonoids 
against HPU have been examined, revealing that the two ortho-hydroxyl groups 
were essential for the inhibitory activity of polyphenol.112–114 In addition, some 
polyphenols from green tea115 have been recently shown to be HPU inhibitors. 
Kinetic studies on the inhibition of JBU by catechol showed an irreversible 
inhibition that takes place in a time- and concentration-dependent manner.116 
In that study, the authors claimed that inhibition could be due to the time- 
dependent oxidation of pyrocatechol to ortho-benzoquinone (OBQ), and 
increasing amounts could cause the increasing rate of urease inactivation.
The actual inhibition mechanism of catechol on urease is not clearly 
understood so far. The chemistry of polyphenols is complex.117 They can be 
oxidized to form reactive ortho-semiquinone radicals and/or OBQs. The latter 
can undergo secondary reactions against protein functional groups, such as 
thiols and amines.118 In addition, polyphenols can coordinate with transi-
tion metals to give catechol–metal complexes.117 The recently reported crys-
tal structure of SPU inhibited by catechol (PDB code 5G4H, Figure 5.10C)119 
reveals that the inhibitor covalently binds the S? atom of ?Cys322 residue, in 
a similar fashion as observed for PBQ.
5.6  Mechanism
In the absence of structural data about reaction intermediates that have 
short lifetimes, the available structures of urease in the resting hydrated state 
bound to boric acid (an analogue of the substrate) and with diamidophos-
phate (an analogue of the possible intermediate of the hydrolysis reaction) 
provided a basis for the proposal of a reaction mechanism for enzymatic urea 
hydrolysis (Figure 5.11).120
81Urease
Fi
gu
re
 5
.1
1 
  St
ru
ct
ur
e-
ba
se
d 
ur
ea
se
 c
at
al
yt
ic
 m
ec
ha
ni
sm
 o
f t
he
 e
nz
ym
at
ic
 h
yd
ro
ly
si
s 
of
 u
re
a.
 T
he
 S
PU
 r
es
id
ue
-n
um
be
rin
g 
sc
he
m
e 
is
 
us
ed
. A
da
pt
ed
 w
ith
 p
er
m
is
si
on
 fr
om
 re
f. 
14
. C
op
yr
ig
ht
 (2
01
4)
 A
m
er
ic
an
 C
he
m
ic
al
 S
oc
ie
ty
.
Chapter 582
In the following discussion, the SPU residue numbering scheme will be 
used. The presence of the tetrahedral water/hydroxide cluster in the prox-
imity of the di-nickel center in the native enzyme (Figure 5.3), together with 
the binding mode of DAP (Figure 5.6A), suggests an orientation-specific 
mode of substrate binding in the enzyme active site that is designed to sta-
bilize a tetrahedral transition state. The mechanism requires that upon urea 
entrance into the active site channel, with the flap in the open conforma-
tion, the structurally characterized hydrated active site of the resting enzyme 
evolves towards an initial substrate-bound intermediate where urea replaces 
the three water molecules bound to the Ni(ii) ions. In particular, urea initially 
binds the more electrophilic and coordinatively unsaturated Ni1 using the 
urea carbonyl oxygen, an event that must be concomitant with the displace-
ment of water molecules from the active site due to steric hindrance. The Ni1-
bound urea O atom is stabilized in this position through the formation of an 
H-bond donated by the NH group of ?His222, analogous to what is observed 
in the structures of native SPU, as well as in SPU complexed with boric acid, 
diamidophosphate, phosphate, acetohydroxamic acid, and sulfite. This step 
is supported by docking and density-functional quantum chemistry calcula-
tions,121 which also suggested that flap closure facilitates urea coordination 
to Ni2 via its –NH2 group. This interaction is stabilized by a specific H-bond-
ing network (H-bond donors on the urea carbonyl oxygen side and H-bond 
acceptors on the urea amide group side) that locates and steers the substrate 
to a precise orientation, thus allowing hydrolysis to occur. Urea is a poor che-
lating ligand because of the low Lewis base character of its –NH2 groups. 
However, the formation of strong H-bonds with the nearby carbonyl oxygen 
atoms could enhance the basicity of the –NH2 group and facilitate the inter-
action of the amide nitrogen with Ni2. The viability of a bidentate urea coor-
dination mode is supported by the crystal structure of SPU in complex with 
B(OH)3 (Figure 5.7). Boric acid has similar triangular shape and dimensions 
as urea, is isoelectronic with it, and has the same neutral charge, so it can be 
considered an inert structural analogue of the substrate. In the structure of 
urease complexed with B(OH)3, two of the borate hydroxide moieties replace 
the water molecules terminally bound to Ni1 and Ni2, while the third borate 
hydroxide replaces the distal solvent molecule. This substrate-binding mode 
involves a direct role of both Ni(ii) ions in binding and activating the sub-
strate, therefore providing a rationale for the presence of a bimetallic active 
site in urease and explaining the lack of reactivity of urease containing a single 
nickel ion.61 The presence of the Ni-bridging hydroxide in the complex of ure-
ase with B(OH)3, placed at 2.1 Å from the B atom, in a direction almost per-
pendicular to the plane of the molecule, supports its role as the nucleophile 
attacking the carbon atom of urea to yield a tetrahedral transition state/inter-
mediate. The bridging urea binding mode is the most efficient method to 
render the central carbon atom of urea electron poor and therefore prone to 
nucleophilic attack by the activated hydroxide. The kinetic inertia of a doubly 
coordinated nucleophile could be overcome by the weakening of the Ni–OH 
bonds upon substrate binding, as suggested by kinetic data on the inhibition 
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of KAU with fluoride,95 by the structure and reactivity of inorganic mod-
els,122 and by theoretical studies.121 The high reactivity of the nickel-bridging 
hydroxide is also supported by the ability of the enzyme to hydrolyze PPD81 
and perhaps PHO, where the enzyme would simply induce an oxygen atom 
(or hydroxide) exchange on the PHO moiety. In this framework, only mol-
ecules able to react with the bridging hydroxide may bind the enzyme in a 
tridentate mode, as observed for DAP and PHO. This would explain why DAP 
strongly inhibits urease when it is formed by enzymatic hydrolysis of PPD, 
whereas it is a weak inhibitor if externally added to the native enzyme.81 The 
nucleophilic attack by the Ni-bridging hydroxide onto the sp2 carbon atom of 
urea yields a tetrahedral transition state containing a sp3 carbon. The forma-
tion of a tetrahedral intermediate located between the two Ni(ii) ions is sup-
ported by the structure of urease containing DAP in the active site (formed 
in situ from PPD, Figure 5.6A) that replaces the cluster of four water/hydroxide 
molecules.53 The tetrahedral DAP bound to the di-nickel center represents an 
ideal transition state, or intermediate, analogue of the enzymatic reaction, 
while the structure of the PHO-inhibited urease (Figure 5.6B) supports the 
idea that the enzyme active site cavity is made to stabilize tetrahedral moi-
eties. Closure of the flap would also be responsible for the stabilization of 
the catalytic transition state through the formation of multiple H-bonds with 
active site residues. The nucleophilic attack onto the Ni-bridging urea mole-
cule profoundly modifies the electronic structure of the substrate and, in par-
ticular, increases the pKa of the distal urea N atom not involved in Ni-binding, 
as supported by quantum mechanical calculations.121 Furthermore, a"er the 
formation of the tetrahedral intermediate, the nickel-bridging –OH group, 
now part of a diamino(hydroxy)methanolate moiety, must now have a very 
low pKa, and can therefore transfer the proton to the distal urea –NH2 group, 
forming a C–NH3+ bond.53 This proton transfer step could be mediated by 
?Asp363 O?2 through a dihedral rotation along the C?–C? bond of the aspar-
tate bound to Ni2, a movement observed to occur in the case of the SPU : AHA 
complex (Figure 5.5),77 to bring this carboxylic oxygen atom, shown to be 
deprotonated,123 close to the bridging hydroxide or, alternatively, to the distal 
–NH2 urea group. The higher pKa observed in the pH versus urease activity 
profile (ca. 9.5) corresponds to the estimated pKa for the bridging hydroxide, 
suggesting that indeed the bridging hydroxide moiety must carry a proton 
for the enzyme to work properly.
By moving closer to the active site upon closure of the flap, the neutral 
imidazole side chain of the conserved ?His323 stabilizes the nascent C–
NH3+ group.53 Therefore, in this structure-based mechanism the bridging 
hydroxide acts as both the nucleophile and the general acid, while ?His323 
stabilizes the positive charge that develops on the transition state acting as 
a H-bond acceptor. This scheme is supported by the structure of DAP-inhib-
ited SPU (Figure 5.6A), in which the active site flap is in the closed confor-
mation, allowing ?His323 to approach the Ni environment in the active site, 
and by the 103-fold reduction in kcat upon mutation of ?Hi320 in KAU (corre-
sponding to ?His323 in SPU).124 The structure of the SPU : PHO (Figure 5.6B) 
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complex also reveals that another active site residue, ?Ala366, is important 
for the modulation of the protonation state of the distal urea –NH2 group by 
adopting two different conformations, acting as a molecular switch able to 
provide stabilization for the protonation of the distal urea –NH2 group by 
providing its backbone carbonyl group as a H-bond acceptor. The formation 
of the C–NH3+ moiety a"er proton transfer, and its stabilization by the cata-
lytic histidine, causes the breakage of the distal C–N bond, with the subse-
quent release of ammonia.121 The resulting carbamate spontaneously reacts 
with water, eventually forming another molecule of ammonia and hydrogen 
carbonate. The opening of the active site flexible flap facilitates the release 
of products, thus allowing bulk water to rehydrate the active site, regener-
ating the resting state of the enzyme. These steps could possibly occur in a 
concerted manner. This structure-based mechanism is in agreement with all 
available kinetic data, in particular with the pH-dependence of the enzyme 
activity and with the non-competitive inhibition by fluoride, which is sug-
gested to replace the bridging hydroxide, and consistent with the hypothesis 
of the bridging hydroxide acting as nucleophile.
The presence of nickel as an enzyme metal cofactor in urease has 
intrigued the bioinorganic chemistry community since its discovery.7 The 
structure-based mechanism discussed above could help to explain the 
requirement for Ni(ii) ions instead of the more common and less toxic d10 
closed-shell Zn(ii) commonly observed in hydrolytic enzymes. The latter ion 
has a large positive charge density, which renders it able to act as a Lewis 
acid by polarizing substrates and preparing them for nucleophilic attack by 
hydroxide, and is resilient towards deleterious redox state changes. How-
ever, these properties are also applicable to Ni(ii), which additionally fea-
tures an open-shell d8 electronic configuration that induces stereoelectronic 
restraints not available in the case of Zn(ii). This property could be exploited 
by Ni(ii) to drive the two substrates, urea and water, into the optimal spa-
tial topology necessary for catalysis. Furthermore, Ni(ii) has a higher affinity 
toward nitrogenous-based ligands than Zn(ii),125 thereby better stabilizing 
the binding of a urea –NH2 group. Finally, Ni(ii) ions possess multiple avail-
able binding sites due to their preference for an octahedral coordination 
sphere (as opposed to Zn(ii), which mostly prefers tetrahedral126), thus facili-
tating both the bridging binding-mode of urea and stable metal ion binding 
to the protein through multiple sites for amino acids ligands.
Attempts to substitute the essential Ni(ii) with other ions such as Zn(ii), 
Co(ii), and Mn(ii) have been carried out to check the viability of a urease- 
based catalysis with non-native metals. Removal of both Ni(ii) ions by treat-
ing JBU with EDTA at low pH causes irreversible inactivation of the pro-
tein.127 Removal of a single Ni(ii) ion from JBU was obtained by dialysis in 
the presence of citrate, and substitution of the more labile metal ion with 
Zn(ii) or Co(ii) produced catalytically inert urease.128 This inactivation was 
also observed for KAU reconstituted with Zn(ii), Co(ii), and Cu(ii), while in 
the case of the Mn-derivative ca. 0.3% of the activity was retained.61 The crys-
tal structure of the Mn-derivative of KAU was determined (PDB code 1EF2), 
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with active site features essentially identical to the native Ni-bound form.129 
Quite recently, an alternative urease in Helicobacter mustelae (HMU) has been 
reported, which is characterized by the absence of Ni(ii), by inactivation in 
the presence of oxygen, and by Fe(ii)-induced expression, observations that 
suggested the presence of Fe(ii) ions in its active site.130 This hypothesis 
was later confirmed, and the reported crystal structure showed little or no 
differences as compared to the Ni(ii)-enzyme, while the catalytic efficiency 
appeared to be much smaller.131 All together, these observations suggest 
that, in addition to the identity of the metal ions, the precise position and 
mobility of the metal ligands, as well as those of protein residues in the active 
site not involved in metal binding, are important in achieving optimal urease 
activity.
5.7  Non-Enzymatic Properties of Urease
Besides the well-established enzymatic aspects, non-enzymatic biological 
properties of ureases have also been established.23 In general, plant and 
microbial ureases have been demonstrated to be toxic against filamentous 
fungi and yeasts by a mechanism involving cell wall and/or membrane per-
meabilization and consequent plasmolysis.132,133 Furthermore, plant and 
some bacterial ureases have potent insecticidal effects, exhibiting neurotox-
icity and affecting other physiological functions, such as diuresis, muscle 
contraction, and immunity.134–137 Toxic effects of ureases have been charac-
terized through in vivo and in vitro studies demonstrating them to be unre-
lated to enzymatic activity.138–141 Although ureases are entomotoxic per se, 
studies conducted on canatoxin (CNTX), an isoform of JBU isolated from jack 
bean seeds142,143 and soybean (Glycine max) embryo-specific urease (SBU), 
show that toxicity against insects derives, at least partly, from a small peptide 
(pepcanatox following canatoxin nomenclature) released from the ingested 
urease a$er its hydrolysis by insect cathepsin-like digestive enzymes. Recom-
binant analogues of these peptides, named Jaburetox and Soyuretox in the 
case of CNTX and SBU, respectively, also feature insecticidal and antifungal 
activity.23,144 Jaburetox has been recently shown to be an intrinsically disor-
dered polypeptide, possibly increasing its secondary structure content upon 
interaction with cell membranes.145
5.8  Microbial Induced Calcite Preparation by 
Ureolytic Bacteria
Calcium carbonate (CaCO3) precipitation is a common (bio)geochemical 
process found in environments such as marine waters, freshwaters, and 
soils.146,147 Different microorganisms are able to induce calcium carbonate 
precipitation (microbial induced carbonate precipitation, MICP) by creating 
an alkaline environment.147,148 Among them, ureolytic microorganisms (i.e. 
S. pasteurii) are the most energy efficient.149 The urease activity (production 
Chapter 586
of bicarbonate (HCO3−) and an overall increase of pH) in turn causes a shi" of 
the bicarbonate equilibrium (pKa(HCO3−) = 10.33 at 25 °C) towards an increase 
of the carbonate moiety (CO32−) that precipitates in the presence of calcium 
ions as calcium carbonate crystals. MICP has been studied for several multi-
disciplinary applications, such as cementation of sands to enhance bearing 
capacity and liquefaction resistance, soil erosion control, remediation of soil 
and groundwater impacted by metals and radioactive elements, and many 
others.150
5.9  Urease Maturation Process: The Role of 
Accessory Proteins
Urease is initially expressed as an inactive apo-protein that undergoes a 
post-translational maturation process yielding a fully active enzyme (Figure 
5.12).
This activation path involves two peculiar steps: (i) lysine carbamylation 
coupled with GTP hydrolysis and (ii) Ni(ii) ion delivery into the urease active 
site (Chapter 14). The urease maturation process is usually carried out by four 
accessory proteins: UreD (called UreH in H. pylori), UreF, UreG, and UreE.13,151 
Genomes of most ureolytic organisms show structural and accessory pro-
teins being encoded by genes clustered in one or more operons, with vari-
able gene order depending on the source.13 Overall, this organization reflects 
the need for both structural and accessory functions to achieve a fully active 
enzyme and suggests that their expression mechanism is concomitantly reg-
ulated.13,151 The “classical” model for urease maturation involves UreD, UreF, 
and UreG acting together as a molecular chaperone in a UreD : UreF : UreG 
supercomplex (UreDFG) that drives GTP hydrolysis and lysine carbamyla-
tion, while UreE acts as the metallochaperone that delivers Ni(ii) ions to the 
complex formed by apo-urease and UreDFG.13,151 Even though the functional 
role of the single accessory proteins is not fully elucidated and no consensus 
has been reached on the sequence of events during the formation of the ure-
ase : UreDFG complex, the following model has been proposed (Figure 5.12A). 
UreD is the first protein to interact with the apoenzyme, being able to directly 
bind to urease.152,153 It is considered to act as a protein scaffold that allows 
the interaction of the other chaperones with the enzyme,154,155 although some 
studies suggest that it also likely facilitates nickel insertion into the active 
site.61 Once the urease–UreD complex is formed, UreF binds it by interacting 
with UreD, inducing a conformational rearrangement of the enzyme.152 UreF 
acts as the binding site for UreG and it has been demonstrated to have a 
role in enhancing the urease activation process, possibly by modulating the 
GTPase activity of UreG through a direct protein–protein interaction156 and 
promoting access to the active site of Ni(ii) ions and the CO2 needed for the 
lysine carbamylation event.157,158 The carbamylation process is carried out 
upon GTP hydrolysis by UreG, possibly through the formation of the carba-
mylating agent carboxyphosphate in the presence of CO2.159 UreG is the first 
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Figure 5.12  (A) Schematic representation of the “classic” proposed mechanisms 
for urease activation. (B) Ribbon diagram of the UreF (le!-hand side) 
UreDF (center), and UreDFG (right-hand side) crystal structures (PDB 
codes 3CXN, 3SF5, and 4HI0, respectively). UreD, UreF, and UreG 
chains are colored in light blue, light green–yellow, and dark red, 
respectively, with the darker and lighter portions highlighting the 
different monomers. (C) Ribbon diagram of the UreE crystal struc-
tures from Sporosarcina pasteurii (le!-hand side), Klebsiella aerogenes  
(center) and Helicobacter pylori (right-hand side). Chains are colored 
grey with the darker and lighter portions highlighting the different 
monomers. (D) Schematic representation of the new proposal for 
urease activation.178
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case of an intrinsically disordered enzyme,160 which can retain enzymatic 
activity owing to the rigidity of the active-site environment,161 and is able 
to dimerize upon Zn(ii) binding.162,163 The macromolecular urease : UreDFG 
complex interacts with UreE, which acts as the metallochaperone that deliv-
ers Ni(ii) to urease in order to complete the enzyme maturation (see Chapter 
14 for a detailed discussion of nickel metallochaperones).13,151 In vivo studies 
using yeast two-hybrid analysis164,165 and co-immunoprecipitation assays,165 
as well as in vitro calorimetry and NMR spectroscopy,166 indicated a direct 
interaction between UreE and UreG from H. pylori. The in vitro interaction 
between UreE and UreG has been observed also in S. pasteurii.167
Even though the structure of urease bound to any of the accessory proteins 
is not yet available, the crystal structure of the (UreF)2 homodimer (PDB code 
3CXN)168 and the structure of the (UreDF)2 (PDB code 3SF5)169 and (UreDFG)2 
(PDB code 4HI0)170 complexes from H. pylori have been recently reported 
(Figure 5.12B). The crystal structure of the (UreDFG)2 complex contains two 
copies of each of UreF, UreD, and UreG, related by two-fold symmetry, form-
ing a dimer of heterotrimers. Structural information on UreE proteins from 
various bacteria has been derived from numerous crystallographic studies: 
UreE from S. pasteurii (PDB codes 1EAR, 1EB0, and 4L3K),171,172 K. aerogenes 
(PDB codes 1GMU, 1GMV, and 1GMW),173 and H. pylori (PDB codes 3L9Z, 
3LA0, 3NXZ, 3NY0, 3TJ8, 3TJ9, and 3TJA)174,175 display a similar fold made 
by a symmetric homodimer (Figure 5.12C), with each monomer composed 
of two domains connected by flexible linkers.176 UreE binds Ni(ii) ions at the 
dimer interface by using one conserved histidine residue from each mono-
mer and completing the coordination sphere by using histidine residues 
found in the C-terminal part of the chain.166,172,175–177
The entirety of the structural information from crystallography, together 
with UV-VIS spectroscopy, light scattering experiments, and GTPase activity 
assays performed on H. pylori UreG, recently suggested a new mechanism 
for the biosynthesis of the urease active site (Figure 5.12D).178 In this new 
proposal, the Ni(ii)-bound UreE dimer binds two apo-UreG monomers, 
facilitating GTP uptake by UreG in the presence of Mg(ii) ions. The UreG 
binding to UreE can, in principle, occur either in a single or in a multistep 
process. In the (UreEG)2 complex, the Ni(ii) ion is then translocated from 
(UreE)2 to (UreG)2. Subsequently, the pre-formed (UreDF)2 complex com-
petes with (UreE)2 for the (UreG)2 : Ni(ii) complex to form the supercomplex 
apo-urease : (UreDFG)2 : Ni(ii). Finally, the GTP hydrolysis performed by UreG 
is catalyzed by KHCO3/NH4HCO3 to complete the nickel insertion into the 
apo-urease. Interestingly, the analysis of the H. pylori UreDFG structure high-
lighted the presence of a large cavity at the interface between UreF and UreG. 
The internal cavity contains several inner water molecules interconnected 
through a network aligned along the horizontal axis of the UreD–UreF2–UreD 
portion of the structure.158 A deeper investigation of the complex structure 
revealed the presence of two nearly identical and symmetric tunnels going 
from the central cavity in the complex and exiting near the UreD C-termi-
nus, passing through UreF and UreD. It has been hypothesized that Ni(ii) 
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ions can proceed through these tunnels to reach the apo-urease active site. 
The importance of the tunnel passing through UreD has been recently high-
lighted in a work conducted on UreD from K. aerogenes.179
Some exceptions in urease maturation systems have been pointed out. 
Plants appear to lack homologs to UreE.19 On the other hand, plant UreGs 
possess an extended nickel-binding nitrogen terminus rich in histidine and 
aspartate residues and it has been suggested to exploit this feature to replace 
UreE during Ni(ii) delivery.19 The genome of Helicobacter mustelae, a gastric 
pathogen of ferrets that additionally produces a Fe(ii)-urease, contains two 
urease clusters.180 The genome of Bacillus subtilis contains only the struc-
tural urease genes; nevertheless, this bacterium can synthesize an active 
nickel-containing urease, although with poor efficiency.181
5.10  Conclusions
The chemistry of the essential Ni(ii) ions in the active site of urease – inves-
tigated by several research groups using different techniques, mainly X-ray 
crystallography, X-ray absorption spectroscopy, and enzymatic assays based 
on optical spectroscopy or calorimetry – has been revealed, and the peculiar-
ities of this metal ion as compared to possible alternatives have been eluci-
dated. This chapter thus represents the starting point from which the design 
and development of new and more efficient urease inhibitors for the control 
of urease activity in medical and agricultural applications will hopefully be 
achieved in the near future.
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Abstract Urease is a nickel-dependent enzyme and a
virulence factor for ureolytic bacterial human pathogens,
but it is also necessary to convert urea, the most worldwide
used fertilizer, into forms of nitrogen that can be taken up
by crop plants. A strategy to control the activity of urease
for medical and agricultural applications is to use enzyme
inhibitors. Fluoride is a known urease inhibitor, but the
structural basis of its mode of inhibition is still undeter-
mined. Here, kinetic studies on the fluoride-induced inhi-
bition of urease from Sporosarcina pasteurii, a widespread
and highly ureolytic soil bacterium, were performed using
isothermal titration calorimetry and revealed a mixed
competitive and uncompetitive mechanism. The pH
dependence of the inhibition constants, investigated in the
6.5–8.0 range, reveals a predominant uncompetitive
mechanism that increases by increasing the pH, and a
lesser competitive inhibition that increases by lowering the
pH. Ten crystal structures of the enzyme were indepen-
dently determined using five crystals of the native form and
five crystals of the protein crystallized in the presence of
fluoride. The analysis of these structures revealed the
presence of two fluoride anions coordinated to the Ni(II)
ions in the active site, in terminal and bridging positions.
The present study consistently supports an interaction of
fluoride with the nickel centers in the urease active site in
which one fluoride competitively binds to the Ni(II) ion
proposed to coordinate urea in the initial step of the cata-
lytic mechanism, while another fluoride uncompetitively
substitutes the Ni(II)-bridging hydroxide, blocking its
nucleophilic attack on urea.
Keywords X-ray crystallography ! Urease ! Fluoride !
Nickel ! Sporosarcina pasteurii ! Enzyme inhibition !
Calorimetry
Introduction
Urease (E.C. 3.5.1.5) is a nickel-dependent non-redox
enzyme [1] that catalyzes the hydrolysis of urea
(Scheme 1) in the last step of organic nitrogen minerali-
zation in bacteria, fungi, plants, algae and invertebrates [2–
5] by increasing the rate of urea hydrolysis 1015 times as
compared to the non-catalyzed hydrolysis reaction [6].
The high urease activity triggers an overall increase in
pH of the surrounding milieu, which in turn causes nega-
tive consequences on human and animal health as well as
in plant crop production [2–5, 7–10]. Therefore, efficient
urease inhibitors are needed for both medical and agricul-
tural applications. These inhibitors could target either the
urease activation process, which involves the interaction of
four accessory proteins named UreD, UreF, UreG and
UreE with the urease apoenzyme, resulting in the insertion
of the two Ni(II) ions in the active site [5, 11], or the
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activated enzyme itself. In the latter case, knowledge of the
structure of the nickel-containing catalytic cavity is
essential. Several structural studies on ureases from dif-
ferent biological sources [12–16] have revealed that the
immediate environment around the two Ni(II) ions at the
active site is conserved, as to induce a common mechanism
of catalysis whose key step is the nucleophilic attack of the
nickel-bridging hydroxide on the urea molecule bound to
the bimetallic nickel cluster via O and N atoms (Scheme 2)
[1, 5, 7, 9, 10, 13]. In this mechanism, the reaction is
accompanied by the formation of an extended network of
second shell hydrogen bonds that stabilizes the binding of
the substrate, and by the movement of a flexible flap that
changes the active site channel from an open to a closed
conformation.
Several classes of inhibitors have been proposed and
tested [4, 17]. Urea structural analogs, such as hydroxy-
urea, formamide, thiourea and alkyl-substituted urea are
competitive inhibitors, and the same behavior is observed
for thiols, phosphate, boric and boronic acids, as well as
Bi(III) complexes [4, 17]. Hydroxamates, heavy metal ions,
as well as amide and ester derivatives of phosphoric and
thiophosphoric acids compose another group of competi-
tive and slow-binding inhibitors, some of which have found
applications in medicine and agriculture because of their
high efficacy; however, they exhibit either toxicity or low
stability and are therefore not optimal for these applications
[4, 17]. Most recently, the synthesis and study of a novel
class of inhibitors based on phosphinic and thiophosphinic
acid skeletons, which contain a hydrolytically stable C–P
bond, have been reported and represent promising leads for
further developments [18–20]. The structural basis for the
inhibition properties of some of these classes of inhibitors
has been established by a series of crystal structures of
ureases from different sources bound to b-mercaptoethanol
[21], acetohydroxamic acid [14, 22, 23], phosphate [15,
24], boric acid [25], and diamidophosphate [13]. Recently,
the structure of a urease bound to citrate revealed the
potential for carboxylates to act as competitive enzyme
inhibitors [26].
Fluoride is a good ligand for metal ions and has been
reported to act as a mixed competitive/uncompetitive [27],
pseudo-uncompetitive slow-binding [28], competitive [29],
and competitive slow-binding [30] urease inhibitor in a
number of kinetic studies. Here, we discuss crystallo-
graphic evidences for the structure of the complex formed
between fluoride and urease from S. pasteurii (SPU) as
compared to the structure of the same enzyme in the native
state. This analysis, concomitantly with a re-evaluation of
the behavior of fluoride as inhibitor of SPU using a calo-
rimetry-based enzymatic assay, allowed us to accurately
identify the active site Ni(II) ligands as solvent molecules
or fluoride ions, and therefore to draw a rationale for the
mechanism of inhibition. This study supports the view that
fluoride inhibits urease using a mixed competitive and
uncompetitive mechanism. This action is exerted by
binding to the active site Ni(II) ion that is thought to be
initially involved in the binding of urea, as well as by
replacing the nickel-bridging hydroxide that appears to act
as the nucleophile in the urea hydrolysis reaction [5, 7, 9,
10, 13].
Materials and methods
Sporosarcina pasteurii (previously known as Bacillus
pasteurii) urease (SPU) was purified using a previously
reported protocol [26].
Kinetic studies
Calorimetric experiments were carried out with a high-
sensitivity VP-ITC (ITC: isothermal titration calorimetry)
micro-calorimeter (MicroCal LLC, Northampton, MA,
USA), using a previously described enzymatic assay [31,
32]. The calorimeter is made of a reference cell filled with
deionized water and a sample cell where the reaction
occurs. Reference and sample cells are maintained at the
Scheme 1 Urease catalysed hydrolysis
Scheme 2 Nucleophilic attack to urea carbon by the bridging
hydroxide upon urea binding to the Ni ions
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same temperature. The method monitors the enzymatic
conversion of substrate by probing the heat (Q, cal) gen-
erated over time, defined as thermal power TP (cal s-1),
necessary to maintain the reaction cell at the same constant
temperature of the reference cell:
TP ¼ dQ
dt
ð1Þ
The heat (Q) is proportional to the moles of substrate
urea converted to products (n) and to the molar enthalpy of
the reaction (DH, cal mol-1):
Q ¼ n$ DH ð2Þ
The number of moles can be calculated as the product of
the molar concentration of the converted substrate ([urea],
mol L-1) times the total volume (V, L) of the solution, and
therefore the overall heat Q can be calculated:
Q ¼ ½urea& $ V $ DH ð3Þ
The reaction rate, defined as the change in substrate
concentration over time can thus be related to the thermal
power:
v ¼ ' d½urea&
dt
¼ ' 1
V $ DH $
dQ
dt
¼ ' 1
V $ DH $ TP ð4Þ
According to the above equation, the reaction rate can
be determined by first establishing the reaction molar
enthalpy DH in an experiment defined as M1, and then by
monitoring the thermal power upon multiple substrate
additions, with an experiment defined as M2.
For both M1 and M2, the SPU samples were eluted
through a Superdex 200 10/300 GL (GE Healthcare) size-
exclusion chromatography column immediately before the
measurements, using a 50 mM HEPES pH 7.0 buffer,
containing 50 mM Na2SO3 and 150 mM NaCl, as eluent.
The protein samples were then diluted with 50 mM HEPES
(at the pH value used in the experiment, 6.5, 7.0 or 8.0) to
the concentrations used for M1 and M2 (indicated below),
degassed, and loaded into the ITC sample cell
(V = 1.4093 mL). The ITC stirring injection syringe was
filled with urea dissolved in the same buffer to the con-
centrations used for M1 and M2 (see below). The reference
cell was filled with deionized water, and the temperature of
the two cells was set and stabilized at 298 K. Stirring speed
was 300 rpm, and thermal power was monitored every 2 s
using high instrumental feedback.
For experiment M1, 30 nM SPU and 20 mM urea
were used in cell and in syringe, respectively, and a
single injection of 5 lL urea was carried out, giving a
final substrate concentration of 0.07 mM in the sample
cell. After the baseline returned to the original level,
indicating that the consumption of the substrate was
complete, a second injection was performed. Numerical
integration of the area under the two single peaks was
carried out, and the average value thus obtained yielded
the molar enthalpy for urea hydrolysis in the utilized
experimental conditions (buffer composition, ionic
strength, temperature and pH).
For experiment M2, 45–105 pM SPU and 0.4–1.0 M
urea were used in the cell and in the syringe, respectively.
After 15 min of enzyme pre-incubation at 25 !C in 50 mM
HEPES pH 6.5, 7.0 or 8.0 with or without fluoride,
depending on the experiment (see below), successive
injections of 5–7 lL urea were carried out every 2–3 min,
a time necessary to allow the thermal equilibrium to return
to a steady-state level after each injection and, at the same
time, maintain pseudo-first-order reaction conditions. The
thermal power obtained from the baseline shift was aver-
aged using the last 15 s prior to the subsequent injection to
obtain an accurate measurement. The calculated thermal
power for each injection was converted to reaction rate
using Eq. (4) and corrected for enzyme concentration.
Experiments were conducted in the same conditions in the
absence and in the presence of 100–800 lM NaF, dis-
solved in both the enzyme and the substrate solutions to
keep the concentration constant. Control experiments were
carried out by injecting the urea solution into the buffer
alone. Data were processed with the Origin package pro-
vided by calorimeter manufacturer. The reaction rates, in
the absence and in the presence of fluoride, were obtained
from the change in thermal power calculated as the dif-
ference between the original baseline and the new baseline
following each injection, using Eq. (4) and the value of
DH determined in M1.
The data analysis was based on the following definitions
of types of enzyme inhibition [33]:
1. the inhibitor binds to the enzyme independently of the
presence of substrate, in a reversible equilibrium of the
type E + I!EI; for this competitive inhibition the
dissociation constant is expressed as Kic; in this case,
the rate of enzymatic reaction is given by the Eq. (5),
in which Vmax = kcat[urease] and Km are the maximum
rate and the Michaelis constant, respectively, while [I]
is the molar concentration of the inhibitor:
v ¼ Vmax $ ½urea&
½urea& þ Km $ 1þ ½I&Kic
! " ð5Þ
2. the inhibitor binds to the enzyme only in the presence
of substrate in an uncompetitive inhibition equilibrium
of the type ES + I!ESI, for which the dissociation
constant is expressed as Kiuc; in this case, the rate of
enzymatic reaction is given by:
J Biol Inorg Chem (2014) 19:1243–1261 1245
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v ¼ Vmax " ½urea$
Km þ ½urea$ " 1þ ½I$Kiuc
! " ð6Þ
3. the inhibitor binds to the enzyme both in the presence
and in the absence of substrate, so that both equilibria
above are operating, in the so-called non-competitive,
or mixed, inhibition; in this case, the rate of enzymatic
reaction is given by:
v ¼ Vmax " ½urea$
Km " 1þ ½I$Kic
! "
þ ½urea$ " 1þ ½I$Kiuc
! " ð7Þ
The kinetic parameters were obtained from a fit of the
experimental reaction rates obtained by calorimetry to the
general inhibition Eq. (7), using non-linear regression
analysis implemented in MacCurveFit (v. 1.5.4 Kevin
Raner software).
Crystallographic studies
Crystallization trials were performed at 293 K using the
hanging-drop method and 1 lL of a 11 mg/mL SPU
solution in 20 mM Na-HEPES, pH = 7.0, containing
50 mM Na2SO3, which was diluted with 1 lL of the pre-
cipitant solution. The drop was equilibrated by vapor dif-
fusion against 1 mL of the precipitant solution using a
Hampton Research 24-well Linbro plate. Protein crystals of
native SPU appeared within 1–3 weeks and grew to a size
of 0.3 9 0.3 9 0.6 mm3 when they were equilibrated
against a solution containing 1.6–1.8 M ammonium sulfate
in a 100 mM sodium citrate buffer and in 50 mM Na2SO3
(final pH *6.5 [26]). Protein crystals of fluoride-inhibited
SPU were obtained using identical conditions except for a
precipitant solution that additionally contained 100 mM
sodium fluoride.
Crystals of native and fluoride-bound SPU were scooped
up using cryoloops, transferred to a cryoprotectant solution
containing 20 % ethylene glycol, 2.4 M ammonium sul-
fate, 100 mM sodium citrate and 50 mM Na2SO3 (100 mM
sodium fluoride was additionally present in the case of the
crystallization of the fluoride complex) and then flash
cooled and stored in liquid nitrogen. Diffraction data were
collected at 100 K using synchrotron radiation at the
EMBL P13 beamline of the Petra III storage ring, c/o
DESY, Hamburg (Germany). The wavelength was set to
0.968 A˚ using a Si(111) crystal monochromator (FMB-
Oxford). The beamline was equipped with a Rayonix
HE225 CCD detector and a MD2 goniometer (Maatel-
EMBL) with an horizontal spindle axis. Reflection data
were collected in two sweeps to accurately record low- and
high-resolution data without overloading the detector. Each
sweep consisted of 360 images with 0.2! oscillation. The
data were processed using XDS [34] and SCALA [35]. The
complete diffraction data statistics of five crystals of native
urease and five crystals of urease obtained in the presence
of fluoride are given in Tables 1 and 2. All the crystals
were highly isomorphic with space group P6322; the
number of molecules per unit cell (Z-number) was 12, with
a resulting solvent content of 55 % and a Matthews coef-
ficient of 2.73 A˚3/Da.
In all cases, the structure solution and refinement followed
exactly the same protocol. The model of SPU in complex
with citrate (PDB code 4AC7), devoid of water and ligands,
was used as a starting model for the rigid body refinement of
the single subunits, conducted using Refmac [36, 37]. The
model building and the water or ligand addition/inspection
were conducted using Coot [38, 39]. The structure was iso-
tropically refined, including the hydrogen atoms in the riding
positions. The final refinement statistics are reported in
Tables 1 and 2. The highest overall quality structures of
native and fluoride-inhibited SPU were deposited in the
RCSB Protein Data Bank with accession codes 4CEU and
4CEX, respectively, while all remaining crystallographic
data are available upon request. Crystallographic figures
were created using PyMOL (The PyMOL Molecular
Graphics System, Schroedinger, LLC.) or Chimera [40].
Results
Calorimetric analysis
The inhibition of S. pasteurii urease by fluoride was
investigated using isothermal titration calorimetry (ITC), a
method that is becoming a major tool to aid enzyme
inhibitor screening and design [31, 32, 41]. The molar
reaction enthalpy was determined using the so-called M1
experiment, in which a single injection of diluted substrate
solution into a concentrated solution of the enzyme caused
a decrease of the instrumental thermal power necessary to
maintain the temperature constant, indicating an exother-
mic reaction. Complete consumption of the substrate
occurred within ca. 25 min (Fig. 1a). The integration of the
curve at pH 7.0 yielded DH = -10.0 kcal mol-1. A sec-
ond injection of substrate into the reaction cell (now con-
taining ammonium ions and bicarbonate, the products of
the reaction) provided a curve with identical shape and
area, confirming the value of DH and showing negligible
inhibition by products (Fig. 1a). The different value of
DH measured in the present study at pH 7.0, as compared
to that obtained previously in the case of jack bean urease
(JBU) (DH = -2.8 kcal mol-1) [29], is ascribed to the
different buffers used in the two calorimetric experi-
ments (HEPES vs. Tris), which have different ionization
enthalpies [DHion (HEPES) = -4.88 kcal mol
-1); DHion
1246 J Biol Inorg Chem (2014) 19:1243–1261
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(Tris = -11.34 kcal mol-1)]. Therefore, an intrinsic urea
hydrolysis reaction enthalpy of -14.9 and -14.1 kcal
mol-1 can be derived from these two studies on SPU and
JBU, respectively, consistently with the values of -14.5
determined for urease from Helicobacter pylori at pH 7.8
[31] and -14.7 kcal mol-1 more recently reported for JBU
at pH 7.0 [32].
The M2 experiment was then carried out using a
diluted enzyme solution in the measuring cell and per-
forming multiple injections of a concentrated substrate
solution to maintain the substrate concentration essen-
tially constant within the measuring time. This experi-
ment revealed an initial increase in thermal power due to
the heat of substrate dilution, followed by a decrease
Table 1 X-ray diffraction data collection and refinement statistics for native (PDB code 4CEU) SPU
Native 4CEU Crystal native #2 Crystal native #3 Crystal native #4 Crystal native #5
Data collection
Wavelength (A˚) 0.968 1.126 1.126 1.126 1.126
Space group P6322 P6322 P6322 P6322 P6322
a = b (A˚) 131.12 131.18 131.66 131.17 131.85
c (A˚) 188.84 189.38 189.25 189.22 189.50
Resolution (A˚)a 97.51–1.58
(1.62–1.58)
113.6–1.47
(1.55–1.47)
114.0–1.54
(1.62–1.54)
189.22–1.63
(1.72–1.63)
189.5–1.47
(1.55–1.47)
Number of measured reflectionsa 1,277,435
(165,497)
3,858,287
(353,561)
1,190,816
(134,547)
1,153,350
(127,802)
2,390,319
(189,425)
Number of unique reflectionsa 130,522 (18,780) 161,048 (21,847) 140,347 (19,090) 117,968 (16,455) 162,414 (22,558)
Rmerge
a,b 0.091 (0.524) 0.106 (0.467) 0.109 (0.657) 0.094 (0.897) 0.090 (0.955)
Rpim
a,c 0.030 (0.187) 0.021 (0.115) 0.039 (0.4) 0.031 (0.333) 0.022 (0.340)
I/r (I)a 23.0 (4.5) 24.3 6.9 13.3 (2.0) 18.2 (2.4) 23.0 (2.6)
Multiplicitya 9.8 (8.8) 24 (16) 8.5 (7.0) 9.8 (7.8) 14.7 (8.4)
Completeness (%)a 100.0 (100.0) 98.6 (92.9) 98.9 (93.5) 99.5 (96.5) 99.4 (95.8)
B-factor from Wilson plot (A˚2) 13.5 12.9 15.6 17.0 14.5
Refinement
R, Rfree
d (%) 13.51, 15.49 13.23, 14.55 16.64, 19.16 14.07, 16.65 14.58, 16.90
Cruickshank’s DPIe based on R (A˚) 0.059 0.047 0.068 0.068 0.052
Cruickshank’s DPIe based on Rfree
(A˚)
0.059 0.047 0.070 0.070 0.054
ESU based on maximum likelihood
(A˚)
0.037 0.028 0.052 0.047 0.039
RMSDf of bond lengths (A˚) 0.011 0.010 0.014 0.014 0.012
RMSDf of bond angles (!) 1.59 1.50 1.68 1.67 1.59
Average B-factor for protein atoms
(A˚2)
14.3 12.9 17.1 17.2 16.47
Average B-factor for water
molecules (A˚2)
27.7 26.5 28.6 28.7 27.7
Average B-factor for Ni atoms (A˚2) 12.25, 11.35 9.93, 8.86 15.52, 14.15 14.83, 13.36 14.66, 13.30
Average B-factor for FB (A˚
2) – – – – –
Average B-factor for FT (A˚
2) – – – – –
Number of protein atoms 6,094 6,151 6,094 6,118 6,117
Number of Ni atoms 2 2 2 2 2
Number of water molecules 859 886 847 856 844
Number of fluoride ions 0 0 0 0 0
Number of sulfate molecules 6 6 5 6 5
Ramachandran most-favored region
(%)
96.8 96.3 95.5 95.7 95.9
Ramachandran additional allowed
region (%)
2.9 2.9 4.5 4.3 4.1
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Table 2 X-ray diffraction data collection and refinement statistics for fluoride-bound (PDB code 4CEX) SPU
Fluoride 4CEX Crystal fluoride #2 Crystal fluoride #3 Crystal fluoride #4 Crystal fluoride #5
Data collection
Wavelength (A˚) 0.968 0.968 0.968 0.968 1.127
Space group P6322 P6322 P6322 P6322 P6322
a = b (A˚) 131.33 131.34 131.08 131.31 131.12
c (A˚) 188.88 188.69 188.39 188.90 188.64
Resolution (A˚)a 113.74–1.59
(1.63–1.59)
113.71–1.62
(1.71–1.62)
188.47–1.72
(1.81–1.72)
113.72–1.68
(1.77–1.68)
113.6–1.63
(1.63–1.72)
Number of measured reflectionsa 1,852,002
(163,038)
1,815,217
(154,629)
1,414,007
(129,367)
962,171 (138,960) 1,165,307
(127,382)
Number of unique reflectionsa 128,776 (18,517) 121,776 (17,531) 101,225 (14,358) 109,143 (15,684) 116,761 (15,890)
Rmerge
a,b 0.100 (0.523) 0.115 (0.492) 0.149 (0.51) 0.073 (0.47) 0.115 (0.537)
Rpim
a,c 0.026 (0.184) 0.030 (0.176) 0.039 (0.158) 0.026 (0.167) 0.037 (0.193)
I/r (I)a 19.7 (4.6) 17.9 (4.5) 20 (4.0) 11 (5.2) 14 (3.6)
Multiplicitya 14.4 (8.8) 14.9 (8.8) 14.0 (9.0) 8.8 (8.9) 10 (8.0)
Completeness (%)a 100.0 (100.0) 100 (100) 99.5 (98.2) 99.8 (99.8) 98.4 (93)
B-factor from Wilson plot (A˚2) 12.3 15.1 15.5 14.83 13.15
Refinement
R, Rfree
d (%) 12.97, 15.02 14.34, 16.21 13.63, 16.17 13.25, 15.24 12.67, 14.83
Cruickshank’s DPIe based on R (A˚) 0.057 0.066 0.077 0.069 0.061
Cruickshank’s DPIe based on Rfree
(A˚)
0.058 0.066 0.077 0.068 0.062
ESU based on maximum likelihood
(A˚)
0.033 0.044 0.051 0.043 0.037
RMSDf of bond lengths (A˚) 0.011 0.014 0.015 0.013 0.012
RMSDf of bond angles (!) 1.53 1.68 1.72 1.62 1.54
Average B-factor for protein atoms
(A˚2)
12.9 16.8 15.6 14.48 13.62
Average B-factor for water
molecules (A˚2)
27.5 28.6 28.1 28.4 28.33
Average B-factor for Ni atoms (A˚2) 8.75, 9.67 12.96, 12.19 12.61, 11.52 11.89, 10.78 10.64, 9.82
Average B-factor for FB (A˚
2) 8.28 12.67 11.42 11.70 11.01
Average B-factor for FT (A˚
2) 13.6 18.48 14.15 14.81 16.54
Number of protein atoms 6,104 6,108 6,114 6,084 6,083
Number of Ni atoms 2 2 2 2 2
Number of water molecules 826 761 807 864 835
Number of fluoride ions 2 2 2 2 2
Number of sulfate molecules 3 3 4 2 3
Ramachandran most-favored region
(%)
96.4 95.2 95.3 95.6 96.0
Ramachandran additional allowed
region (%)
3.2 4.8 4.7 4.4 4.0
a The values in parentheses are for the highest-resolution shell
b Rmerge ¼ RhklRi Ii hklð Þ $ I hklð Þh ij j=RhklRi Ii hklð Þj j
c Rpim ¼ Rhklð1=N $ 1Þ1=2Ri Ii hklð Þ $ I hklð Þh ij j
.
RhklRi Ii hklð Þj j , where Ii(hkl) is an individual intensity measurement and I hklð Þh i is the average
intensity for this reflection
d R and Rfree ¼ Rhkl Foj j $j jFcjj=Rhkl Foj j; for calculating Rfree, a subset of reflections (5.0 %) was randomly chosen as a test set
e DPI Diffraction-component precision indicator (of the atom position)
f RMSD Root-mean-square deviation from ideal Engh–Huber parameters
g These data are relative to the native and the F-complex structures determined with the highest quality among those determined in this study
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required to maintain isothermal conditions for the exo-
thermic reaction (Fig. 1b). The rate of heat generated by
the enzyme is equivalent to the decrease in thermal
power after each injection, ever increasing as the sub-
strate concentration increases. The reaction rate could
thus be monitored as a function of substrate concentra-
tion and pH, as shown in Fig. 2. These data, indicating a
progressive urease inhibition by increasing concentration
of fluoride in the 0–800 lM range, were fit to Eq. (7)
and yielded the kinetic parameters reported in Table 3.
The increase of kcat as a function of pH in the explored
range parallels previous reports [42], while the Michae-
lis–Menten constant, similar to the value of 17.3 mM
reported in phosphate buffer [42, 43] is invariant with
pH. Tables 4 and 5 also reports the values obtained for
the competitive (Kic) and uncompetitive (Kiuc) inhibition
constants: Kiuc is generally smaller than Kic, indicating a
predominance of the uncompetitive inhibition within the
Fig. 1 Typical plots of thermal power as a function of time in M1
(a) and M2 (b) experiments. Experimental conditions: 30 nM SPU,
0.1 mM urea, 20 mM HEPES, 50 mM Na2SO3, 150 mM NaCl, pH
7.0
Fig. 2 Michaelis–Menten plots of S. pasteurii urease activity as a
function of fluoride concentration (red dots 0 lM, orange dots
300 lM, yellow dots 400 lM, green dots 500 lM, blue dots 800 lM)
at pH 6.5 (a), pH 7.0 (b) and pH 8.0 (c). The lines represent calculated
non-linear regression analysis fits carried out using Eq. (7). Exper-
imental conditions described in ‘‘Materials and methods’’
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explored pH range. In addition, an increase of the
uncompetitive inhibition mechanism upon pH increase is
observed, while the contribution from competitive inhi-
bition decreases and becomes negligible at pH 8.0.
Crystallographic analysis of the protein structure
The protein structure was determined independently for
five crystals of the native enzyme and for five crystals of
urease obtained in the presence of fluoride in the crystal-
lization buffer. The crystals were selected using the same
conditions but different hanging drops from independent
crystallization trials. In the following discussion, the
structures of the highest quality datasets deposited in the
PDB are described unless explicitly stated.
The structure of wild-type S. pasteurii urease in the native
form has been determined with the highest resolution so far
available (1.58 A˚) for ureases from bacteria or plant origin
[5], resulting inmore precise structural parameters, while the
structure of the enzyme obtained in the presence of fluoride
has been refined using data at 1.59 A˚ resolution, thus
allowing us to analyze the effect of the inhibitor on the fine
structural details of the enzyme active site. The two struc-
tures show the well-known heteropolymeric nature of this
enzyme, with its threefold symmetric (abc)3 quaternary
structure (Fig. 3), an a-subunit made of an (ab)8 TIM barrel
domain and a b-type domain, a b-subunit characterized by
numerous b strands, and a c-subunit built as a two-layer ab
sandwich. The structure of the enzyme obtained in the pre-
sence of fluoride closely matches that of the native protein,
with a global pairwise root-mean-square devia-
tion RMSD ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
N
PN
i¼1
d2i
s !
, where d is the distance
betweenN pairs of equivalent atoms) per residue between the
backbone atoms of the two structures of only 0.18, 0.06, and
0.06 A˚ for the a, b, and c subunits, respectively, and an
overall RMSD of 0.16 A˚. The analysis of the residue-aver-
aged backbone B-factors (Fig. 4) confirms, as previously
observed [26], the presence of two characteristic helix-loop-
helix regions in the a-subunit that feature a significantly
larger mobility than the rest of the protein: one of these
(region A, residues 375–405, Fig. 5a) is located on a surface
patch that has been proposed [26] to be implicated in the
formation of protein–protein complexes with the accessory
proteins that form the supercomplex necessary for the
incorporation of the Ni(II) ions into the active site and con-
sequent urease activation [5, 44], while the other (region B,
residues 310–340, Fig. 5b) is the flap that modulates sub-
strate access to the active site cavity. Consistently with their
larger backbone mobility, the analysis of the global residue
backbone root-mean-square deviation (RMSD) reveals sig-
nificant differences in these two regions between the struc-
tures of the enzyme obtained in the absence and presence of
fluoride, with the active site flap found in the open confor-
mation in both cases, but slightly more closed in the case of
latter structure (Fig. 5b). So far, only in the case of urease
inhibited by diamidophosphate (DAP), an analog of the
catalytic intermediate or transition state, the S. pasteurii
active site urease flap has been found in the fully closed
conformation [13]. Plots of the difference in / and w protein
backbone angles (Fig. 4) show a relatively small modifica-
tion of these parameters in the active site flap, indicating that
the residues in region B move all together consistently,
leaving unaltered the inner structure of this motif (Fig. 5b).
On the other hand, large changes are observed in region A,
coherently with the observed largely modified structure of
the loop between the two helices (Fig. 5a). In addition, the
plot of RMSD per residue (Fig. 4) also reveals another
protein segment that undergoes significant changes in the
presence of fluoride: this is the loop comprising residues
365–368 in the a subunit, located in close proximity to the
Ni(II) ions in the active site (Fig. 5c), and within which a
large change of / (113.7!) and w (97.9!) for aAla366 is
observed.With this exception, the positions of the conserved
amino acid residues that are not involved in nickel binding
but are thought to be important in the catalytic mechanism
(aAla170, aHis222, aGlu223, aAsp224, aGly280, aHis323,
and aMet367) are largely invariant between the native and
fluoride-bound urease.
Crystallographic analysis of the active site
Fluoride ions are isoelectronic with water molecules and
therefore in crystallographic structures the expected
heights of electron density peaks are very similar.
Moreover, the radii of fluoride (1.36 A˚) and water
(1.40 A˚) are so similar that they cannot be used alone to
identify one ligand over the other. The main difference
between fluoride and water (or hydroxide ions) rests in
the capability of the latter, and not of fluoride, to act as
hydrogen-bonding donor. Therefore, the identification of
fluoride ions in protein structures must rely on either
very-high-resolution crystallographic data, and/or upon
other criteria, such as differences in the overall protein
structural environment around the putative fluoride-
binding site, in addition to other evidence derived from
non-crystallographic data.
Table 3 Kinetic parameters for the inhibition of SPU with fluoride
pH kcat (s
-1) KM (mM) Kic (mM) Kiuc (mM)
6.5 (3.90 ± 0.24) 9 103 15.0 ± 2.0 0.79 ± 0.26 0.43 ± 0.09
7.0 (9.01 ± 0.20) 9 103 16.5 ± 0.7 3.00 ± 0.79 0.39 ± 0.02
8.0 (1.57 ± 0.19) 9 104 13.0 ± 1.0 – 0.28 ± 0.02
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Table 4 Selected distances and angles around the Ni(II) ions in the five crystals of native SPU
Native
4CEU
Crystal native
#2
Crystal native
#3
Crystal native
#4
Crystal native
#5
Average Standard
deviation
Ni–L distances (A˚)
Ni1–aLys220* Oh1 1.94 1.96 1.96 1.95 1.95 1.95 0.01
Ni1–LB
a 2.08 2 2 1.98 2.01 2.01 0.03
Ni1–L1b 2.24 2.21 2.2 2.14 2.21 2.20 0.03
Ni1–aHis249 Nd 2.03 2.03 2.05 2.03 2.03 2.03 0.01
Ni1–aHis275 Ne 2.02 2.03 2.01 2.04 2.03 2.03 0.01
Ni2–aLys220* Oh2 2.08 2.02 2 2.02 2.01 2.03 0.03
Ni2–LB 2.12 2.05 2.04 2.03 2.04 2.06 0.04
Ni2–L2c 2.07 2.14 2.07 2.06 2.14 2.10 0.04
Ni2–aHis137 Ne 2.11 2.07 2.07 2.06 2.06 2.07 0.02
Ni2–aHis139 Ne 2.08 2.06 2.06 2.05 2.07 2.06 0.01
Ni2–aAsp363 Od1 2.10 2.05 2.06 2.06 2.04 2.06 0.02
Ni1–Ni2 3.67 3.61 3.61 3.56 3.61 3.61 0.04
L1–L2 2.37 2.35 2.35 2.28 2.33 2.34 0.03
L–Ni–L angles (!)
aLys220* Oh1–Ni1–
aHis249 Nd
100.4 99.3 99.0 99.5 99.5 99.5 0.5
aLys220* Oh1–Ni1–
aHis275 Ne
107.2 107.7 107.6 106.4 106.7 107.1 0.5
aLys220* Oh1–Ni1–LB 96.6 93.7 94.1 93.3 92.9 94.1 1.5
aLys220* Oh1–Ni1–L1 108.2 107.5 108.0 108.0 108.2 108.0 0.3
aHis249 Nd–Ni1–
aHis275 Ne
98.6 96.0 96.5 95.5 96.4 96.6 1.2
aHis275 Ne–Ni1–LB 94.6 95.2 94.9 92.5 94.6 94.3 1.1
LB–Ni1–L1 67.0 72.6 68.8 75.6 72.4 71.3 3.4
L1–Ni1–aHis249 Nd 89.3 88.2 89.9 88.8 89.1 89.1 0.6
aHis249 Nd–Ni1–LB 154.2 159.5 157.7 162.4 160.3 158.8 3.1
aHis275 Ne–Ni1–L1 141.6 143.4 142.2 144.1 143.1 142.9 1.0
aLys220* Oh2–Ni2–
aHis137 Ne
90.8 91.3 89.5 90.5 91.0 90.6 0.7
aLys220* Oh2–Ni2–
aHis139 Ne
91.7 91.7 92.0 91.3 92.1 91.8 0.3
aLys220* Oh2–Ni2–L2 92.9 94.1 95.0 96.3 94.4 94.5 1.2
aLys220* Oh2–Ni2–LB 95.6 93.9 94.3 94.6 93.4 94.4 0.8
aAsp363 Od1–Ni2–
aHis137 Ne
82.8 82.6 82.1 82.9 82.7 82.6 0.3
aAsp363 Od1–Ni2–
aHis139 Ne
86.4 85.6 84.7 85.2 85.0 85.4 0.7
aAsp363 Od1–Ni2–L2 94.5 93.1 94.8 91.9 93.1 93.5 1.2
aAsp363 Od1–Ni2–LB 89.1 91.2 92.5 91.2 91.9 91.2 1.3
L2–Ni2–LB 67.7 72.2 71.1 75.1 73.7 71.9 2.8
LB–Ni2–aHis137 Ne 95.0 91.4 93.6 86.8 91.1 91.6 3.1
aHis137 Ne–Ni2–
aHis139 Ne
108.5 108.1 108.2 110.1 107.9 108.6 0.9
aHis139 Ne–Ni2–L2 88.4 87.9 86.7 87.5 86.9 87.4 0.6
aLys220* Oh2–Ni2–
aAsp363 Od1
172.4 172.2 169.5 171.0 171.8 171.4 1.2
LB–Ni2–aHis139 Ne 155.3 159.6 157.4 162.1 160.2 158.9 2.6
aHis137 Ne–Ni2–L2 162.6 163.0 164.3 161.1 164.1 163.0 1.3
Ni1–LB–Ni2 122.1 125.6 127.0 124.8 126.2 125.1 1.9
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Table 5 Selected distances and angles around the Ni(II) ions in the five crystals of fluoride-inhibited SPU
Fluoride
4CEX
Crystal
fluoride #2
Crystal
fluoride #3
Crystal
fluoride #4
Crystal
fluoride #5
Average Standard
deviation
Ni–L Distances (A˚)
Ni1–aLys220* Oh1 1.94 1.95 1.94 1.94 1.94 1.94 0.01
Ni1–LB
a 2.02 2.02 2 2.02 2.04 2.02 0.01
Ni1–L1b 2.08 2.09 2.04 2.07 2.08 2.07 0.02
Ni1–aHis249 Nd 2.06 2.04 2.04 2.05 2.05 2.05 0.01
Ni1–aHis275 Ne 2.06 2 2.04 2.04 2.03 2.03 0.02
Ni2–aLys220* Oh2 2.06 2.02 2.01 2.01 2.02 2.02 0.02
Ni2–LB 2.01 2.04 2.08 2.04 2.03 2.04 0.03
Ni2–L2c 2.11 2.08 2.03 2.07 2.08 2.07 0.03
Ni2–aHis137 Ne 2.11 2.07 2.05 2.04 2.07 2.07 0.03
Ni2–aHis139 Ne 2.08 2.06 2.06 2.06 2.06 2.06 0.01
Ni2–aAsp363 Od1 2.14 2.06 2.05 2.05 2.04 2.07 0.04
Ni1–Ni2 3.53 3.55 3.54 3.54 3.54 3.54 0.01
L1–L2 2.53 2.4 2.54 2.48 2.47 2.48 0.06
L–Ni–L angles (!)
aLys220* Oh1–Ni1–aHis249 Nd 99.1 99.2 99.2 98.9 99.6 99.2 0.3
aLys220* Oh1–Ni1–aHis275 Ne 107.1 106.2 105.5 106.3 106.3 106.3 0.6
aLys220* Oh1–Ni1–LB 92.6 91.7 93.9 93.4 92.7 92.9 0.8
aLys220* Oh1–Ni1–L1 107.4 107.1 108.7 107.9 108.4 107.9 0.7
aHis249 Nd–Ni1–aHis275 Ne 92.4 93.9 94.0 93.5 94.1 93.6 0.7
aHis275 Ne–Ni1–LB 90.6 90.3 92.0 89.6 90.1 90.5 0.9
LB–Ni1–L1 84.4 81.5 81.7 82.9 81.9 82.5 1.2
L1–Ni1–aHis249 Nd 85.7 88.0 86.5 86.7 86.9 86.8 0.8
aHis249 Nd–Ni1–LB 166.5 166.7 164.6 166.0 165.3 165.8 0.9
aHis275 Ne–Ni1–L1 145.3 145.9 145.2 145.4 144.5 145.2 0.5
aLys220* Oh2–Ni2–aHis137 Ne 92.1 92.3 90.5 91.0 91.7 91.5 0.8
aLys220* Oh2–Ni2–aHis139 Ne 90.3 91.3 90.3 91.0 91.6 90.9 0.6
aLys220* Oh2–Ni2–L2 96.1 95.1 98.6 96.8 98.2 96.9 1.5
aLys220* Oh2–Ni2–LB 95.3 95.1 96.5 95.5 96.0 95.7 0.6
aAsp363 Od1–Ni2–aHis137 Ne 82.5 82.7 81.2 82.5 81.8 82.1 0.6
aAsp363 Od1–Ni2–aHis139 Ne 84.6 84.3 85.0 84.2 85.1 84.6 0.4
aAsp363 Od1–Ni2–L2 90.7 91.5 91.3 91.2 89.5 90.8 0.8
aAsp363 Od1–Ni2–LB 91.4 91.0 90.8 91.2 89.4 90.7 0.8
L2–Ni2–LB 82.1 80.8 80.5 81.3 80.7 81.1 0.7
LB–Ni2–aHis137 Ne 84.6 84.3 86.7 85.7 85.5 85.4 0.9
aHis137 Ne–Ni2–aHis139 Ne 108.3 110.6 108.0 107.4 108.9 108.6 1.2
aHis139 Ne–Ni2–L2 84.2 83.9 84.0 84.8 83.9 84.2 0.4
aLys220* Oh2–Ni2–aAsp363 Od1 171.0 171.7 168.6 170.3 171.2 170.6 1.2
LB–Ni2–aHis139 Ne 165.7 163.8 163.8 165.3 163.6 164.4 1.0
aHis137 Ne–Ni2–L2 165.0 163.6 165.0 165.5 163.7 164.6 0.8
Ni1–LB–Ni2 121.9 122.2 120.0 121.3 120.8 121.1 0.9
a LB indicates the atom bridging Ni1 and Ni2
b L1 indicates the terminal atom bound to Ni1, interpreted as water for the native enzyme and fluoride for the inhibited enzyme
c L2 indicates the terminal atom bound to Ni2, interpreted as water for both the native and the fluoride complex
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In this case, clear and macroscopic differences are
consistently observed between the two sets of SPU struc-
tures in the absence and presence of fluoride in the crys-
tallization solution. First, a large change consistently
involves residues 365–368 (Fig. 5c): in this loop the
aAla366 residue modifies its conformation from pointing
the backbone carbonyl C=O group away from the active
site Ni(II) ions in the native enzyme to pointing towards
them in the fluoride-inhibited complex, forming an H-bond
with the terminal ligand of Ni2, which must thus carry a
hydrogen atom, excluding the presence of fluoride in this
position. Only in the case of the enzyme complexed with
DAP [13] or phosphate [24] was the aAla366 residue
observed to exist in the same conformation as found in the
fluoride-inhibited urease, indicating that the presence of
fluoride has analogously altered the active site structure of
the native enzyme. A second macroscopic structural dif-
ference between the two sets of structures is the consistent
presence of a sulfate ion in the vicinity of the nickel active
site in the case of native urease, while this moiety is absent
in the case of the enzyme crystallized in the presence of
fluoride (Figs. 6, 7). This is a strong argument in favor of
the binding of fluoride ions at the active site because the
increased negative charge brought by the latter would repel
the negative charge of the sulfate ion and alter the hydro-
gen-bonding network that stabilizes the sulfate in that
position.
In addition to these two macroscopic structural dif-
ferences, finer modifications of distances and angles are
observed between the two highest quality structures
(Tables 4, 5), whose significance is discussed here
below. In the case of native SPU, the electron density in
the active site is well defined, as shown in Fig. 6a; the
corresponding structural model is presented in Fig. 7a.
The Ni(II) ions are ordered (B-factors of 9.67 and
8.65 A˚2 for Ni1 and Ni2, respectively) and separated by
3.67 A˚. They are bridged by a ligand, interpreted as a
hydroxide ion, WB [13], with distances to Ni1 and Ni2
of 2.08 and 2.12 A˚, respectively, and by the carboxylate
group of the carbamylated aLys220* (Ni1–
Oh1 = 1.94 A˚; Ni2–Oh2 = 2.08 A˚). The B-factors of
the bridging (13.75 A˚2) and terminal (13.99 and
11.98 A˚2) solvent Ni(II) ligands are consistent with full
occupancy. Ni1 is further coordinated by aHis249 Nd (at
2.03 A˚) and by aHis275 Ne (at 2.02 A˚), while Ni2 is
bound to aHis137 Ne (at 2.11 A˚), aHis139 Ne (at
2.08 A˚), and aAsp363 Od1 (at 2.10 A˚) (Fig. 7a). The
two Ni(II) ions are additionally bound to a terminal
ligand, interpreted as a water molecule [13], (Ni1–
W1 = 2.24 A˚; Ni2–W2 = 2.07 A˚), making Ni1 penta-
coordinated in a tetragonal pyramidal geometry and Ni2
hexa-coordinated and pseudo-octahedral. A fourth distal
solvent molecule (W3) completes a tetrahedral cluster of
electron density peaks in the urease active site, with
distances consistent with the formation of hydrogen
bonds (W3–W1 = 2.33 ; W3–W2 = 2.37 A˚; W3–
WB = 2.47 A˚) and a B-factor that indicates full occu-
pancy (15.72 A˚2).
In the case of SPU complexed with fluoride (Figs. 6b,
7b for the highest quality structure of this set), a series of
structural modifications are observed (Tables 4, 5). To
statistically analyze these differences it is necessary to
estimate the standard deviations of the atomic positional
parameters, or estimated standard uncertainties (ESU).
The currently most accepted method to perform this
analysis has been proposed by Cruickshank [45]. In this
method, the uncertainties [diffraction-component preci-
sion indicator (DPI)] are estimated based on atom type
and number, average B-value, as well as data complete-
ness, crystallographic R-factor and resolution. These
parameters are reported in Tables 1 and 2, together with
additional average-based positional error estimates, which
are less restrictive as compared to the analysis carried out
below, based on DPI. First of all, the Ni–Ni distance
decreases from 3.67 to 3.53 A˚, a difference significant
with a confidence level of 90.7 % (using r12 = 2 ! DPI,
and Z = Ddistance/r12). A decrease is also observed for the
distance between the penta-coordinated Ni1 and its ter-
minal ligand (from 2.24 to 2.08 A˚), statistically significant
at the 94.5 % confidence level. This modification is
Fig. 3 Ribbon scheme of native S. pasteurii urease; the a, b and c
subunits of one (abc) trimer are shown in red, yellow and blue, while
the positions of the Ni(II) ions in the active sites are shown as green
spheres
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accompanied by the decrease from 2.84 to 2.72 A˚ (sta-
tistic significance of 85.0 %) of the distance between the
protonated aHis222 Ne and the atom terminally bound to
Ni1, an interaction that involves a hydrogen bond. The
distance between the bridging ligand and the nickel ions
decreases from 2.08 and 2.12 A˚ in native SPU to 2.02 and
2.01 A˚ for Ni1 and Ni2, respectively. These differences
correspond to a statistic significance of 52.9 and 81.3 %
confidence level. The distance between the hexa-coordi-
nated Ni2 and its terminal ligand increases from 2.07 to
2.11 A˚ (36.9 % significance level).
Several additional modifications are observed in the
structure of SPU obtained in the presence of fluoride. In
particular, the distance between the distal water molecule
W3 (slightly disordered or not fully occupied, as indicated
by its B-factor = 26.93 A˚2) and the three other centers that
compose the tetrahedron of electron density maxima,
interpreted as solvent molecules in the structure of native
urease, increases significantly (3.20 vs. 2.33 A˚, 3.54 vs.
2.37 A˚, and 3.05 vs. 2.47 A˚). Moreover, while in the case
of the native enzyme W3 forms a hydrogen bond with
aGly280 at 3.52 A˚, in the structure of urease in the pre-
sence of fluoride this hydrogen bond measures only 2.69 A˚
(Fig. 7).
The similarity of the radii of fluoride and water or
hydroxide cannot be used to identify the metal ligand
based only on bond distances. However, the scattering
factor of fluoride is generally larger at the resolution
corresponding to the limit of our data (International
Tables for X-ray Crystallography). Therefore, we carried
out an alternative refinement of the crystallographic data
collected on the crystal of SPU obtained in the presence
of fluoride using a model that contained oxygen atoms
terminally bound to Ni1 and in the nickel-bridging
position. This refinement provided a B-factor value for
the bridging atom significantly smaller (5.88 A˚2) than
that determined using fluoride in this position (8.28 A˚2),
and even smaller than that of the nickel atoms (9.67 and
8.75 A˚2 for Ni1 and Ni2, respectively), an unrealistic
result that strongly supports the presence of fluoride in
the bridging position. This refinement further yielded a
B-factor value of 10.91 A˚2 for the oxygen atom bound to
Ni1, suggesting the presence of fluoride (B-factor of
13.60 A˚2), but not ruling out, if based only on this
calculation, partial occupancy of fluoride and water in
this position. The differences between the two highest
quality datasets, described above, are further supported
by the analysis of the distances determined for two
independent sets, each made of five crystals of urease
obtained, respectively, in the absence and presence of
fluoride in the crystallization solution (Tables 4, 5). The
average Ni1–Ni2 distance in the native enzyme is
3.61 ± 0.04 A˚, while in the presence of fluoride a dis-
tance of 3.54 ± 0.01 A˚ is observed; the Ni1–L1 average
distances are 2.20 ± 0.03 vs. 2.07 ± 0.02 A˚, the Ni2–L2
average distances are 2.10 ± 0.04 vs. 2.07 ± 0.03 A˚,
and the L1–L2 average distances are 2.34 ± 0.03 vs.
2.48 ± 0.06 A˚.
In addition to bond distances, some modifications
between the two structures also involve bond angles, with
the largest changes involving the terminal and bridging
ligands of the Ni(II) ions (see Tables 4, 5). In particular,
the geometry around the penta-coordinated Ni1 in the two
structures can be compared using the structural s parameter
based on Scheme 3, shown below:
where s ¼ b"að Þ60 , and a and b (b C a) are the two largest
angles around the metal ion. s = 1 for a perfectly trigonal
bipyramidal (TB) geometry, whereas s = 0 for a square
pyramidal geometry (SPY) [46]. The Ni1 atom in the
native urease has s = 0.21, while that observed for the
fluoride-bound enzyme has s = 0.35, indicating a distor-
tion from the mainly SPY geometry to a more TB coor-
dination. Tables 4 and 5 further report a comparison of
bond angles around the Ni(II) ions among all structures
determined in this study, from which significant differences
are found mainly in the case of angles involving the LB, L1
and L2 positions. The picture emerging from this analysis
is somehow consistent with the interpretation of the elec-
tron density map obtained at 2.2 A˚ resolution for the
complex of JBU with fluoride (PDB code 4GOA) as con-
taining a nickel-bridging fluoride, while an additional F-
ion was assigned in the position occupied by W3 in the
native enzyme. In that case, it is not clear, in the absence of
a published report, how the model could be accurately
refined at this resolution.
In conclusion, in the presence of fluoride the structure of
the nickel environment in the enzyme active site has been
bFig. 4 Comparison of the structural parameters between the a, b and
c subunits of native (PDB code 4CEU) and fluoride-bound (PDB code
4CEX) S. pasteurii urease: global pairwise RMSD per residue of the
backbones (top panels), residue-averaged backbone B-factors (middle
panels), and absolute values of the D/ and Dw protein backbone
angles (bottom panels)
Scheme 3 Geometry around
the penta-coordinated Ni1
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significantly altered. The largest modifications involve the
rearrangement of the protein backbone in the proximity of
the active site and the removal of molecules of water and
sulfate from the enzymatic cavity. In addition, statistically
significant distances and angles that feature non-protein-
based ligands are observed, highlighting on one hand the
substantial rigidity of the enzyme on nickel-coordination
sites defined by the protein framework, and on the other
hand the flexibility of active cavity positions occupied by
solvent molecules in the native form.
Discussion
The first report on urease inhibition by fluoride dates back
to 1928, when Mystokowski revealed that NaF is a pow-
erful inhibitor of ordinary urease [47], followed by a study
by Pearson and Smith in 1943, in which the effect of
fluoride on the activity of bovine rumen urease was
described [48]. Following their first evidence of the
essentiality of nickel for urease activity in 1975 [49] and in
the absence of any structural information yet derived from
crystallography, Dixon, Blakeley and Zerner reported in
1980 pioneering and insightful experiments that indicated
that fluoride is a inhibitor of jack bean urease (JBU) by
virtue of binding to the active site Ni(II) ions [27]. The
support for this proposal was the similarity of the disso-
ciation constant of a Ni(II)–fluoride complex
(1.23 ± 0.10 mM) determined by monitoring the metal-
based electronic transitions by visible spectroscopy, and
the kinetically determined fluoride competitive inhibition
constant, Kic, at pH 7. The latter corresponded to
1.01 ± 0.10 mM for the instantaneously formed fluoride–
urease complex (pre-steady state), and to 0.83 ± 0.27 mM
for an analogous complex formed overtime (steady state)
with a rate of formation of 0.53–2.3 min-1 depending on
fluoride and urea concentrations [27]. The authors further
proposed that this time-dependent process involved the
formation of a ternary complex of JBU–fluoride–urea (or
JBU–fluoride–carbamate), for which the apparent dissoci-
ation constant of the fluoride ion is ca. 0.23 mM [27]. The
authors did not explicitly use the term ‘‘uncompetitive
inhibition’’, even though they reported double-reciprocal
plots at steady state that showed parallel lines, consistent
with this type of inhibition. With the knowledge of the
presence of two Ni(II) ions in the active site, but in the
bFig. 5 Structure of the backbone mobile regions of S. pasteurii
urease in the native (blue) and in the fluoride-inhibited (red) form:
a residues 375–405; b residues 310–340; c residues 365–368
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absence of any structural information on the enzyme, the
authors acknowledged that the kinetic methods that were
used could not indicate whether fluoride and urea (or car-
bamate) bind to the same or to different nickel ions [27]. In
1997, Saboury and Moosavi-Movahedi described the
application of isothermal titration calorimetry for the
determination of the kinetic enzymatic parameters for JBU
[29]. In particular, the effect of fluoride on the enzyme
kinetics was reported as being competitive, with
Kic = 0.94 mM. In 2000, Todd and Hausinger investigated
the inhibition of urease from Klebsiella aerogenes (KAU)
by fluoride, and concluded that KAU is slowly inhibited by
this anion (and not its protonated form HF) in both the
presence and absence of urea, consistently with a non-
classical uncompetitive slow-binding inhibition mechanism
[28]. In particular, the time constant for the slow inhibition
process, complete in about 5 min, ranged between 0.26 and
0.98 min-1, depending on fluoride concentration (in the
2.5–10 mM range), similarly to what reported by Dixon
et al. [27] for JBU. The value of Kiuc at pH 7, estimated
using a plot of the pH dependence of this parameter
reported in the article, is ca. 0.16 mM. The authors also
proposed that fluoride binds to a form of the enzyme
generated during the catalytic process, because greater
inhibition is observed in the presence of substrate [28]. The
Fig. 6 Atomic model of the active site of native (panel a, PDB code
4CEU) and fluoride-bound (panel b, PDB code 4CEX) S. pasteurii
urease. The nickel-coordination environment is shown superimposed
on the final 2Fo–Fc electron density map contoured at 1.7 r. The
carbon, nitrogen, oxygen, fluorine, sulfur and nickel atoms are grey,
blue, red, gold, yellow and green, respectively
Fig. 7 Crystallographic structural model for the active site obtained
for native (panel a, PDB code 4CEU) and fluoride-bound (panel b,
PDB code 4CEX) S. pasteurii urease. Figures created using Crystal-
Maker. The carbon, nitrogen, oxygen, fluorine and nickel atoms are
grey, blue, red, gold and green, respectively. Hydrogen bonds are
shown as thin blue lines. Spheres are drawn using the relative atomic
radii values in CrystalMaker
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onset of uncompetitive inhibition is usually observed for
multi-substrate enzymes, and on this basis the authors
suggested that fluoride binds to a site different from that
used for urea binding and occupied instead by the co-
substrate, that is, the catalytic water molecule. The authors
interpreted these results using the structure of urease by
then available from different bacterial sources [12, 13, 21].
In particular, they speculated that fluoride binds to the
urease metallocenter with displacement of the nickel-
bridging hydroxide (WB) and excluded substitution of W1
or W2, replaced by urea during catalysis, because no
competitive inhibition was detected [28]. Finally, in 2001
Krajewska et al. [30] reported kinetic data on JBU inter-
preted with a model in which fluoride binds to urease in a
competitive slow-binding mechanism, consisting of an
initial rapid formation of a urease–fluoride complex having
a dissociation constant Kic = 1.0 mM, that slowly evolves
to a more stable complex with a dissociation constant of
0.02 mM.
In the present study, enzymatic measurements of fluo-
ride inhibition of urease were carried out on SPU using a
calorimetric assay, and the results were corroborated
thorough the analysis of high-resolution crystallographic
data of native and fluoride-inhibited urease. The experi-
mental conditions of the enzymatic assay covered the
6.5–8.0 pH range. SPU was incubated in the presence of
different fluoride concentrations, with no difference
observed on the kinetic parameters using either 15 or
60 min of incubation time. This ensured that the data
obtained were related to the steady-state fluoride-bound
enzyme, and not to any time-dependent form of the
enzyme. This choice was dictated by the nature of the
assay, which requires a much longer time than the few
minutes necessary for the onset of the steady-state condi-
tion for JBU and KAU [27, 28].
The calorimetric data show that fluoride inhibits the
activity of SPU at pH 7.0 with mixed competitive and
uncompetitive mechanisms. In particular, the uncompeti-
tive inhibition constant is ca. sevenfold lower than the
competitive inhibition constant (Kiuc = 0.39 ± 0.02 vs.
Kic = 3.00 ± 0.79 mM), indicating the predominance of
the uncompetitive effect. These values are similar to those
reported by Dixon et al. (Kiuc = 0.23 mM,
Kic = 0.83 ± 0.80 mM), by Saboury et al. (Kic = 0.94 -
mM) and by Krajewska et al. (Kic = 1.0 mM) for JBU, and
by Todd et al. (Kiuc ca. 0.16 mM) for KAU. Furthermore,
the pH dependence of the two inhibition constants indicates
that while the effect of uncompetitive mechanism increases
with pH, the contribution of the competitive inhibition
considerably decreases to negligible levels upon increasing
the pH.
These kinetic data require the determination of the
fluoride-binding positions in the enzyme active site to
firmly rationalize the mechanism of inhibition. The iden-
tification of fluoride ions vs. exchangeable solvent mole-
cules bound to metal centers in metalloenzymes using
protein crystallography demands very precise structural
data, because structural changes are generally fractions of
A˚ and could remain unnoticed unless the resolution is
exceptionally high. X-ray structures of proteins at true
atomic resolution (\1.2 A˚) are still scarce, currently rep-
resenting ca. 2 % of the overall Protein Data Bank. The
structures of fluoride complexes of a series of metalloen-
zymes containing a di-metallic core have been reported for
Mn(II)-containing inorganic pyrophosphatase at 1.20 A˚
[50] and arginase at 2.40 A˚ [51], for Mg(II)-containing
enolase at 1.36 A˚ [52] and diphosphoinositol polyphos-
phate phosphohydrolase-1 at 1.65 A˚ [53], for Zn(II)/
Fe(III)-containing purple acid phosphatase at 2.20 A˚ [54]
and for Ni(II)-dependent JBU at 2.20 A˚ (PDB code 4GOA,
unpublished).
The crystallographic analysis to a resolution better than
1.72 A˚ of the ten replicated structures of SPU obtained
here in the absence and presence of fluoride provided
refined atomic models with very small positional errors
(see Table 1) allowing us to determine the statistic signif-
icance of distance differences between the two sets of
structures. In general, the electron density maps clearly
show that fluoride alters the active site environment sur-
rounding the Ni(II) ions by (1) inducing a conformational
change of the protein backbone in correspondence of
aAla366, promoting the formation of a H-bond between its
carbonyl O atom and the terminal ligand of Ni2, (2) dis-
rupting the hydrogen bond network that holds the distal
solvent molecule W3 close to W1, W2 and WB in the
native form of the enzyme, (3) preventing sulfate binding
in the active site cavity, (4) decreasing the Ni1–Ni2 dis-
tance, (5) decreasing the distance between the nickel atoms
and the bridging ligand, (6) decreasing the distance
between Ni1 and its terminal ligand, and (7) increasing the
distance between Ni2 and its terminal ligand. These mod-
ifications of the coordination environment of the metal ions
in the urease active site can be interpreted as the result of
the presence of a fluoride ion in the bridging position (FB)
in place of the hydroxide ion found in the native enzyme,
and the substitution of the neutral water molecule W1
bound to Ni1 by a second fluoride ion (F1) (Fig. 5a, b). The
increase of the uncompetitive inhibition mechanism upon
pH increase was already reported and discussed in the case
of KAU [28]. On the other hand, the decrease of the
competitive inhibition mechanism upon raising the pH has
not been observed so far in the case of urease, and could be
explained by a progressive deprotonation of W1, which
would lead to a more difficult substitution by fluoride. The
observation in the crystal structure of a fluoride ion ter-
minally bound to Ni1 could be due to the pH of the
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crystallization solution (6.5): indeed, in these conditions, a
measurable value for the competitive inhibition constant
can be calculated from the fit of the kinetic data.
The presence of fluoride in the nickel-bridging position,
at a metal-binding site in which the electrostatic positive
charge is expected to be greatest within the active site [55],
would explain the decreased Ni–Ni distance, the decrease
of the Ni1–L1 distance, and the alterations of the bond
angles around Ni(II) in the presence of fluoride. Similar
modifications were indeed observed in the case of native
and fluoride-inhibited Mg(II)-enolase determined at 1.36 A˚
resolution [52]. The apparent substitution of W1, and not
W2, by fluoride could be rationalized by the larger positive
charge expected on Ni1, which is less coordinatively sat-
urated as compared to Ni2, thus inducing a selective
reactivity of the two Ni(II) ions. Fluoride binding to Ni1
would also be stabilized by the interaction with the pro-
tonated His222 NHe2, which is indeed located at 2.84 A˚ in
native SPU and at 2.72 A˚ in the case of the fluoride–urease
complex. The presence of fluoride in place of W1 could
explain the larger distance between Ni2 and its terminal
ligand in the fluoride-inhibited enzyme, interpreted as a
water molecule W2 as due to a greater electron density on
the di-nickel metal cluster induced by an increase in the
number of negatively charged ligands, thus decreasing the
electrophilic character of the two Ni(II) ions. In turn, the
larger distance between Ni2 and W2 in the fluoride-
inhibited urease could explain, together with a decrease of
the occupancy of the W3 solvent molecule, the change in
the backbone conformation that brings the carbonyl group
of aAla366 close to W2, located at a distance that, in the
case of the fluoride-bound active site and not in the native
enzyme, allows the formation of a hydrogen bond. The
latter conformational change could also be allowed by the
dislodgment of the W3 water molecule, which would
increase the steric volume available for aAla366 O. If the
fluoride anion, and not water, was bound to Ni2, this
movement would indeed bring two atoms with partial
negative charges closer to each other. This observation
could also be used to further support the mechanism step
that entails the chelating mode of urea binding to the di-
nickel active site of urease: the effect of substituting the
neutral W1 on Ni1 by an anionic (fluoride) or neutral but
polarized ligand (urea) would have the effect of weakening
and lengthening the Ni2–W2 bond, favoring the interaction
of urea nitrogen with Ni2 upon displacement of W2, in a
structure stabilized by H-bonding interactions of urea –
NH2 group with the carbonyl group of aAla366. The
resulting substitution of two of the four solvent molecules
in the tetrahedral cluster present in the active site of native
urease with two fluoride ions apparently disrupts the
hydrogen-bonding network among the four solvent mole-
cules observed in the case of the native enzyme [13], thus
explaining the large change observed in the position and
occupancy/mobility of the distal water molecule. Further-
more, the lack of the sulfate ion near the nickel active site
in the case of SPU crystallized in the presence of fluoride
could then be rationalized by an increased negative charge
in the vicinity of the active site upon substitution of a
neutral water and a hydroxide ion, as found in the native
enzyme, by two fluoride anions.
This picture for SPU is consistent with the prediction by
Dixon et al. [49] on the direct interaction of fluoride with
the Ni(II) ions in the active site of JBU: fluoride bound to
Ni1 competes with the substrate urea for this electrophilic
metal ion, in agreement with the currently most accepted
urease catalytic mechanism [1, 5, 7, 9, 10, 13]. Moreover,
the suggestion by Todd and Hausinger [28] for the sub-
stitution of the bridging hydroxide by fluoride, observed in
the crystal structure of inhibited SPU, is also consistent
with an uncompetitive mechanism in which fluoride com-
petes with the second substrate of the enzymatic catalysis,
namely the nucleophilic hydroxide, leaving Ni1 free to
bind urea. This interpretation can be summarized by stating
Scheme 4 Native and fluoride
inhibited S. pasteurii urease
active sites. The competitive
inhibition of fluoride is ascribed
to the L1 position, while the
uncompetitive inhibition
involves the LB position
J Biol Inorg Chem (2014) 19:1243–1261 1259
123
that the competitive inhibition of fluoride is ascribed to the
L1 position, while the uncompetitive inhibition involves
the LB position (Scheme 4):
This is consistent with the proposed weakening of the
bonds between the bridging hydroxide and the two Ni(II)
ions upon urea binding to Ni1, as also implied in the pro-
posed catalytic mechanism [1, 5, 7, 9, 10, 13]. The present
study thus structurally clarifies the mechanism of urease
inhibition by fluoride, and, at the same time, provides hints
to understand and rationalize the role of Ni(II) in the
enzymatic mechanism.
The conclusions from our study on the urease inhibition
by fluoride allow us to discuss in more general terms the
interaction of this anion with two other classes of binuclear
metallohydrolases, namely the Mn(II)-dependent enzyme
arginase [56] and the Fe(III)–M(II) [M = Fe, Zn] depen-
dent purple acid phosphatase (PAP) [57, 58]. In the case of
rat liver arginase, fluoride acts as an uncompetitive inhib-
itor [59], while for bovine liver arginase a non-competitive
(mixed) mechanism has been reported [60]; in both cases,
the inhibition decreases by increasing pH. In the case of rat
liver arginase, a single fluoride appears to bind to the
[Mn(II)]2 cluster, while at higher pH the binding of two F
-
ions was observed [51]. The 2.4 A˚ resolution X-ray
structure of rat liver arginase was interpreted as containing
two fluoride ions, one bridging the two Mn(II) ions and one
terminally bound to the least coordinatively saturated
Mn(II) ion [51]. In the case of pig PAP, which contains the
Fe(III)–Fe(II) dinuclear cluster in the active site, fluoride
inhibition is uncompetitive at pH 4.9 and lower but non-
competitive (mixed) at higher pH values [61]; this pH-
dependent behavior is somehow opposite to what observed
for the analogous human PAP, for which the uncompetitive
inhibition is dominant at pH 4.9 and above, but becomes
non-competitive (mixed) at lower pH; the binding of two
fluoride ions was also reported [62]. On the contrary, in the
case of the Fe(III)–Zn(II) containing plant PAP the inhi-
bition mechanism is competitive and independent of pH
[61]. In all these cases, a similar order of magnitude for the
inhibition constants, in the mM range, was reported, similar
to the case of urease. The 2.2 A˚ resolution X-ray structure
of red kidney bean PAP in complex with fluoride was
interpreted as containing one F- bound in the position
bridging the Fe(III) and the Zn(II) ions [54]. A general
trend is thus observed, with the bridging position of the
dinuclear center of metallohydrolases being reactive
towards fluoride substitution, while the different pH de-
pendences might be the result of the influence of the dif-
ferent amino acid residues in the vicinity of the active site.
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Urease is the most efﬁcient enzyme known to date, and catalyzes the hydrolysis of urea using two Ni(II) ions in
the active site. Urease is a virulence factor in several human pathogens, while causing severe environmental and
agronomic problems. Sporosarcina pasteurii urease has been used extensively in the structural characterization of
the enzyme. Sodium sulﬁte has beenwidely used as a preservative in urease solutions to prevent oxygen-induced
oxidation, but its role as an inhibitor has also been suggested. In the present study, isothermal titrationmicrocal-
orimetrywas used to establish sulﬁte as a competitive inhibitor for S. pasteurii urease, with an inhibition constant
of 0.19 mM at pH 7. The structure of the urease–sulﬁte complex, determined at 1.65 Å resolution, shows the in-
hibitor bound to thedinuclear Ni(II) center of urease in a tridentatemode involving bonds between the twoNi(II)
ions in the active site and all three oxygen atoms of the inhibitor, supporting the observed competitive inhibition
kinetics. This coordination mode of sulﬁte has never been observed, either in proteins or in small molecule com-
plexes, and could inspire synthetic coordination chemists as well as biochemists to develop urease inhibitors
based on this chemical moiety.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Urease (urea aminohydrolase, EC 3.5.1.5) is a nickel-dependent
non-redox enzyme whose catalytic function is the hydrolysis of
urea to yield ammonia and carbamate at a rate 1015 times higher than
the uncatalyzed reaction, making it the most efﬁcient enzyme known
to date [1]. Carbamate then spontaneously evolves to produce another
molecule of ammonia and carbon dioxide. Urease catalyzes this last
step of organic nitrogen mineralization in bacteria, fungi, plants, algae
and invertebrates [2–5]. The overall hydrolysis of the products generat-
ed by urease activity determines an increase in pH of the surrounding
milieu, causing negative consequences in medical and agricultural
settings [2–7]. This enzyme represents the main virulence factor for a
large variety of ureolytic human pathogens such as Helicobacter pylori
[8], Mycobacterium tuberculosis [9], Yersinia enterocolitica [10], Crypto-
coccus neoformans [11], and Proteus mirabilis [12]. Furthermore,
ureolytic bacteria expressing urease are widespread in soils that are
treated with urea, a nitrogen fertilizer used worldwide [13], and their
activity contributes to a number of signiﬁcant environmental and eco-
nomic problems such as loss of nitrogen from soil and release of ammo-
nia in the atmosphere, ammonia toxicity for plants, and seedlings
damage [14]. In all these instances, a tight control of urease activity is
required to counteract its deleterious effects. For this purpose, several
classes of molecules have been proposed and tested, both in medicine
and agriculture, as urease inhibitors [4,15–18].
Knowledge about the structure of the nickel-containing active site
cavity has been derived through studies on native ureases isolated
from several sources [19–22], which revealed a conservation in the co-
ordination environment around the two Ni(II) ions (Fig. 1A).
On the basis of structural information obtained from the crystal
structures of native Sporosarcina pasteurii (formerly known as Bacillus
pasteurii) urease (SPU) [18,20] and of its complexes with a range of
other ligands [18,20,23–27], a general scheme of the catalytic mecha-
nism of ureases was proposed [1,5,20,28–31]. In this mechanism, the
nickel-bridging hydroxide acts as the nucleophilic group that attacks
the urea molecule chelating the bimetallic nickel cluster using an oxy-
gen atomand a nitrogen atom. An extendednetwork of second shell hy-
drogen bonds appears to stabilize the substrate binding during the
catalytic process. In addition, a ﬂexible ﬂap changes the active site chan-
nel from an open to a closed conformation (Fig. 1B).
Sulﬁte has been extensively used as a preservative in solutions of
jack bean (Canavalia ensiformis urease, JBU) [32,33] and SPU [18,20,
23–27,34,35]. The role of sulﬁte as a stabilizer of the urease activity
has been interpreted in the past as due to the maintenance of the
redox state of the conserved cysteine residue on the enzyme active
site ﬂap, which is essential for enzyme activity in its reduced thiol
form (Fig. 1B, C). Indeed, it is known that the thiol groups of cysteines
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can form oxygen derivatives such as sulfenic (Cys-SOH), sulﬁnic (Cys-
SO2H), and sulfonic (Cys-SO3H) functionalities [36], while stable
sulfenic acids may be produced by mild oxidation of sterically hindered
thiols [37]. In the case of the sulfenic functional group, the role of sulﬁte
could be the intermediate formation of an enzymatically inactive S-
sulfocysteine (Cys-S-SO3−), in turn undergoing hydrolysis to sulfate
and back to Cys-SH:
In addition, it has been shown that the enzymatic activity of JBU so-
lutions, stored in the presence of β-mercaptoethanol (BME) but in con-
tact with air oxygen, decreases [32] because of the formation of a mixed
disulﬁde bond involving BME and the conserved active site ﬂap Cys592
[22]. This process is reverted by treatment of inactivated urease with
sulﬁte [32] possibly through the reduction of this disulﬁde bond [38]:
The opposite action of BME and sulﬁte on JBUwas also suggested on
the basis of an increase in the anodic electrophoretic mobility of native
urease treated with sodium sulﬁte caused by an increased negative
charge of the protein molecule; this process could be reversed by treat-
ment with BME andwas explained by the formation of S-sulfocysteines
involving the several cysteine residues on the surface of JBU [39].
In addition to a protective action on the urease active site cysteine,
sulﬁte has been reported to be an inhibitor of JBU,with a competitive in-
hibition mechanism deduced from the temperature dependence of the
activation energy of the urea enzymatic hydrolysis as a function of sul-
ﬁte concentration [40]. A pH-dependent kinetic study further suggested
that the bisulﬁte mono-anion, and not the sulﬁte di-anion, is the actual
inhibitor of JBU with inhibition constants in the milli-molar range, and
that this process does not entail an interaction of bisulﬁte with the sulf-
hydryl group of essential cysteines, but rather an addition to the active
site, whose naturewas still very obscure at the time [41]. These early re-
ports were later supported by a study that indicated sulﬁte acting as a
competitive inhibitor for JBU with an inhibition constant Ki = 2.23 ±
0.45 mM at pH 7.0 [42]. This inhibition role of sulﬁte on urease was
then proposed to involve a direct interaction with the Ni(II) ions in
the active site on the basis of an apparent increase of the nickel afﬁnity
of JBU in the presence of this anion [38].
In this study, we report amolecular characterization of the inhibi-
tion of SPU by sulﬁte. In particular, we describe and discuss the re-
sults of pH-dependent kinetic measurements carried out using a
calorimetry-based assay, indicating that sulﬁte acts as a competitive
inhibitor of SPU. This conclusion is supported by the crystal structure
of the SPU–sulﬁte complex at 1.65 Å resolution, showing an unprec-
edented binding of the inhibitor to the active site Ni(II) ions through
its three oxygen atoms.
2. Materials and methods
2.1. Protein puriﬁcation
S. pasteurii DSM 33 cells were obtained using a modiﬁcation of a
previously described procedure [18], and SPU was isolated in a pure
form to a speciﬁc activity of about 2500 units per milligram using the
following protocol. S. pasteurii cells, resuspended in a buffer containing
50 mMphosphate pH 7.5, 50 mMNa2SO3, 1 mM EDTA (buffer A), addi-
tionally containing 10mMMgCl2 and 20 μg/mLDNAse I, were disrupted
by three passages through a French® pressure cell press (SLM Aminco)
at 20,000 psi. The soluble fraction was obtained by differential centrifu-
gation, ﬁrst at 30,000 ×g for 30 min and then at 150,000 ×g for 2 h, in
order to remove cell debris and aggregates. The crude extract was
dialyzed overnight against buffer A and then loaded onto a Q Sepharose
XK 50/20 (GE Healthcare) anionic exchange column, previously
equilibrated with the same buffer. A step gradient procedure was used
to elute the protein with increasing ionic strength (NaCl in buffer A
was used at concentrations of 150, 350, 450 mM) at a ﬂow rate of
5mLmin−1. The active fractions, eluted and detected at a concentration
of 350mMNaCl, were pooled and the ionic strength raised to 1M using
(NH4)2SO4. After centrifugation at 30,000 ×g for 15 min to remove the
precipitate, the solution was loaded onto a Phenyl Sepharose XK 26/20
(GE Healthcare) hydrophobic interaction column equilibrated with
buffer A containing 1 M (NH4)2SO4 and eluted with a linear gradient
from 1 M to 0 M at a ﬂow rate of 3 mL min−1. Urease, eluted with
400 mM (NH4)2SO4, was concentrated using an Amicon ultraﬁltration
cell equipped with a membrane of 100,000 Dalton molecular weight
cut-off. The resulting enzyme solution was loaded onto a Superdex
200 XK 16/60 (GE Healthcare) gel ﬁltration column equilibrated with
buffer A, containing 150 mM NaCl in order to prevent non-speciﬁc
Fig. 1. (A) Details of the active site of native SPU. Atoms are colored according to the atom type. (B) Superimposition of the open (blue ribbons, 4CEU) and closed (yellow ribbons, 3UBP)
conformation of theﬂexibleﬂap. Ni(II) ions are shown as green spheres. TheαCys322 side chain is reported as “sticks”. (C)Multiple sequence alignment of theﬂap region of theureases for
which a crystal structure is available: SPU, Klebsiella aerogenes urease (KAU), Helicobacter pylori urease (HPU), jack bean urease (JBU), and pigeon pea urease (PPU). The position of SPU
αCys322 and αHis323 are in red, while the α-helices are highlighted in yellow. The asterisks indicate the fully conserved amino acids.
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interaction between the protein and the resin, and eluted at a ﬂow rate
of 1 mLmin−1. The active fractions were pooled, and the ionic strength
was decreased by dilution. The obtained solution was loaded onto
aMonoQHR10/10 (Pharmacia) anionic exchange column, equilibrated
with buffer A. Urease was eluted using a linear gradient of increasing
ionic strength from 0 to 500 mM NaCl in buffer A. The active fractions
were concentrated and further puriﬁed to homogeneity using a
Superdex 200 10/300 GL (GE Healthcare) gel ﬁltration column equili-
brated with 20 mM N-(2-hydroxyethyl)piperazine-N′-ethane-sulfonic
acid sodium salt (HEPES), pH 7.5, containing 150 mM NaCl and
50 mM Na2SO3 (buffer B) at a ﬂow rate of 0.5 mL min−1. Urease active
fractions from the last step were concentrated to 11 mg/mL and stored
in buffer A at 4 °C.
2.2. Kinetic studies
Calorimetric experiments were carried out with a high-sensitivity
VP-ITC (ITC: Isothermal Titration Calorimetry) micro-calorimeter
(MicroCal LLC, Northampton, MA, USA), using a previously described
enzymatic assay [18,43]. SPU was eluted through a Superdex 200
10/300 GL (GE Healthcare) size-exclusion chromatography column im-
mediately before themeasurements, using a 50mMHEPES pH 7.5 buff-
er, containing 50mMNa2SO3, 2mMEDTA, and 150mMNaCl, as eluent.
The protein samples were then diluted to the concentrations used for
the calorimetric experiments described below, using 50 mM HEPES
containing 2 mM EDTA, at the pH value (7.0, 7.5 or 8.0) used in the
experiment. The obtained enzyme solution was degassed and loaded
into the ITC sample cell (V = 1.4093 mL). The ITC stirring injection
syringe was ﬁlled with urea dissolved in 50 mM HEPES containing
2 mM EDTA to the concentrations used for the different experiments
described below. The reference cell was ﬁlled with deionized water,
and the temperature of the two cells was set and stabilized at 298 K.
Stirring speed was 300 rpm, and thermal power was monitored every
2 s using high instrumental feedback. In order to determine the molar
enthalpy of the reaction (M1 experiments), 30 nM SPU and 20 mM
ureawere used in cell and in syringe, respectively, and a single injection
of 5 μL urea was carried out, giving a ﬁnal substrate concentration of
0.07 mM in the sample cell. After the baseline returned to the original
level, indicating that the consumption of the substrate was complete,
a second and a third injection were performed, following the same pro-
cedure. Numerical integration of the area under the three single peaks
was carried out using the native Origin package provided by the calo-
rimeter manufacturer, and the average value thus obtained was used
to calculate the molar enthalpy for urea hydrolysis. In order to derive
the kinetic parameters Km and kcat (M2 experiments) 50 pM SPU and
0.5M ureawere used in the cell and in the syringe, respectively. The en-
zyme was pre-incubated for 15 min at 25 °C in 50 mM HEPES, 2 mM
EDTA, at pH 7.0, 7.5 or 8.0, and in the presence of a predeﬁned amount
of sulﬁte depending on the experiment (see below). Successive injec-
tions of 5 μL urea solution, containing sulﬁte at the same concentration
of the enzyme solution, were carried out every 180 s, a time necessary
to allow the thermal trace to return to a steady-state level after each in-
jection and, at the same time,maintain pseudo-ﬁrst-order reaction con-
ditions. The thermal power obtained from the baseline shift was
averaged using the last 15 s prior to the subsequent injection to obtain
an accuratemeasurement. The calculated thermal power for each injec-
tion was converted to reaction rate and corrected to take into account
enzyme dilution. Control runs were carried out by injecting the urea so-
lution into the buffer alone. All calorimetric experiments were carried
out using a minimum required amount of sulﬁte (20 μM), which was
strictly necessary in order to keep the enzyme active during the course
of the measurement. Indeed, analogous experiments performed in the
total absence of sulﬁte indicated a progressive decrease of enzyme ac-
tivity. Datawere processedwith the native Origin package. The reaction
rates were obtained using a previously described protocol [18,43].
The data analysis was based on the classic deﬁnitions of competitive,
uncompetitive andmixed enzyme inhibition [44,45]. In themost gener-
al case, the rate of enzymatic reaction is given by:
v ¼ V max " urea½ $
Km " 1þ I½ $Kic
! "
þ urea½ $ " 1þ I½ $
Kiu
! " : ð1Þ
In this expression, Vmax= kcat[urease] and Km are themaximum rate
and the Michaelis constant, respectively, [I] is the molar concentration
of the inhibitor, and Kic and Kiu are the competitive and uncompetitive
inhibition constants, respectively. The kinetic parameters were obtain-
ed from a ﬁt of the experimental reaction rates obtained by calorimetry
to the general inhibition Eq. (1), using non-linear regression analysis
implemented in the Origin package.
2.3. Crystallization, data collection and structural determination
Crystallization was performed at 293 K using the hanging-drop
method. A solution of urease (11 mg mL−1, 3 μL) in 20 mM HEPES,
pH 7.5, containing 150 mM NaCl and 50 mM Na2SO3, was diluted with
3 μL of the precipitant solution (1.8–2.0 M ammonium sulfate in a
50 mM sodium citrate buffer pH 6.3 containing 50 mM Na2SO3 and 1–
5% dimethylsulfoxide, DMSO). The drop was equilibrated by vapor dif-
fusion against 1 mL of the precipitant solution using a Hampton Re-
search 24-well Linbro plate. Rice-shaped protein crystals appeared
within 1–3 weeks and grew to a size of 0.1 × 0.1 × 0.3 mm3. Crystals
were scooped up using cryoloops, transferred to a cryoprotectant solu-
tion containing 20% ethylene glycol, 2.4 M ammonium sulfate, 50 mM
sodium citrate and 50 mM Na2SO3, and then ﬂash-cooled and stored
in liquid nitrogen.
Diffraction data were collected at 100 K using synchrotron radiation
at the EMBL P13 beamline of the Petra III storage ring, c/o DESY Ham-
burg (Germany), equipped with a Si(111) crystal monochromator
(FMB Oxford), a DECTRIS Pilatus 6 M detector, and a MD2 goniometer
(MAATEL-EMBL) with a horizontal spindle axis. Reﬂection data were
collected from two crystals (1500 images for each crystal), by
performing helical scans through the crystal to achieve higher resolu-
tion and minimize radiation damage. The data were processed using
XDS [46] and AIMLESS [47]. The crystals are isomorphous with those
of apo-SPU and other complexes of this enzyme (Table 1).
The model of SPU in complex with citrate (PDB code 4AC7, 1.50 Å
resolution) [27], devoid of water molecules and ligands, was used as a
starting model for the rigid body reﬁnement of the single αβγ protein
trimer, carried out using Refmac [48,49]. Manual model building was
conducted using Coot [50,51]. The structure was isotropically reﬁned,
including the hydrogen atoms in the riding positions. The diffraction
data and ﬁnal reﬁnement statistics are given in Table 1. The structure
was deposited in the Protein Data Bank under the accession code
5A6T. Crystallographic ﬁgures were created using Chimera [52] or
CrystalMaker 8.7 (http://www.crystalmaker.com/).
2.4. Theoretical calculations
Density functional theory (DFT) computations were carried out
using the program ORCA 3.0.3 [53] and the Becke three-parameter hy-
brid functional combined with Lee–Yang–Parr correlation functional
(B3LYP/G) [54,55] as deﬁned in the Gaussian software [56]. All atoms
were described by the Dunning correlation-consistent polarized triple
zeta basis set with the inclusion of diffuse functions (aug-cc-pVTZ)
[57]. Frequency computations were performed to determine the nature
of the various critical points.
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3. Results
3.1. Calorimetric analysis
The inhibition of S. pasteurii urease by sulﬁte was investigated using
isothermal titration calorimetry (ITC), a method that provides a univer-
sal approach to determining the kinetic behavior of enzymes by yield-
ing, in a single experiment, a complete set of kinetic parameters for an
enzyme-catalyzed reaction [43,58–61]. A very similar approach has
been recently described for other metallo-hydrolases [62].
Themolar reaction enthalpy (ΔH) of the hydrolysis of urea by urease
was determined using a so-called M1 experiment, in which a single in-
jection of the substrate solution into a concentrated enzyme solution
determined a decrease of the instrumental thermal power necessary
tomaintain the reference and the sample cell at a constant temperature,
indicating an exothermic reaction. Complete consumption of the sub-
strate occurred in the range 500–2000 s, depending on the working
pH in the 7.0–8.0 range (Fig. 2A). Two further injections of substrate
into the reaction cell provided curves with identical proﬁle, showing
negligible inhibition by products (Fig. 2A). The integration of the curves
yieldedΔH=−11.3± 0.2 kcalmol−1. A progressive increase of the re-
action rate with increasing pH was observed in the 7.0–8.0 range, con-
sistent with the known pH dependence of the enzyme activity for SPU
[63].
The so-called M2 experiments (Fig. 2B) were performed using a di-
luted enzyme solution in the sample cell and carrying out multiple in-
jections of a concentrated substrate solution, in the pH range 7.0–8.0.
These experiments revealed an initial increase in thermal power due
to the heat of substrate dilution, followed by a decrease required to
maintain isothermal conditions for the exothermic reaction. The rate
of heat generated by the enzyme is equivalent to the decrease in ther-
mal power after each injection, steadily increasing as the substrate con-
centration increases. Analogous experiments carried out using 1.6 mM
sulﬁte (Fig. 2B) showed a decrease of the reaction rate. Monitoring the
latter as a function of substrate concentration and pH (in the range
7.0–8.0), as shown in Fig. S1 (Supplementary information), yielded a se-
ries of data that were ﬁt to Eq. (1), resulting in the kinetic parameters
reported in Table 2. The increase of kcat as a function of pH in the ex-
plored range is in complete agreement with previous literature data in-
dicating an optimum pH for SPU of ca. 7.7 [63]. The Michaelis–Menten
constant, slightly smaller than the value of 17.3 mM reported in phos-
phate buffer [34,63], is invariant with pH. The parameters in Table 2 fur-
ther show values of Kic « Kiu, indicative of a competitive mechanism of
inhibition of urease by sulﬁte in the investigated pH range. This inhibi-
tion effect strongly decreases upon pH increase, becoming undetectable
at pH 8.0.
Table 1
X-ray diffraction data collection and reﬁnement statistics for sulﬁte-bound Sporosarcina
pasteurii urease (PDB code 5A6T).
Data collection
Wavelength (Å)a 1.033
Crystal-to-Detector distance (mm) 271.8
Oscillation angle (degrees) 0.075
Number of images 3000
Space group P6322
Unit cell (a, b, c, Å) 131.24, 131.24, 188.88
Resolution range (Å)a 97.46–1.65 (1.68–1.65)
Total number of reﬂectionsa 2,478,074 (69,467)
Unique reﬂectionsa 115,020 (5576)
Multiplicitya 21.5 (12.5)
Completenessa (%) 99.8 (99.2)
Rsyma,b (%) 0.102 (0.471)
Rpima,c (%) 0.030 (0.199)
Mean I half-set correlation CC(1/2) 0.969
Mean I/σ(I)a 29.4 (5.7)
Reﬁnement statistics
Number of monomers in the asymmetric unit 3
Rfactord (%) 12.87
Rfreed (%) 15.25
Cruickshank's DPI for coordinate errore based on
Rfactor (Å)
0.063
Wilson plot B-factor (Å2) 12.9
Average all atom B-factorf (Å2) 19.155
B-factor of Ni atoms Ni1: 18.5; Ni2: 16.1
B-factor of sulﬁte atoms S: 25.1, O1: 23.5; O1: 28.2; O1:
22.1
RMS (bonds)d 0.022
RMS (angles)d 2.067
Total number of atomsc 6864
Total number of water molecules 636
Solvent content (%) 55.23
Matthews coefﬁcient (Å3/Da) 2.75
Ramachandran plotg
Most favored region (%) 90.7
Additionally allowed region (%) 8.4
Generously allowed region (%) 0.8
Disallowed region (%) 0.2
a Highest resolution bin in parentheses.
b Rsym ¼∑hkl∑ j jI j−hIij=∑hkl∑ j I j , where I is the intensity of a reﬂection, and 〈I〉 is
the mean intensity of all symmetry related reﬂections j.
c Rp:i:m: ¼∑hklf½1=ðN−1Þ%∑ j jI j−hIijg1=2=∑hkl∑ jI j , where I is the intensity of a re-
ﬂection, and 〈I〉 is themean intensity of all symmetry related reﬂections j, andN is themul-
tiplicity [76].
d Taken from REFMAC [48,49]; Rfree is calculated using 5% of the total reﬂections that
were randomly selected and excluded from reﬁnement.
e DPI ¼ Rfactor & Dmax & compl−
1=3
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Natoms
ðNrefl−Nparams Þ
q
, where Natoms is the number of the atoms
included in the reﬁnement, Nreﬂ is the number of the reﬂections included in the reﬁnement,
Dmax is the maximum resolution of reﬂections included in the reﬁnement, compl is the com-
pleteness of the observed data, and for isotropic reﬁnement, Nparams≈ 4Natoms [77].
f Taken from BAVERAGE [78].
g Taken from PROCHECK [78].
Fig. 2. Typical plots of thermal power of S. pasteurii urease activity as a function of time in
M1 experiments (A) at pH7.0 (red line), pH7.5 (orange line) and pH8.0 (blue line), and in
M2 experiments at pH 7.5 in the presence of 0.02 mM (blue line) and 1.6 mM (red line)
sodium sulﬁte (B). Experimental conditions are described in Materials and Methods.
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3.2. Structural analysis
The crystal structure of sulﬁte-inhibited SPU, showing the well-
established architecture of this metallo-enzyme, closely matches that
of the native protein (PDB code 4CEU, used here as reference for com-
parison because it has been reﬁned to the highest resolution so far avail-
able, 1.58 Å) [18]. The global pairwise root mean square deviation
(RMSD) per residue between Cα atoms of the two structures is only
0.11, 0.06 and 0.05 Å for the α, β and γ subunits, respectively, and the
overall RMSD is 0.10 Å. The analysis of the residue-averaged backbone
B factors, as well as the ϕ and φ protein backbone angles (Figs. S2–
S4), reveals two regions in theα subunit that feature a signiﬁcantly larg-
er mobility than the rest of the protein. Region A (residues 380–405) is
located on a surface patch and involves a helix and a solvent-exposed
loop. This region has been proposed [27] to participate in either the
catalytic mechanism or the interactionwith UreD, the accessory protein
that, along with its partners UreF, UreG and UreE, forms the
supercomplex that is necessary for the delivery of the two Ni(II) ions
into the active site cavity and for the consequent urease activation [5,
64]. Region B (residues 305–350) corresponds to the ﬂap, consisting of
a helix–loop–helix motif, responsible for the modulation of the sub-
strate access to the active site cavity (Fig. 1B). The sulﬁte-bound SPU
structure displays an “open” ﬂap, as observed in the case of native ure-
ase [18,20], as well as in all the other cases of SPU-inhibitor complex
structures so far determined [18,23–27], except for urease inhibited by
diamidophosphate (DAP), whose crystal structure presents the ﬂap in
the completely “closed” position [20]. Since DAP is generated in situ
from the hydrolysis of phenylphosphorodiamidate, simulating the cata-
lytic intermediate or transition state, the closed-ﬂap conformation was
proposed to stabilize the intermediate or transition state of the catalysis
[20]. In the reﬁned model (Figs. 3A and 4), the two Ni(II) ions are
bridged by the carboxylate group of the carbamylated Lys220*, which
is bound to Ni(1) by Oθ1 and to Ni(2) by Oθ2, allowing the two Ni(II)
ions to be properly placed for the catalytic process. Ni(1) is further coor-
dinated by His249 Nδ and by His275 Nε, whereas Ni(2) is bound to
His137 Nε, His139 Nε, and Asp363 Oδ1.
The unbiased electron density map calculated with Fourier coefﬁ-
cients Fo–Fc and phases derived from the model of SPU in complex
with citrate (PDB code 4AC7, 1.50 Å resolution) [27], devoid of water
molecules and ligands, displays an electron density in the volume
around and between the Ni(II) ions that clearly indicates the existence
of a trigonal pyramidal non-protein ligand bound to the two metal
ions (Fig. 3B). This electron density is very different from what would
be expected if four solvent-derivedmoleculeswere present in the active
site (see, for example, themaps reported in [18]). Given the presence of
sulﬁte in the crystallization solution, this moiety was modeled into the
electron density and reﬁned with full occupancy (Fig. 4). In the reﬁned
model, the sulﬁte molecule is bound in a tridentate bindingmode to the
two Ni(II) ions in the active site, replacing the terminal and the bridging
solventmolecules thatwere bound toNi(1) andNi(2) in thenative form
of the enzyme. This type of coordination is unprecedented both in pro-
tein and in small molecules structures. In this mode, sulﬁte binds the
two Ni(II) ions at the active site using two oxygen atoms [Ni(1)–
O(1) and Ni(2)–O(2), respectively], placing its third oxygen atom,
O(B), in the bridging position. The positions of the conserved amino
acid residues, which are not involved in the Ni(II) binding but are
known to be crucial in the catalytic mechanism (Ala170, His222,
Glu223, Asp224, Gly280, His323, Ala366 and Met367), are largely
conserved between the native and inhibited urease. This conservation
of the structure of the active site residues is generally observed also in
all other structures of SPU.
A comparison of the geometric parameters around the two Ni(II)
ions in the active site of native and sulﬁte-bound urease, presented in
Table S1, reveals that the structure is rigidly maintained.
The molecule of sulﬁte bound to urease is slightly asymmetric, with
S–O(1)= 1.67 Å, S–O(2)= 1.57 Å, and S–O(B)= 1.83 Å. Moreover, the
sulﬁtemolecule forms a series of hydrogen bondswith the residues that
surround the active site cavity (Fig. 4): O(1) forms a hydrogen bond
with His222 Nε (at 2.65 Å) that is protonated and acts as a hydrogen-
bond donor, as deduced from the interaction of His222 Nδ with the
Asp224 peptide NH group at 2.88 Å. Furthermore, two water molecules
are H-bonded to O(1) at 3.19 Å and 3.21 Å. The sulﬁte oxygen O(2),
bound to Ni(2), is placed at 2.78 Å from the carbonyl backbone Ala170
O, suggesting a possible H-bond in which the sulﬁte O(2) could be
protonated. Finally, the bridging sulﬁte O(B) is placed at 2.48 Å from
Table 2
Kinetic parameters for the inhibition of SPU with sulﬁte.
pH kcat (s-1) KM (mM) Kic (mM) Kiu (mM)
7.0 7953 ± 36 10.3 ± 0.1 0.19 ± 0.03 »1
7.5 11,631 ± 70 12.0 ± 0.2 1.17 ± 0.02 »1
8.0 9939 ± 49 11.7 ± 0.2 – –
Fig. 3. Atomic model of the active site of sulﬁte-bound Sporosarcina pasteurii urease (PDB
code 5A6T). In panel (A), the nickel-coordination environment is shown superimposed on
the ﬁnal 2Fo–Fc electron density map contoured at 1.5 σ (cyan). In panel (B), the unbiased
electron density map calculated with Fourier coefﬁcients Fo–Fc and phases derived from
the model before the atoms corresponding to S, O(1), O(2), and O(B) of sulﬁte were
added, is shown contoured at 3 σ (magenta). The carbon, nitrogen, oxygen, sulfur and
nickel atoms are gray, blue, red, yellow and green, respectively.
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Asp363 Oδ2, again suggesting that these two atoms could share a hy-
drogen atom through an H-bond.
4. Discussion
The present study focuses on the biochemical and structural features
of the interaction of the urease from S. pasteurii with sulﬁte, a known
urease inhibitor [40–42] as well as a stabilizer of urease activity [18,
20,23–27,32–35]. Enzymatic measurements of sulﬁte inhibition of ure-
asewere performed on SPU using a calorimetricmethod, and the results
were integrated with the analysis of high-resolution crystallographic
data of sulﬁte-inhibited urease. The calorimetric data show that sulﬁte
inhibits the activity of SPU with a pH-dependent competitive mecha-
nism in the 7.0–8.0 range. These results, obtained on SPU, are in agree-
ment with early data on JBU [41], and suggest a commonmechanism of
urease inhibition by sulﬁte among ureases from different sources.
Among the several classes of urease inhibitors known to date [4], the
competitive inhibition constant determined for sulﬁte at pH 7.0
(0.19 mM) compares well with the analogous value reported for boric
acid (0.08–0.35 mM) and BME (0.72 mM), while it performs better
then urea analogs (1.45–980 mM), phosphate (19 mM), and bismuth
derivatives (1.74–1.84 mM).
The competitive nature of the inhibition indicates that sulﬁte, in one
of its protonated forms, competes with the substrate urea for the active
site Ni(II) ions. In particular, the inhibition decreases almost an order of
magnitude by increasing the pH from 7.0 to 7.5, and becomes negligible
upon further increase of the pH up to 8: this observation excludes that
the inhibitor takes the di-anionic SO32− form, but does not in principle dis-
tinguish between themono-anionic and the neutral non-dissociated form
of sulﬁte (pKa1 = 1.85 and pKa2 = 7.20 [65]) because of the limited pH
interval that could be explored without causing enzyme degradation at
low pH. Even though the crystallization buffer pH = 6.3 would support
the presence of the mono-anionic inhibitor as the main form of sulﬁte
in solution, the presence of the neutral form of the inhibitor in the urease
active site cannot be excluded on the sole basis of these criteria.
Consistentwith these kinetic observations, high resolution crystallo-
graphic data demonstrate that the inhibitor binds in the active site
displacing three solvent-derived Ni(II)-bound molecules and replacing
these position with its three oxygen atoms, blocking access of urea to
the key metal ions. This tripodal coordination mode of sulﬁte has
never been observed either in proteins or in smallmolecules complexes,
and represents an exciting twist in the chemistry of Ni(II) in urease.
Binuclear metallo-hydrolases are not new to this kind of tripodal ligand
coordination mode: sulfate binds theMn-Mn center of bacteriophage λ
protein phosphatase [66], while phosphate binds the Fe-Mn center in
purple acid phosphatase from sweet potato [67] and Lupinus luteus
[68], as well as the di-nickel center of urease [25], using three out of
the four oxygen atoms of the anion.
The structure of the bisulﬁte ion has actually been the subject of
some debate: the HSO3− ion could adopt either a C3v structure (HSO3−),
in which the H atom is bound to sulfur, or a C1 structure [SO2(OH)]−,
in which a OH group is bound to S. Previous experimental data and
quantum mechanical calculations showed that, in the ﬁrst case, the
three S–O bonds should be identical (bond distance ca. 1.47 Å, bond
order = 5/3), while in the second case the S–OH bond would be longer
(ca. 1.75–1.78 Å, bond order = 1) than the other two S–O bonds (ca.
1.49–1.50 Å, bond order = 3/2) [69]. In aqueous solution the C1 isomer
is more energetically stable than the C3v isomer by only 4.9 kcal mol−1
Fig. 4. Crystallographic structural model for the active site obtained for the sulﬁte-bound Sporosarcina pasteurii urease (PDB code 5A6T). The carbon, nitrogen, oxygen, sulfur and nickel
atoms are gray, blue, red, yellow and green, respectively. Putative H-bonds are shown as thin blue lines. Spheres are drawn using the relative atomic radii values in CrystalMaker.
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[70], suggesting that the adopted structure would depend on the chem-
ical environment [69]. The sulﬁte ion SO32−, on the other hand, can
adopt only C3v geometry with identical S–O bond distances of 1.53 Å
in solution (bond order = 4/3) [71]. In order to distinguish between
the different protonated forms of sulﬁte, we carried out quantum me-
chanical calculations, and compared the computed structural parame-
ters with those determined in the crystal structure of sulﬁte-inhibited
SPU (Tables 3 and S2).
Our calculations largely conﬁrm these previously reported values,
additionally indicating that the neutral form H2SO3 would possess one
short and two long S–O distances. The asymmetric collection of S–O
bond distances found in the crystal structure of SPU bound to this
inhibitor (1.57 Å, 1.67 Å, and 1.83 Å for S–O(1), S–O(2) and S–
O(B) respectively), in a short–short–long distribution (Table 3), are nei-
ther compatible with the SO32− ion (as also suggested by the previous
considerations on the crystallization pH vs. the pKa of HSO3−), nor with
the C3v isomer of this anion, nor with the neutral form of the inhibitor,
supporting instead the presence of the [SO2(OH)]− mono-anionic
form of sulﬁte bound to the active site Ni(II) ions. In particular, the
long S–O(B) distance and the short O(B)–Oδ2 Asp363 distance
(2.48 Å) suggest the presence of a hydrogen shared between these
two O atoms. On the other hand, the longer distance involving S–
O(1) vs. S–O(2) could be determined by the presence of the
hydrogen-bonding donor His222 NεH in the close vicinity of O(1) (at
2.65 Å) that could have an effect of decreasing the negative charge on
O(1); this consideration would also justify the longer distance
(2.20 Å) between Ni(1) and O(1) as compared to the distance (2.10 Å)
betweenNi(2) andO(2). In general, the S–Odistances found in the crys-
tal structure of the complex are ca. 0.1–0.2 Å longer than those expected
for the bisulﬁte C1 isomer in aqueous solution: this could be due to the
presence of the two Ni(II) ions bound to the anion. Indeed, a similar ef-
fect has been observed in the case of the structure of human carbonic
anhydrase II complexedwith bisulﬁte (PDB code 2CBD) [72]: this struc-
ture, solved at 1.67 Å resolution, together with an older structure of the
same enzyme solved at 2.0 Å resolution (PDB code 5CAC) [73], is the
only case that shows a sulﬁte ion bound to a metal ion in a protein,
namely Zn(II), in a terminal mode, using a presumably protonated O
atom, as manifested by the network of H-bonds around it [72]. In this
case, the length of the S–O(H) bond involving the oxygen atom bound
to Zn(II) is 1.82 Å, a value essentially identical to the S–O(B) distance
in the SPU–sulﬁte complex, while the other two S–O bond lengths, in-
volving O atoms not bound to other metal ions, are 1.46–1.47 Å, consis-
tent with the distances observed for the C1 isomer of HSO3−. All these
considerations further support the presence of the mono-anionic C1
form of sulﬁte. However, the possibility of an additional H-bond formed
between sulﬁte O(2) and the carbonyl backbone Ala170 O does not rule
out the presence of the neutral, fully protonated, sulfurous acid.
The presence of sulﬁte bound tometal ions in proteins is not unique:
a research performed using the MetalPDB search server (http://
metalweb.cerm.uniﬁ.it) [74] reveals that, in addition to the above men-
tioned carbonic anhydrase II, sulﬁte is detected bound to the heme Fe
atom in the active site of sulﬁte and nitrate reductases. In all those in-
stances, however, sulﬁte is bound to the metal ion through the S atom
and not using the whole set of O atoms as found in the active site of
sulﬁte-inhibited S. pasteuri urease. A search of the Cambridge Crystallo-
graphic Database (http://www.ccdc.cam.ac.uk), containing small
molecules, gave no hits for this coordination mode of sulﬁte, further
reinforcing the novelty of this coordination mode. In this context, it is
worth mentioning that the effect of sulﬁte on a newly discovered Ni-
containing enzyme, lactate racemase (Lar), has been recently reported
[75]. This enzyme contains an organometallic nickel-containing pros-
thetic group, and sulﬁte was shown to act as a potent mixed inhibitor
as well as being able to stabilize Lar activity and delay Ni loss; however,
the molecular details of these effects have not been clariﬁed [75].
5. Conclusions
The kinetics of inhibition of S. pasteurii urease with sulﬁte, deter-
mined using an enzyme assay based on microcalorimetry, indicate
that this molecule acts as a competitive inhibitor. This result is con-
ﬁrmed by the structure of the urease–sulﬁte complex, which shows
the inhibitor bound to the active site Ni(II) ions and blocking access to
urea, the natural substrate for this enzyme. The structure of the
nickel-bound sulﬁte described in the present article is unprecedented
and expands the coordination chemistry of this inorganic molecule to
include a tridentate mode. The latter might inspire model inorganic
chemists towards the synthesis of analogous complexes and investigate
their chemical and reactivity properties. At the same time, the results il-
lustrated here could stimulate research towards urease inhibitors based
on oxidized sulfur functional groups, demonstrated here to be able to
act as efﬁcient modulators of enzyme activity.
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Table 3
B3LYP/G aug-cc-pVTZ distances (Å) of sulfurous acid, bisulﬁte ion in the C1 and in the C3v forms, and sulﬁte ion compared with the distances found in the sulﬁte inhibited SPU crystal
structure.
Crystal structure
S–O1 1.647 1.782 1.440 1.554 1.87
S–O2 1.647 1.492 1.440 1.554 1.57
S–O3 1.469 1.506 1.440 1.554 1.67
O1–H1 0.972 0.967
O2–H2 0.972
S–HS 1.343
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Inactivation of urease by 1,4-benzoquinone:
chemistry at the protein surface†
L. Mazzei,a M. Cianci,b F. Musiania and S. Ciurli*a
The high activity of urease, a Ni(II) enzyme, has several adverse
eﬀects on human health and agriculture, and its modulation needs
the use of inhibitors. 1,4-Benzoquinone (BQ) irreversibly inacti-
vates Sporosarcina pasteurii urease (SPU), with ﬁrst order kinetics
for both the inhibitor and the enzyme. This reaction is stoichio-
metrically quenched in the presence of sulphite. The 2.07 Å crystal
structure of SPU bound to BQ shows the presence of a 1,4-hydro-
quinone moiety covalently bound to the thiol group of αCys322, a
key residue found on the mobile ﬂap regulating the substrate
access to the active site. The 1.75 Å crystal structure obtained
when sulphite is added to a solution of SPU previously incubated
with BQ shows the presence of a 2,5-dihydroxy-benzenesulph-
onate moiety bound to the αCys322 thiol group. These data reveal
how the active site cysteine reacts with a prototypical BQ moiety,
found in a large number of natural substances potentially suitable
to control the urease activity.
The rapid hydrolysis of urea catalysed by the Ni(II)-containing
enzyme urease1 in bacteria, fungi, algae and plants causes an
abrupt increase of pH and, consequently, negative side eﬀects
on human health2 and the environment.3 Ureases show a qua-
ternary structure made of a functionally minimal trimer, diﬀer-
ently assembled in higher order structures depending on the
biological source.1 Each unit of the trimer hosts one enzyme
active site, constituted by two Ni(II) ions (Ni1 and Ni2) bridged
by a carbamylated lysine residue (αLys220* in SPU) and by a
hydroxide ion (Fig. 1A). The Ni(II) ions are further coordinated
by two histidine residues, and are distinguished by the presence
of a carboxylate O atom from an aspartate residue bound to Ni2.
The coordination geometry of each Ni(II) ion is completed by a
water molecule, leading to a pseudo-square pyramidal penta-co-
ordinated Ni1 and a pseudo-octahedral hexa-coordinated Ni2. A
third water molecule completes, together with the bridging
hydroxide, a cluster of solvent-derived O atoms that defines a tet-
rahedral cavity that is assumed to stabilize the transition state
of the catalysed reaction.4 The active site is found at the end of a
ca. 15 Å-deep pocket characterized by the presence of a helix-
turn-helix flap located at its entrance (Fig. 1B and 1-ESI†). This
flap was observed to adopt diﬀerent conformations, and has
been suggested to modulate both the access of substrate to the
enzyme active site and the dimensions of the catalytic cavity.4a,5
The design and synthesis of novel and potent urease inhibi-
tors necessary to modulate its catalytic activity to counter-
balance its negative eﬀects require the knowledge of the
structural details of the inhibition mechanism. Several urease
structures reveal how the Ni(II) ions in the active site could
be targeted by competitive inhibitors.1b,6 On the other hand,
the most eﬃcient urease inhibitors known so far contain the
Fig. 1 (A) Coordination environment of the Ni(II) ions in the active site
of SPU (PDB code 4CEU). (B) Superimposition of the open (white and
light blue ribbons, PDB code 4CEU) and closed (grey and blue ribbons,
PDB code 3UBP) conformations of the ﬂexible ﬂap in SPU, highlighting
the side chain of αLys220* and αCys322.
†Electronic supplementary information (ESI) available: Materials and methods,
structural parameters and unbiased electron density maps of BQ inhibited SPU,
details of the SPU surface, and the results of the quantum mechanical calcu-
lations. See DOI: 10.1039/c6dt00652c
aLaboratory of bioinorganic Chemistry, Department of Pharmacy and Biotechnology,
University of Bologna, Viale G. Fanin 40, I-40127 Bologna, Italy.
E-mail: stefano.ciurli@unibo.it
bEuropean Molecular Biology Laboratory, DESY, Notkestraße 85, 22607 Hamburg,
Germany
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1,4-benzoquinone moiety (BQ, 1, Scheme 1).7 Quinones are
known to react with thiols, leading to the formation of the
corresponding thiol-substituted benzene-1,4-diol.8 The
sequence of the urease mobile flap contains the highly
conserved residue αCys322 (residue numbering as in SPU),
which is crucial for the activity of urease,9 and whose position
with respect to the active site is also modulated by the flap
movement (Fig. 1B). Covalent modifications of this residue
by the formation of a disulphide bond in the presence of
2-mercaptoethanol, demonstrated by crystallography,10 lead to
enzyme inhibition.11 These observations support the hypo-
thesis that the conserved cysteine in the flap is the target for
quinone-based inhibitors, as shown in Scheme 1, by the
formation of 2.7d Here, we describe a kinetic characterization
of the inhibition of SPU by 1,4-benzoquinone, and report, for
the first time, the high-resolution crystal structure of the
urease–BQ covalent complex, shedding light on the long-
awaited molecular details of this interaction.
Kinetic measurements (see the ESI†) were performed at
room temperature by using a spectrophotometric assay that
monitors the decrease of urease activity as a function of time
in the presence of increasing amounts of BQ (Fig. 2). The data
were optimally fitted to a single exponential decay, and the
resulting time constant kapp (s−1) showed a linear dependence
on the concentration of BQ (inset of Fig. 2). This behaviour is
consistent with an irreversible process that has two reactants
(SPU and BQ) and is first-order with respect to both of them,
leading to an inactive form of SPU, hypothetically represented
by compound 2 in Scheme 1:
BQþ SPUactive "!k SPUinactive
v ¼ k ½BQ% ½SPUactive% ¼ kapp ½SPUactive%; kapp ¼ k ½BQ%
The value for the second-order kinetic constant resulting
from the linear fit is k = 1.24 ± 0.06 × 103 M−1 s−1. The inter-
cept of the linear fit in the inset of Fig. 2 crosses the abscissa
at a value of 18.4 ± 1.5 µM; this value indicates the minimum
concentration of BQ above which an inhibition eﬀect can be
detected. This observation was interpreted by considering the
presence of ca. 20 µM sodium sulphite in the enzymatic assay
solution, added as a stabilizer of urease6a but also known to
react stoichiometrically with BQ to give 2,5-dihydroxy-benzene-
sulphonate (3, Scheme 1).12 The evident lack of reactivity
between 3 and SPU, compared to the reactivity of 1, could be
ascribed to the increase of the reduction potential caused by
the electron withdrawing eﬀects of the sulphonate moiety,
which prevents the oxidation of 3 by dissolved molecular
oxygen to the quinone level necessary for the reaction with the
cysteine thiol (Scheme 1).12,13
In order to elucidate the structural basis of urease
inactivation by BQ, SPU was incubated with 1 for two hours in
the absence of sulphite in solution before crystallization. The
resulting 2.07 Å crystal structure of SPU inhibited by BQ (see
Table 1 and the ESI† for full details of crystallization, X-ray
data collection, elaboration and analysis) confirmed the well-
established architecture of the enzyme, as well as the rigidity
of the protein scaﬀold, with a root mean square deviation
(RMSD) for the Cα residue atoms of only 0.12 Å with respect to
the structure of native urease (PDB code 4CEU).
Scheme 1 Reactivity of 1,4-benzoquinone with the thiol group of solvent-exposed SPU cysteine residues in the absence and presence of sulphite.
The structures of compounds 2 and 5 have been established by X-ray diﬀraction crystallography. The wiggled line represents the protein surface on
which the reactive cysteines are located.
Fig. 2 SPU residual activity vs. time plot at diﬀerent BQ concentrations.
The inset shows a plot of kapp as a function of the BQ concentration. In
both panels, the lines represent the result of an exponential or linear ﬁt
of the data.
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No significant changes were observed for the Ni(II) coordi-
nation environment (Table 1-ESI†). The mobile flap covering
the active site cavity is found in the open conformation, as in
all SPU structures determined so far with the notable excep-
tion of the complex with diamidophosphate (DAP), an
analogue of the intermediate or the transition state of the reac-
tion.4a The unbiased omit electron density map calculated
with Fourier coeﬃcients Fo–Fc and phases refined using the
model of the citrate-inhibited SPU (PDB code 4AC7, 1.50 Å
resolution14), shows an additional electron density in the vicin-
ity of the flap and proximal to the αCys322 residue
(Fig. 2A-ESI†). This electron density could be successfully mod-
elled with full occupancy using the aromatic dihydroxylated
moiety of the inhibitor, as shown by the 2Fo–Fc map (Fig. 3A).
The final refined structure features a covalent bond between
αCys322 Sγ and an aromatic C atom of the inhibitor, with a
C–S distance of 1.64 Å (Fig. 3B). The same covalent
modification is also observed for αCys555, a residue located on
the protein surface far from the active site, with a similar C–S
distance of 1.67 Å (Fig. 3-ESI†). The remaining αCys520, pro-
tected from the solvent, is not aﬀected by this modification.
Table 1 X-ray diﬀraction data collection and reﬁnement statistics for
BQ-bound SPU in the absence (PDB code 5FSE) and in the presence
(PDB code 5FSD) of sulphite
Data collection
5FSE (BQ) @
2.07 Å
5FSD (BQ + HSO3
−)
@ 1.75 Å
Wavelength (Å) 0.954 1.214
Crystal-to-detector
distance (mm)
378.1 256.9
Oscillation angle (°) 0.10 0.10
Number of images 400 1200
Space group P6322 P6322
Unit cell (a, b, c, Å) 131.83, 131.83,
188.58
131.31, 131.31,
188.92
Resolution rangea (Å) 188.58–2.07
(2.13–2.07)
97.43–1.75
(1.78–1.75)
Total number of reflectionsa 257 019 (18 993) 1 243 307 (51 825)
Unique reflectionsa 58 491 (4412) 96 874 (4696)
Redundancya 4.4 (4.3) 12.8 (11.0)
Completenessa (%) 98.8 (97.6) 100.0 (100.0)
Rsym
a,b (%) 13.5 (90.8) 10.1 (145.4)
Rpim
a,c (%) 8.8 (55.1) 4.2 (66.5)
Mean I half-set correlation
CC(1/2)
0.620 0.723
Mean I/σ(I)a 9.0 (1.6) 20.0 (1.6)
Refinement statistics
Number of urease subunits in
the asymmetric unit
3 3
Rfactor
d (%) 14.4 13.4
Rfree
d (%) 19.1 16.9
Cruickshank’s DPI for
coordinate errore based
on Rfactor (Å)
0.15 0.08
Wilson plot B-factor (Å2) 22.6 21.5
Average all atom B-factor f (Å2) 30.77 29.16
Cys322 B-factor f (Å2) (Cβ, Sγ) 63.2, 76.5 52.4, 61.7
Cys555 B-factor f (Å2) (Cβ, Sγ) 37.9, 42.2 39.4, 42.1
Average ligand – Cys322
B-factor f (Å2)
66.5 55.6
Average ligand – Cys555
B-factor f (Å2)
41.1 43.1
RMS (bonds)d 0.016 0.019
RMS (angles)d 1.803 1.973
Total number of atomsc 6800 7012
Total number of water
molecules
465 642
Solvent content (%) 55.50 55.23
Matthews coeﬃcient (Å3/Da) 2.76 2.75
Ramachandran plotg
Most favoured region (%) 90.1 91.6
Additionally allowed region (%) 9.0 7.5
Generously allowed region (%) 0.6 0.8
Disallowed region (%) 0.3 0.2
aHighest resolution bin in parentheses. b Rsym = ∑hkl ∑j|Ij − <|>|/∑hkl
∑jIj, where I is the intensity of a reflection, and <|> is the mean
intensity of all symmetry related reflections j. c Rp.i.m. = ∑hkl{[1/(N − 1)]-
∑j|Ij − <|>|}1/2/∑hkl∑jIj, where I is the intensity of a reflection, and <|>
is the mean intensity of all symmetry related reflections j, and N is the
multiplicity.15 d Taken from REFMAC;16 Rfree is calculated using 5% of
the total reflections that were randomly selected and excluded from
refinement. eDPI = Rfactor·Dmax·compl−1/3·[Natoms/(Nrefl − Nparams)]1/2,
where Natoms is the number of the atoms included in the refinement,
Nrefl is the number of the reflections included in the refinement, Dmax
is the maximum resolution of reflections included in the refinement,
compl is the completeness of the observed data, and for isotropic
refinement, Nparams ≈ 4Natoms.17 f Taken from BAVERAGE.18 g Taken
from PROCHECK.19
Fig. 3 An atomic model of the active site of BQ-inactivated SPU (PDB
code 5FSE) in the absence of sulphite. In panel (A), the nickel-coordi-
nation environment is shown superimposed on the ﬁnal 2Fo–Fc electron
density map contoured at 1σ; the map of the inhibitor is shown in
yellow. In panel (B), the corresponding structural model is shown.
H-bonds are shown as thin blue lines.
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This result finally provides full structural support to the
mechanism by which the solvent-exposed side chain thiols of
cysteine residues in ureases are the reactive groups involved in
the formation of covalent adducts with BQ.7d
In the case of αCys322, the O atom in the meta position
with respect to the thiol substituent points towards the
entrance of the active site channel (Fig. 3B), forming a
hydrogen bond with a water molecule (at 2.85 Å) that is also
stabilized by H-bonds with αLeu365 O (at 2.66 Å) and αLys169
O (at 2.76 Å).
The 1.75 Å resolution structure of SPU obtained from the
crystals generated by adding 50 mM sodium sulphite to the
crystallization drop obtained as before discloses further details
of the reactivity of the enzyme inactivated by BQ. In this case,
while the overall protein structure is maintained (as revealed
by a value of 0.10 Å for the RMSD with respect to the structure
obtained in the absence of sulphite, and no changes around
the Ni(II) ions, see Table 1-ESI†), an additional electron density
was identified in the unbiased omit Fo–Fc map calculated
using the refined model of the 2.07 Å structure described
above, in the proximity of the inhibitor aromatic ring bound to
αCys322 (Fig. 2B-ESI†). This additional electron density was
successfully modelled as a sulphonate group covalently bound
to the aromatic ring in the para position with respect to the
cysteine thiol, with 70% occupancy (Fig. 4A). One of the O
atoms of the sulphonate group forms a H-bond with αLys169
Nζ (at 2.85 Å, Fig. 4B). The same covalent modification is also
observed for αCys555, albeit with a lower occupancy (Fig. 4-
ESI†). A comparative analysis of the solvent-excluded surfaces
of the enzyme active site channel, in the absence and presence
of the covalent modifications of αCys322 with and without sul-
phite in the crystallization milieu (Fig. 5-ESI†) shows that the
channel is not physically closed in the presence of the bound
inhibitor, independently of the sulphonate modification,
suggesting that the inactivation of the enzyme is not caused by
the blockage of substrate transport through the path leading
into the active site, but it is rather due to the prevention of the
flap to close, as necessary for the catalysis to occur.5 A site-
directed mutation of the conserved cysteine with tyrosine in
K. aerogenes urease, supposedly having a similar eﬀect on the
active site entrance, causes the abolition of catalytic activity.9
The oxidation state (BQ or 1,4-hydroquinone, HQ) of the
inhibitor bound to αCys322 and αCys555 was also a matter of
investigation. In order to discern between these two possibili-
ties, both moieties were used as initial models for crystallo-
graphic refinement, yielding a negligible diﬀerence in data
statistics. Quantum-mechanical calculations were thus carried
out on the two possible redox moieties (see the ESI†): a
comparison of the key C–O distances for the covalently
modified urease cysteines obtained by crystallography with
those derived from these calculations (see Tables 3, 4-ESI and
Fig. 6, 7-ESI†), did not allow us to unequivocally discern
between the oxidized or reduced form in the crystal. However,
a comparison of the C1–C2–Sγ–Cβ dihedral angle (see
Scheme 1-ESI†) suggests the presence of the reduced form,
characterized by a value close to 90° both in the crystal struc-
ture and in the theoretical model (see Tables 5, 6-ESI and
Fig. 6, 7-ESI†). This particular conformation is known to be
due to the formation of an intra-molecular hydrogen-bond
between a S atom p-orbital and the O–H group of the HQ.20
The final refinement for both structures was thus carried out
using the reduced form of BQ. The reaction of the
BQ-inactivated enzyme with sulphite in solution, leading to
the crystallographically characterized compound 5 (Scheme 1),
requires however the presence of the oxidized form 4, which
must be obtained from the initial product 2 by reaction with
dissolved molecular oxygen (Scheme 1). The presence of the
reduced form 2 in the solid state could thus be due to
photo-reduction. In the case of the sulphonate-substituted
compound 5, on the other hand, the presence of the reduced
form is consistent with its known stabilization by the electron-
withdrawing properties of the sulphonate group, as discussed
for compound 3.
In this paper we have described and discussed the reactivity
of αCys322, a key residue for the catalytic activity of urease,
towards 1,4-benzoquinone, and established the molecular
structural details of the resulting irreversibly inactivated
enzyme. This information is essential for the development of
Fig. 4 An atomic model of the active site of BQ-inactivated SPU (PDB
code 5FSD) in the presence of sulphite. (A) The nickel-coordination
environment superimposed on the ﬁnal 2Fo–Fc electron density 1σ map;
(B) the corresponding structural model. The ﬁgure settings are the same
as in Fig. 3.
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structure-based design and structure–activity relationship
studies of novel urease inhibitors based on this moiety.
Moreover, considering the conservation of the cysteine on the
mobile flap of ureases from other sources, such as the
pathogenic bacterium Helicobacter pylori, the results of our
study have wider general applications. Finally, the large class
of quinonoid compounds, containing 1 as their basic core, is
widely distributed in nature and play pivotal roles as electron
transfer agents in primary metabolic processes such as photo-
synthesis, respiration and oxidative phosphorylation.21 A large
number of chemical derivatives of diﬀerently substituted
quinones are also involved in pharmacological applications for
their activity as antibiotics, antitumor, antimalarial, anti-
neoplastic, anticoagulant and herbicidal agents. Therefore, the
structural information obtained in our study could have far
reaching consequences in the comprehension of the reactivity
of this class of compounds with thiol groups in proteins,
enzymes and enzyme cofactors.22
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Urease is a Ni(II)-containing enzyme that catalyzes the hydrolysis of urea to yield ammonia and carbamate at a
rate 1015 times higher than the uncatalyzed reaction. Urease is a virulence factor of several human pathogens, in
addition to decreasing the efﬁciency of soil organic nitrogen fertilization. Therefore, efﬁcient urease inhibitors are
actively sought. In this study, we describe a molecular characterization of the interaction between urease from
Sporosarcina pasteurii (SPU) and Canavalia ensiformis (jack bean, JBU) with catechol, a model polyphenol. In par-
ticular, catechol irreversibly inactivates both SPU and JBU with a complex radical-based autocatalytic multistep
mechanism. The crystal structure of the SPU-catechol complex, determined at 1.50Å resolution, reveals the struc-
tural details of the enzyme inhibition.
© 2016 Elsevier Inc. All rights reserved.
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1. Introduction
Urease is a non-redox metallo-enzyme involved in the global nitro-
gen cycle in plants, algae, fungi, and several microorganisms [1,2]. Its
fully conserved bimetallic Ni(II)-containing reaction site (Fig. 1A) cata-
lyzes the rapid hydrolytic decomposition of urea to give ammonia and
carbamate [1,2]. The uncatalyzed hydrolysis of these reaction products
causes an overall pH increase that has negative implications for
human health [3] aswell as for the environmental ecosphere [4]. In par-
ticular, urease plays an essential role in the virulence of the human
pathogenHelicobacter pylori. This bacterium is able to use the urease ac-
tivity to create a local pH environment compatible with its survival in
the acidic conditions of the gastric mucosa [5]. It has been estimated
that approximately two-thirds of theworld's population harborH. pylori
[6]. Thismicroorganismhas been classiﬁed, uniquely among bacteria, as
a class-I carcinogen in humans [7]. As a consequence of these facts, ure-
ase is the ideal target for the treatment of diseases caused by a large va-
riety of ureolytic human pathogens in addition to H. pylori, such as
Cryptococcus neoformans, Yersinia enterocolitica, Proteus mirabilis, and
Mycobacterium tuberculosis [8–11]. The urease inhibitors characterized
so far [12] can be roughly divided in two main classes, based on the
mode of interaction with the enzyme. The ﬁrst class contains molecules
(phosphorodiamidate, phosphate, thiols, sulﬁte, ﬂuoride as well as
hydroxamic, citric and boric acids) directly binding to the Ni(II) ions
in the active site [1,2,13,14]. The second class of inhibitors is composed
ofmolecules such as 2-mercapto-ethanol (BME) [15] and 1,4-benzoqui-
none (PBQ) [16] that have been proven to bind to the Sγ atom of the
conserved αCys322 [Sporosarcina pasteurii urease (SPU) numbering].
This residue is located onto a mobile helix-turn-helix motif (ﬂap) that
is essential for catalysis bymodulating the transit of substrate and prod-
ucts through the active site cavity (Fig. 1B). BME can actually be ascribed
to both classes, because it is able to further use its thiol moiety to
coordinatively bridge the Ni(II) ions in the active site [15]. On the
other hand, PBQ is a representative of the most efﬁcient class of urease
inhibitors characterized so far [17]. The structure of SPU inactivated by
PBQ shows that the thiol group of αCys322 forms a covalent adduct
with PBQ, blocking enzyme activity by rendering the ﬂap unable to
move [16]. A similar inactivation mode could potentially represent the
basis for the inhibitory activity of polyphenols towards urease. These
molecules comprise a wide class of natural compounds found in fruits,
vegetables, cereals, tea, coffee and wine, and are generally recognized
as beneﬁcial to human health for their antioxidant properties [18].
This class of urease inhibitors has also been recently described as efﬁ-
cient againstH. pylori, but their mode of action has not been understood
so far [19–22]. Here we present the kinetic and structural characteriza-
tion of SPU and Canavalia ensiformis (jack bean, JBU) inactivation by cat-
echol (benzene-1,2-diol, CAT), the simplest molecule featuring a
polyphenol scaffold that was identiﬁed as the most promising inhibitor
of soil urease [17].
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2. Materials and methods
2.1. Enzymes
Sporosarcina pasteurii urease was expressed and puriﬁed from the
native source, following a previously described protocol [14–16]. The
protein was quantiﬁed by measuring the activity and considering its
speciﬁc activity of 2500 unitsmg−1 andMr=250 kDa. Jack bean urease
type C-3, powder (≥600,000 units/g) was purchased from Sigma-Al-
drich and was quantiﬁed following manufacturer's information.
2.2. Kinetic measurements
Pre-incubation experiments were carried out at room temperature
by using a spectrophotometric assay in which cresol red is exploited
as a probe to follow the overtime increase of pH due to urease activity,
following a protocol previously described [16]. In the case of SPU – cat-
echol experiments, a solution of 50 nM SPU dissolved in 2 mM HEPES
buffer, pH 7.5, 1mMNa2SO3, was diluted down to 1 nMﬁnal concentra-
tion in the cresol red reaction solution, containing 30mg L−1 cresol red
in 2 mM HEPES buffer, pH 7.5, 2 mM EDTA. By doing this, Na2SO3 was
diluted 50-fold as well, down to 20 μM ﬁnal concentration. In the case
of JBU – catechol experiments, a solution of 250 nM JBU dissolved in
2 mM HEPES buffer, pH 7.5, without Na2SO3, was directly diluted to
2.5 nM in the same cresol red solution. Then, different concentrations
of catechol solutions (4–16 mM and 5–40 μM for the experiments on
SPU and JBU, respectively) dissolved in 2 mM HEPES buffer, pH 7.5
(containing 20 μM Na2SO3 in the case of experiments on SPU) were
added, taking the time when the enzyme solution and the ligand are
mixed as zero time of incubation. After appropriate periods of time, ali-
quots were withdrawn from the incubation solution, 100 mM urea was
added, and the change in absorbance over time was monitored (λ =
573 nm). The activity was calculated by a linear ﬁtting of the straight
portion in the absorbance vs. time curve and normalized to the activity
measured at time zero incubation.
2.3. Crystallization, data collection and structural determination
A solution of Sporosarcina pasteurii urease (SPU, 1 mg mL−1) in
20 mM HEPES buffer, pH 7.5, was incubated in the presence of 1 mM
catechol (dissolved in the same buffer) for 2 h and then concentrated
to 11 mg mL−1. Subsequently, 2 μL of this solution was diluted with
2 μL of the precipitant solution (1.6–2.0 M ammonium sulfate in a
50 mM sodium citrate buffer pH 6.3). Crystallization was performed at
293 K using the hanging-drop method, equilibrating the drop against
0.5 mL of the precipitant solution using Quiagen EasyXtal 15-Well
plates. Rice-shaped protein crystals appeared in 1–2 weeks and grew
to a size of 0.1 × 0.1 × 0.3 mm3. Crystals were scooped up using
cryoloops, transferred to a cryoprotectant solution containing 20% eth-
ylene glycol, 2.4 M ammonium sulfate in a 50mM sodium citrate buffer
at pH 6.3 and then ﬂash-cooled and stored in liquid nitrogen. Diffraction
data were collected at 100 K using synchrotron radiation at the EMBL
P13 beamline of the Petra III storage ring, c/o DESY, Hamburg (Germa-
ny). Diffraction images were collected by performing helical scans
Fig. 1. (A) Coordination environment of the Ni(II) ions in the active site of SPU (PDB code 4CEU [13]). Ribbons and longitudinal section of the open (B, PDB code 4CEU) and closed (C, PDB
code 3UBP [42]) conformations of the ﬂexible ﬂap in SPU.
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along the crystal to achieve higher resolution by minimizing radiation
damage. Data were processed using XDS [23] and AIMLESS [24]. The
crystals were isomorphous with those of native urease and other com-
plexes of the sameenzyme. Themodel of SPUwith its highest resolution
available so far, that is in complex with citrate (PDB code 4AC7, 1.50 Å
resolution [25]) and devoid of water molecules and ligands, was used
as a starting model for the rigid body reﬁnement of the singleαβγ pro-
tein trimer, carried out using Refmac [26]. Model building and water or
ligand addition/inspection were conducted using Coot [27]. The struc-
ture was reﬁned using isotropic atomic displacement parameters
(ADPs), including the hydrogen atoms in the riding positions, and
then reﬁned using anisotropic ADPs. The model was then validated
using the PDB_REDO web server [28]. The ﬁnal R and Rfree were 12.12
and 15.42, respectively. The diffraction data and ﬁnal reﬁnement statis-
tics are given in Table S2. The structure was deposited in the Protein
Data Bank under the accession code 5G4H. Figures were generated
using UCSF Chimera [29], PyMol [30], and CrystalMaker (http://www.
crystalmaker.com).
2.4. Quantum mechanical calculations
Density functional theory (DFT) computations were carried out
using the program ORCA 3.0.3 [31] and the Becke three-parameter hy-
brid functional combined with Lee-Yang-Parr correlation functional
(B3LYP/G) [32,33] as deﬁned in the Gaussian software [34]. The forma-
tion of the bond between the C3 atom of ortho-benzoquinone
(cyclohexa-3,5-diene-1,2-dione, OBQ) or ortho-semiquinone [(2-
hydroxyphenyl)-oxidanyl, OSQ] and αCys322(Sγ) was investigated
using relaxed scan computations [31], which involve constrained opti-
mizations for different values of a selected reaction coordinate. The cho-
sen coordinate, in this case the bond distance, is ﬁxed to a certain value
while the remaining coordinates of the molecule are optimized. After
completion of one optimization cycle, the value of the reaction coordi-
nate is changed and another optimization cycle is carried out. This pro-
cedure was used to trace a path (theoretically close to a minimum-
energy path) from the separated OBQ (or OSQ) and a molecule of
methanethiol, used to model αCys322 thiol, to the product. For relaxed
scan calculations all atomswere described by the Pople-style 6-311G(d,
p) [35] basis set. The Dunning correlation-consistent polarized double
zeta basis set (cc-pVDZ) [36] was used to calculate the hydrogen bond
network around the catechol moiety bound to the mobile ﬂap of SPU,
while the Dunning correlation-consistent polarized triple zeta basis
set, with the inclusion of diffuse functions (aug-cc-pVTZ) [36], was
used for computations on small molecules. Frequency computations
were executed on the molecules (reported in Fig. S3 and Table S5) as
well as on the critical points reported in Fig. 4, in order to determine
their nature.
3. Results and discussion
The inhibition of Sporosarcina pasteurii urease (puriﬁed according to
previously published protocols [14–16]) by catechol was studied by
pre-incubating the enzyme with different concentrations of inhibitor
for increasing periods of time in the absence of substrate, and the resid-
ual activity was monitored using a spectrophotometric assay [16]. The
data in Fig. 2A show the presence of an initial lag phase, whose extent
decreases as the concentration of catechol increases, followed by an ac-
celeration that eventually yields the complete inhibition of the enzyme.
This behavior is typical for irreversible enzyme inactivators, known to
form stable covalent adducts between the inhibitor and essential func-
tional groups of the enzyme [37].
The observed kinetic response suggests the presence of a process
that converts catechol, inactive at the start of the reaction, into another
compound, which then acts as the actual inactivator of the enzyme. Cat-
echol is known to undergo oxidation in neutral aqueous solutions upon
exposure to air [38]. The need for dissolved molecular oxygen was
conﬁrmed by the essential lack of SPU inactivationwhen the kinetic ex-
periments described above were performed in controlled oxygen-free
atmosphere (Fig. S1 in the Supplementary material).
According to the known reduction potentials (see Table S1), the for-
mation of the ortho-semiquinone radical or of ortho-benzoquinone are
thermodynamically favorable processes, as is the disproportionation of
the ortho-semiquinone to form ortho-benzoquinone and catechol.
These reactions are expected to be much faster than the observed lag
phase [39], which therefore cannot be ascribed to these processes. We
thus investigated the possibility that sulﬁte, needed in the assay solu-
tion to stabilize SPU activity [14], could quench the urease inactivation
by acting as a reducing agent of either OBQor OSQ, or both, as suggested
by the reduction potentials shown in Table S1. In addition, sulﬁte can
also react with quinones, forming dihydroxybenzene-sulphonates
shown to be inactive towards the cysteine thiols of SPU [16]. In order
to explore this hypothesis, the same kinetic experiments were conduct-
ed using, in place of SPU, Canavalia ensiformis urease (jack bean urease,
JBU), which does not require the presence of sulﬁte as a preservative.
Fig. 2B shows that, in this latter case, the initial lag phase is almost
completely abolished, supporting the role of sulﬁte in slowing down
the inactivation of SPU. In addition, the concentration of catechol need-
ed to exert similar effects on urease activity is three orders ofmagnitude
smaller in the case of JBU as compared to that needed for SPU. The sig-
moidal shape of the JBU inactivation data as a function of incubation
time suggests the occurrence of a collectively autocatalytic process,
namely a set of chemical reactions that yield, as reaction products, one
or more catalysts that accelerate the inhibition of JBU [40]. The nature
of this autocatalytic process for JBU inactivation must involve the pro-
duction of derivatives of catechol generated by reaction with dioxygen,
Fig. 2. Plots of SPU (A) and JBU (B) residual activity vs. time of incubation at different
catechol concentrations. In panel B, the lines represent the result of the global ﬁts of the
data for JBU using Eq. (1) (see below).
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namely OSQ and/or OBQ. We speculate here that a similar autocatalytic
process also occurs for SPU, but only upon consumption of sulﬁte, when
the fast phase of SPU inactivation is initiated by unrestrained formation
of the oxidation products of catechol.
The derivation of a complete kinetic model able to interpret the data
requires the identiﬁcation of the reacting species and of the reaction
product(s). Previous studies on the inactivation of JBU by catechol
were interpreted with the covalent modiﬁcation of αCys592 (corre-
sponding toαCys322 in SPU) through aMichael-type nucleophilic addi-
tion by its thiol group on OBQ, even though a radical-based mechanism
was not ruled out [41]. In themost general case, this residue could react
with either OSQ or OBQ, depending on the nature of the reactionmech-
anism: a nucleophilic Michael-type addition on OBQ or a radical addi-
tion on OSQ. Furthermore, two different products could be a priori
obtained, depending on the formation of a S\\C covalent bond in
ortho (C3 carbon) or in meta (C4 carbon) with respect to the hydroxyl
groups on the aromatic ring. In order to understand the structural
basis of urease inactivation by catechol, a crystallographic structural
study of the products of inactivation of SPU by this inhibitor was carried
out.
SPU was incubated with catechol for two hours before crystalliza-
tion. The resulting crystals were amenable to X-ray diffraction analysis,
yielding a 1.50 Å resolution structure (see Table S2 for the full details of
X-ray data collection, processing and analysis). The structure conﬁrms
thewell-knownmolecular architecture of SPU togetherwith the rigidity
of the protein scaffold (root mean square deviation for the Cα residue
atoms = 0.08 Å with respect to the structure of native urease; PDB
code 4CEU). The coordination environment of Ni(II) is almost identical
to that observed in the case of native SPU (Table 1 and Table S3). The
mobile ﬂap covering the active site cavity is found in the open confor-
mation, as also found in all SPU structures determined so far, with the
distinguished exception of the complex with diamidophosphate
(DAP), an analogue of the intermediate or transition state of the reac-
tion [42].
The unbiased omit electron densitymapwas calculatedwith Fourier
coefﬁcients Fo–Fc and phases derived from the reﬁnement of SPU-cate-
chol structure using the citrate-inhibited SPU (PDB code 4AC7, 1.50 Å
resolution [25]) as a starting model after removal of the citrate moiety
and other water molecules/ligands present in the 4AC7 model. This
omit map showed an additional electron density in the vicinity of the
ﬂap and proximal to the αCys322 residue (Fig. S2), which was success-
fully modeled with full occupancy using the aromatic dihydroxylated
moiety of the inhibitor (Fig. 3A). The ﬁnal reﬁned structure features a
covalent bond betweenαCys322 Sγ and the aromatic C3 atom of the in-
hibitor, with a C\\S distance of 1.65 Å (Fig. 3B and Table S4). The
dihydroxylated aromatic moiety points towards the Ni(II) ions. The sol-
vent-exposed αCys555, far from the active site, is not modiﬁed by cate-
chol, as observed in the case of PBQ bound SPU [16], emphasizing the
peculiarity of the environment around αCys322. This feature could be
related to the presence of the αHis323 residue in the adjacent position,
which is conserved and known to be essential for urease activity. A third
cysteine residue (αCys520) is protected from the solvent and is not af-
fected by any modiﬁcation.
The oxidation state of the group bound toαCys322 Sγ (reduced cat-
echol or oxidized ortho-benzoquinone) was investigated using quan-
tum-mechanical calculations carried out on these two possible redox
moieties (see Supplementary material for details). The results suggest
Table 1
Selected distances around the Ni(II) ions in native (PDB code 4CEU) and catechol-bound
SPU (PDB code 5G4H).
Ni - L distances (Å) 4CEU 5G4H
Ni(1) - αLys220* Oθ1 1.94 2.02
Ni(1) - O(B)a 2.08 1.90
Ni(1) - O(1) 2.24 2.21
Ni(1) - αHis249 Nδ 2.03 2.04
Ni(1) - αHis275 Nε 2.02 2.09
Ni(2) - αLys220* Oθ2 2.08 2.09
Ni(2) - O(B) 2.12 1.97
Ni(2) - O(2)c 2.07 2.17
Ni(2) - αHis137 Nε 2.11 2.10
Ni(2) - αHis139 Nε 2.08 2.10
Ni(2) - αAsp363 Oδ1 2.10 2.13
Ni(1) ⋯ Ni(2) 3.67 3.57
O(1) ⋯ O(2) 2.37 2.33
Fig. 3. Atomic model of the active site of catechol-inactivated SPU (PDB code 5G4H). In
panel (A), the nickel-coordination environment is shown superimposed on the ﬁnal
2Fo–Fc electron density map contoured at 1.2σ; the map of the inhibitor is shown in
yellow. In panel (B), the corresponding structural model is shown. H-bonds are shown
as thin blue lines. Table S7 reports the corresponding numbers of the water molecules in
the deposited PDB ﬁle.
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the presence of the reduced form, and the ﬁnal crystallographic reﬁne-
mentwas thus carried out accordingly. In order to assess the position of
the hydrogen atoms around the catechol moiety covalently bound to
αCys322 Sγ, attention was focused on the network of H-bonds involv-
ing this modiﬁed residue and the water molecules in its proximity
(see Supplementary material for details). In particular, WA and WB are
bound to CAT O1 with O\\O distances of 2.52 and 3.05 Å, respectively,
while WC is at H-bond distance from both CAT O1 and O2 (at 3.14 and
2.54 Å, respectively). WA also forms two H-bonds with the backbone
O atoms of αLys169 and αLeu365. WC is at H-bond distance from
bothαAla366O andWG, and the latter is H-bonded to the sulfate ion lo-
cated next to the Ni(II) ions. Quanto-mechanical optimization of the H-
bonding network between the catechol moiety, the surrounding resi-
dues and water molecules suggest that WA is actually the hydronium
H3O+ ion; this induces the H atoms of the hydroxyl groups of catechol
to lie on the same plane of the aromatic ring, forming an intra-molecular
H-bond between a αCys322 Sγ p-orbital and the O\\H group bound to
the C2 atom of catechol [43].
The present crystal structure of SPU inactivated by catechol, with the
αCys322 thiol bound to the C3 atom of the aromatic ring, rules out the
formation of the meta adduct (cysteine thiol bound to the C4 atom of
catechol). In order to distinguish between the nucleophilic attack on
OBQ and the radical-based reaction mechanism involving OSQ,
quanto-mechanical calculations were carried out (see Supplementary
material for details). In both cases, the reaction involves the formation
of a bond between OBQ/OSQ(C3) and αCys322(Sγ). The ﬁrst mecha-
nism taken into account was the nucleophilic attack performed by the
methanethiol (MeSH) sulfur atom to the C3 atom of OBQ. The relaxed
surface scan for this reaction coordinate leads to a gradual energy in-
crease as the OBQ(C3)-MeSH(S) distance is shortened, without the for-
mation of any critical point on the potential energy surface (Fig. S5).
This result is somehow expected, considering that the C3 atom of OBQ
has a slightly negative partial charge (Table S5), not compatible with a
nucleophilic attack.We then took into account the direct interaction be-
tween OSQ(C3) andMeSH(S) (blue pathway in Fig. 4). The surface scan
along the OSQ(C3)-MeSH(S) coordinate resulted in a barrier of ca.
Fig. 4. Results of the relaxed surface scan computations and critical points identiﬁed along the reaction pathways betweenOSQ andMeSH. Atoms are colored accordingly to atom type. The
inset reports the spin density calculated for the OSQ moiety.
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39 kcal/mol and the identiﬁcation of a transition state (TS1) character-
ized by C3 in a distorted tetrahedral geometry, together with a larger
MeSH S\\H bond distance as compared to that found in MeSH. Along
this pathway, TS1 then evolves to a radical reaction intermediate
(INT1) characterized again by C3 in a distorted tetrahedral geometry
and full protonation of the two hydroxyl groups on the aromatic ring.
The detailed analysis of the molecular orbitals of OSQ subsequently
showed that the largest fraction of the spin density is localized on the
O2 atom (Table S5), suggesting that the reaction could actually occur
in two steps (Scheme 1), as previously suggested [44,45]: i) in the ﬁrst
step the thiol H (HS) is taken up by the O2 of OSQ to form a molecule
of catechol and a methylsulfanyl radical (MeS•), and ii) the S atom of
MeS• then attacks the C3 of catechol to give the reaction products (red
pathway in Fig. 4). The exploration of the OSQ(O2)-MeSH(HS) reaction
coordinate (Fig. 4) revealed a ﬁrst energy maximum located at ca.
14 kcal/mol higher than the initial molecules, leading to the identiﬁca-
tion of the transition state TS2 characterized by the MeSH hydrogen al-
ready bound to OSQO2 atom. TS2 then evolves to yield catechol and the
MeS• radical. The exploration of the CAT(C3)-MeS•(S) reaction coordi-
nate then leads to a second energy maximum characterized as the tran-
sition state (TS3) located at ca. 9.5 kcal/mol higher than the adduct
formed by catechol and the MeS• radical. TS3 features the C3 atom of
catechol in a distorted tetrahedral geometry. TS3 then evolves into the
same radical reaction intermediate INT1 observed in the reaction path-
way initially explored, with very similar geometry and energy with re-
spect to TS3. In both pathways, INT1 can be eventually stabilized by a
third molecule able to extract a radical H atom and give the reaction
product observed in the crystal structure of catechol-bound SPU. This
third player could be either molecular oxygen or another molecule of
OSQ (to give the fully reduced catechol-like moiety), or OBQ (to give
OSQ). These calculations, coupledwith the structural data, strongly sup-
port the involvement of the ortho-semiquinone radical in the reaction
with the active form of urease to give the inactive enzyme.
The working hypothesis for urease inactivation by catechol thus im-
plicates the set of reactions portrayed in Scheme 2. The OSQ radical can
be generated by oxidation of catechol by dissolved O2 through the for-
mation of superoxide (reaction 1) and by comproportionation of cate-
chol and ortho-benzoquinone (reaction 2). The active form of urease
(JBUact in the case of JBU) then reacts with OSQ to give the inactive en-
zyme (JBUinh) according to the reaction mechanism based on quanto-
mechanical calculations, as described above (reaction 3). The ﬁnal reac-
tion 4 takes into account a step that produces ortho-benzoquinone.a
This model involves a number of variables, one of them being the
concentration of dissolved oxygen ([O2]). Considering that the experi-
ments were carried out using vessels always open to air, and given the
relatively long time scale of the enzyme inactivation (thousands of sec-
onds), it is assumed that the oxygen concentration is constant during
the process and equal to the initial air-saturated value [O2]0 at the tem-
perature of the experiments, i.e. [O2]≈ [O2]0 = 0.2 mM [46]. The fol-
lowing, reasonably simple analytical expression can be derived (see
the Supplementary material for the details of the mathematical treat-
ment) [47] to give a good ﬁt to the detected curves [Eq. (1)].
JBUact½ " ¼ JBUact½ "0 exp −kapp1t−kapp2t2
! " ð1Þ
In this equation, kapp1 and kapp2 are functions of the kinetic constants
k1, k2, k3 and k4 in Scheme 2, as well as the initial concentration of cate-
chol, [CAT]0, as indicated in Eq. (2) and Eq. (3), which were derived
through solution of the system of simultaneous ordinary differential
equations by applying the steady state approximation and the Taylor se-
ries comparison technique [48] (see Supplementarymaterial for the full
mathematical treatment):
kapp1 ¼ k1k3k4 CAT½ "0 ð2Þ
kapp2 ¼ 2k1k2k3k4 CAT½ "
2
0−
k1
2k3
k4
O2½ "0 CAT½ "0 ð3Þ
A simultaneous ﬁt of the data obtained for JBU at four different initial
catechol concentrations using this model provided a very good agree-
ment between theory and experiment (Fig. 2B), yielding the following
values: k1 = 0.9 ± 0.1 M−1 s−1, k2 = 49 ± 4 M−1 s−1 and k3/k4 =
Scheme 1. Proposed reaction pathway for the SPU inactivation by OSQ leading to the formation of INT1, based on quanto-mechanical calculations.
Scheme 2.Working hypothesis for the mechanism of inactivation of urease by catechol.
a Superoxide is not a reactant in any of the considered reactions in Scheme 2; most
probably it will undergo dismutation to generate dioxygen and hydrogen peroxide, but
this reaction does not inﬂuence the kinetic signature analyzed here.
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29±4.b Themuch larger value of k2 as compared to k1 is consistentwith
the observed autocatalytic process, while the k3/k4 value signiﬁcantly
larger than one implies that the reaction continues until complete con-
sumption of the active enzyme.
4. Conclusions
The molecular details of the urease irreversible inactivation by cate-
chol have been elucidated. Thismolecule inactivates urease by a radical-
based mechanism that yields a covalent adduct with the conserved
αCys322 located on the ﬂap that modulates the opening and closing
of the active site channel, blocking it in the open position (see Fig. S6).
This seems a general trait, common to aromatic poly-hydroxylated ure-
ase inhibitors, as it has been observed recently also for the case of urease
irreversible inactivation by para-benzoquinone [16]. The role of reduc-
ing agents such as sulﬁte on this reaction has also been clariﬁed. Finally,
a kinetic scheme of urease inactivation by catechol was elaborated and
positively tested against experimental data. The obtainment of key
structure-activity relationships for the development of improved poly-
hydroxylated aromatic molecules as urease inactivators, with potential
applications in medicine as well as in agro-environmental settings, is
under active investigation in our laboratory.
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